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Longitudinal bone growth and the growth plate
Longitudinal growth occurs at the epiphyseal plate or growth plate, a thin layer of cartilage 
entrapped between epiphyseal and metaphyseal bone, at the distal ends of the long bones. This 
growth plate is highly organized and consists of chondrocytes in three principal layers: the resting 
zone, proliferative zone and hypertrophic zone (fig 1). The resting zone is located at the epiphyseal 
end of the growth plate and contains resting chondrocytes, originating from mesenchymal stem 
cells, forming a proliferative reservoir for the entire growth plate. Resting chondrocytes enter 
the proliferating zone in organized columns and undergo cell-divisions in longitudinal direction 
regulated by a multitude of hormones and growth factors. In this zone chondrocytes start 
producing significant amounts of extracellular matrix proteins (ECM) essential for the structure 
of the growth plate. More towards the hypertrophic zone chondrocytes lose their proliferating 
capacity and begin to increase in size while they differentiate into hypertrophic chondrocytes. 
In the hypertrophic zone chondrocytes increase their size 6-10 fold and secrete a large amount 
of matrix proteins. Longitudinal bone growth is the result of proliferation, enlargement of 
hypertrophic chondrocytes and production of ECM proteins in the proliferative and hypertrophic 
zone.
From the adjacent metaphyseal bone osteogenic progenitors and osteoclasts are recruited to 
remodel the newly formed cartilage and deposit trabecular bone at the bottom of the growth plate. 
During childhood the growth plate matures, its total width decreases and eventually it disappears 
at the end of puberty with complete replacement by bone along with cessation of longitudinal 
growth (1). 
Figure 1: The structure of the growth plate
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Extracellular matrix (ECM) proteins
Chondrocytes are embedded in an extracellular matrix consisting of various large and 
multifunctional molecules. An important group consists of the collagens, of which collagen type II is 
most abundantly present throughout the proliferative and hypertrophic zone. Another important 
collagen in the growth plate, often used as a marker for hypertrophic chondrocytes, is collagen 
type X that is solely expressed in the hypertrophic zone of the growth plate. Dysplasias caused by 
mutations in these collagens are associated with growth disorders and short stature (2;3). Another 
group of ECM molecules are the glycosaminoglycans (GAGs), heteropolysaccharide molecules. 
The majority of GAGs in the body are linked to core proteins, forming large mucopolysaccharide 
proteoglycans cross-linking the matrix. Members of this proteoglycan group are aggrecan, 
biglycan, glypican and chondroitin.
Within the ECM there are endopeptidases called Matrix Metalloproteinases (MMPs), remodelling 
these molecules, and tissue inhibitors of MMPs, preserving the integrity of the ECM (4). In addition 
the MMPs initiate angiogenesis for vascular invasion of growth plate cartilage together with 
various growth factors like vascular endothelial growth factor (VEGF) produced by chondrocytes 
in the growth plate (4-6). Besides controlling angiogenesis, VEGF has also been shown to modulate 
chondrocyte differentiation and survival, osteoblast differentiation and osteoclasts recruitment 
(7-9).
The ECM is furthermore a reservoir for various growth factors, hormones and proteins like 
Transforming growth factor beta (TGF-β), Fibroblast growth factors (FGFs), Indian Hedgehog 
(Ihh), Parathyroid hormone-related peptide (PTHrP), Wnt signalling factors and Bone 
Morphogenetic Proteins (BMPs), interacting together to tightly control chondrocyte proliferation 
and differentiation in the growth plate (1). 
Hormones and their influence on the growth plate
Longitudinal bone growth is influenced by a variety of hormones and growth factors acting directly 
or indirectly on the growth plate. A fine and tight control of several hormone systems is obligatory 
to control longitudinal bone growth. For example triiodothyronine (T3) and thyroxine (T4) in the 
hypothalamic-pituitary-thyroid axis are crucial for normal skeletal growth and bone maturation 
illustrated by cases of congenital or acquired hypothyroidism that show a severe retardation of 
growth and skeletal maturation, while hyperthyroidism is associated with an increased growth 
velocity and bone maturation (10-12). Glucocorticoids are strong inhibitors of growth and long-
term treatment often leads to growth failure, which might be the result of an inhibiting effect 
on chondrocyte proliferation and a stimulating effect on apoptosis of growth plate chondrocytes 
(13;14). In children suffering from chronic inflammatory diseases growth failure is frequently 
observed. These disorders are associated with increased circulating cytokine levels acting locally 
in the growth plate or through systemic effects on other growth regulatory mechanisms (15).
Growth hormone and IGF-I are the most well-known hormones involved in longitudinal growth, 
whereas estrogen is thought to be the most important hormone during pubertal growth and 
epiphyseal fusion. Both hormonal systems are described in more detail in the following sections 
and interactions between these systems and the ones described above frequently occur.
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Growth hormone and insulin-like growth factor-I (IGF-I)
Growth hormone and IGF-I are important stimulators of longitudinal bone growth. Both GH and 
IGF-I receptors are expressed in the growth plate (16). Defects in GH and IGF-I pathways result in 
marked growth disorders (17-20). GH can stimulate skeletal growth directly by local action in the 
growth plate and indirectly by liver-derived IGF-I (21;22).
The effect of GH on longitudinal growth has been a captivating subject of research through the 
years. The original hypothesis was the somatomedin hypothesis in which it was thought that GH 
stimulates hepatic production of somatomedin (IGF-I), which in turn stimulates chondrocytes 
locally in the growth plate (23). In 2001 this hypothesis was questioned by Le Roith et al who 
found little effect on the growth rate in mice with a selective igf1 deletion in their liver while their 
circulating IGF-I was 20-25% of normal (24). The terminal hypertrophic zone in the growth plates 
of these mice was reduced and therefore it was thought that IGF-1 is responsible for chondrocyte 
differentiation (24). 
The majority of circulating IGF-I is bound to a complex with IGF binding protein 3 (IGFBP-3) and 
the acid labile subunit (ALS). Knocking out the als gene or the igf1 gene results in just a small effect 
on longitudinal growth in mice (24;25). On the contrary, a deletion of the igfbp-3 gene results in 
an increase in linear growth in mice.  A double knock out mouse of als and igf1 as well as a triple 
knockout of each gene results in significant growth retardation, suggesting that there might be 
a threshold level of circulating IGF-I to control skeletal growth and that both ALS and IGF-I are 
crucial participators (26). 
Nowadays it is well known that GH not only generates liver produced IGF-1, but also acts locally 
on chondrocytes in the growth plate. These findings were described in the dual effector hypothesis, 
in which GH acts locally on chondrocytes in the resting zone to enhance the recruitment of resting 
chondrocytes in the proliferative state and to stimulate local IGF-I production, resulting in an 
increase in proliferation by both GH and IGF-I stimulation (21;27-29). Several clinical reports 
and laboratory results have demonstrated the importance of both IGF-I and GH in the regulation 
of longitudinal bone growth, however the exact contributions and roles of circulating and local 
effects of these hormones still need to be clarified in more detail. 
Estrogen and its effect on longitudinal bone growth
Estrogens are known to play a key role in longitudinal bone growth through growth plate 
maturation, epiphyseal fusion and augmentation of accrual of bone. The main active form of 
estrogen is 17β-estradiol (E2) that can be synthesized from estrone and testosterone (figure 2). 
Other estrogen metabolites are less active and have less affinity for the estrogen receptors. The 
effects of estrogen have been suggested to be mediated mainly through the nuclear receptors ERα 
and ERβ, both expressed in growth plate chondrocytes of several species, including the human 
(30-33). Expression patterns co-localize throughout the whole growth plate with a more abundant 
expression in the resting and proliferative zone (32). The two receptors show high conservation in 
their DNA-binding domain (97%) and share considerable homology (55%) in their ligand-binding 
domain (34). Recently a new membrane G protein-coupled estrogen receptor was discovered, 
the GPR30 receptor, which was shown to be expressed in human and mice and was shown to be 
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functional in the growth plate of mice (35;36). Estrogen receptor gene polymorphism is reported 
to have an effect on adult height. There are two studies demonstrating that a mutation in a certain 
region of the estrogen receptor allele can result in an average of 3 cm increase in adult height 
(37;38).
The important role of estrogen is supported by several clinical observations. Premature estrogen 
exposure in for example precocious puberty accelerates skeletal maturation, whereas on the 
contrary hypogonadism results in delay in skeletal maturation. Smith et al in 1994 described a 
male with an inactivating mutation in the estrogen receptor a that showed no pubertal growth 
spurt and continued to grow into adulthood due to absence of growth plate fusion, resulting in 
tall stature (210 cm) and osteoporosis (39). A similar phenotype was described in a second report 
of two boys with a mutation in the aromatase gene (40). Aromatase catalyzes the conversion of 
androgens into estrogens, thus also in these boys there was a lack of estrogen action. Thirdly, from 
clinical observations it is known that high levels of estrogen inhibit longitudinal bone growth (41). 
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Estrogen action
Estrogens can exert their effect through several mechanisms. In the classical way estrogen diffuses 
through the plasma membrane into the cytosol where it binds cytoplasmic receptors to form 
hormone-receptor complexes. These complexes dimerize and are translocated into the nucleus 
where they bind estrogen response elements in or close to a promoter region of a specific gene to 
activate gene transcription (42).
In a non-classical way estrogen can also act without binding to the DNA. Estrogen receptors can 
have an effect through interaction with DNA-bound proteins that function as transcription factors 
or co-regulators like cyclic AMP-response element binding protein (CREB), specificity protein-1 
(SP-1) and activator protein-1 (AP-1) (43-45). Alternatively, estrogens act through interaction 
with membrane-bound receptors, like GPR30 that results in a relatively rapid non-genomic 
estrogen response through intracellular signaling pathways (46). 
Not only do estrogenic ligands regulate ER-dependent gene expression, but the ER can also be 
phosphorylated and activated by a variety of signaling pathways such as pathways involving IGF-
1 and epidermal growth factor (EGF) (47;48). Vice versa estrogens can influence the GH-IGF-I 
axis, demonstrated by increasing GH but decreasing IGF-1 levels in patients with oral estrogen 
treatment (49;50). High dose of estrogen treatment decreases IGF-1 levels by 35% (51). However, 
transdermally administered estrogens increase IGF-1 levels (52). In addition, in puberty an 
increase in the amplitude of GH-secretion is seen and blocking estrogen signaling results in a drop 
of GH level (53). It has been suggested that estrogen can act on an AP-1 motif in the promoter site 
of the IGF-1 gene (54). Another indirect effect of estrogen on longitudinal growth might be through 
interference with components of the Indian Hedgehog/PTHrP growth restraining feedback loop 
suggested by experimental data in rats where estrogen increased mRNA expression of PTHrP and 
its receptor (55).
Senescence
The mechanism by which estrogens exert their effect on longitudinal growth and finally growth 
plate fusion is not fully understood. One of the postulated hypothesis is that estrogen accelerates 
the senescent decline (56). Senescence is a term for the structural and functional changes over 
time in the growth plate, such as a gradual decline in the overall growth plate height, proliferative 
zone height, hypertrophic zone height, size of hypertrophic chondrocytes and column density (56). 
Growth plate transplantation experiments showed that the growth rate of a transplanted growth 
plate depends on the age of the donor and not on the age of the recipient, suggesting that growth 
velocity in time is regulated by a local mechanism intrinsic to the growth plate besides hormonal 
regulation in time (57). It is believed that the growth plate fuses when senescence reaches a 
critical point in the growth plate. Recent evidence indicates that senescence might occur because 
stem-like cells in the resting zone have a finite proliferative capacity, which is gradually exhausted 
(58;59).  Estrogen is thought to advance growth plate senescence, causing earlier proliferative 
exhaustion, and thus earlier fusion. This might explain that estrogen treatment does not induce 
fusion rapidly, but often must act for years before fusion occurs. In addition, the period of estrogen 
treatment required for growth plate fusion is longer in cases of precocious puberty and shorter in 
adults with a deficiency in aromatase than for normal individuals.
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SERMS
Estrogen is known to be a major regulator of longitudinal growth and growth plate fusion. A low 
estrogen concentration increases growth velocity, while a high concentration inhibits growth 
(60;61). A high dose of estrogen is used in the treatment of extremely tall girls to reduce adult 
height. However, it not only affects longitudinal growth but has also potential side-effects like an 
increased risk for breast and uterus cancer and decreased fertility (62). These side effects can 
partially be circumvented by the use of selective estrogen receptor modulators (SERMs), that 
display both pro- and anti-estrogenic activity in a tissue-specific manner (63). 
One of the best-studied SERMs is raloxifen, which prevents postmenopausal bone loss but has 
minimal effects on breast and uterus tissue (64). In rabbits it induces growth plate fusion without 
influencing uterus weight (65). Tamoxifen, a SERM widely used in the treatment of breast cancer 
appears to act as a estrogen antagonist at the growth plate in the treatment of progressive 
precocious puberty in McCune-Albright patients (66;67). A more detailed understanding of 
estrogen action and interactions on tissues is needed to enable the use of SERMs in the modulation 
of longitudinal growth.
Intracrinology
The major source of sex steroids acting on the growth plate is the gonads, which secrete sex 
steroids into the circulation in a classical endocrine fashion. In addition to this endocrine route, 
estrogen can also be produced locally. This phenomenon is seen with many other hormones as 
well and is called intracrinology. Sex steroids can be formed from various precursors by locally 
expressed enzymes in many tissues like adipose tissue, bone, breast tissue or brain (68;69). Oz et 
al showed aromatase expression in the human growth plate which was confirmed together with 
17β-estradiol production in rat costochondral chondrocytes (70;71).
A few years later more of these converting enzymes, i.e. 17β-hydroxysteroid dehydrogenase, steroid 
sulfatase and type I 5α-reductase, were detected in the surroundings of the growth plate at time 
of sexual maturation, suggesting that bone cells possess the capacity to metabolize sex steroids 
necessary for skeletal growth (72). Van der Eerden et al showed that various enzymes involved in 
sex steroid metabolism are upregulated with puberty in the rat growth plate, suggesting a role for 
these enzymes and the steroids they produce during pubertal growth (73).
Catch-up growth
Following a period of growth inhibition, height velocity usually exceeds the normal range. This 
phenomenon is termed catch-up growth, and was first described by Prader et al. (74). Tanner 
proposed the hypothesis that catch-up growth is regulated by a neuroendocrine system that 
compares the individual’s actual body size to the target size of the individual. This target size 
is described as the ‘time tally’ most likely localized in the brain.  The growth rate is adjusted 
according to the degree of mismatch (75). More recent studies however suggest that catch-up 
growth is due to intrinsic factors of the growth plate like delayed growth plate senescence (58;76). 
Growth-inhibiting conditions slow growth plate chondrocyte proliferation, thus conserving the 
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proliferative capacity of the chondrocytes and consequently decreasing senescence of the growth 
plate. When growth inhibition conditions are abolished these chondrocytes are less senescent 
and retain a greater proliferative capacity resulting in a higher growth rate than expected for age, 
thus in catch-up growth (77). The relationship between catch-up growth and delayed growth 
plate senescence has only been studied in rabbits and rats so far (77;78). In catch-up growth after 
food restriction animal studies showed that HIF-1alpha protein and mRNA are upregulated in the 
growth plate together with IGF-1R and GHR protein levels (79;80). Recently Pando et al. reported 
an additional possible mechanism in nutritional catch-up growth involving microRNAs in the 
growth plate of rats.
Puberty and epiphyseal fusion
Puberty is a complex biologic process involving sexual development, adrenal maturation, 
gametogenesis and increase in growth velocity known as pubertal growth spurt which accounts 
for 15-20% of final height (81). The secretion of gonadotropin-releasing hormone by the 
hypothalamus represents the first step, initiating release of the gonadotropins (LH and FSH) 
that in turn stimulates the gonads to secrete sex steroids (estrogen and testosterone). Increase 
in sex steroids level induces the external signs of puberty (secondary sex characteristics) and the 
accompanying pubertal growth spurt. Estrogen mediates pubertal bone growth in both males and 
females. Along with an increase in estrogen also GH secretion increases 1.5 to 3-fold in puberty 
together with IGF-I levels (82). Peak levels of circulating GH coincide with Tanner stage B3-4 in 
girls and at Tanner stage G4 in boys (83). Estrogen levels and GH concentration show a positive 
correlation through puberty in females, demonstrating the relationship in their actions (84). 
In addition, estrogen has also a direct stimulatory effect on the growth plate chondrocytes, as 
demonstrated in Laron patients with GH resistance that still undergo a pubertal growth spurt 
(85). Furthermore, estrogen receptor beta and GPR30 expression is downregulated in the human 
growth plate during pubertal progression (32;35). Estrogen stimulates differentiation of the 
chondrocyte rather than proliferation (86) resulting in growth plate maturation and eventually 
growth plate fusion with cartilage being replaced by bone. Although the exact role of the estrogen 
receptor beta is still unclear, from mice experiments a crucial role in growth plate fusion was 
hypothesized (87). However, the male patient with an estrogen receptor alpha mutation had 
incomplete epiphyseal closure and a history of continued linear growth into adulthood, suggesting 
a role for estrogen receptor alpha in growth plate fusion. This patient was still able to produce 
a 46-kDa isoform of the estrogen receptor alpha which is shown to suppress estrogen receptor 
activation (88;89). Chagin et al speculated that this isoform might as well suppress the estrogen 
receptor beta and this might be the cause of delay of growth plate fusion in this patient (90). 
The final step in epiphyseal fusion is not completely understood up to now. In endochondral 
ossification, a nowadays generally accepted hypothesis is that terminally hypertrophic 
chondrocytes die by the process of apoptosis leaving behind a scaffold of cartilage matrix for 
osteoblasts that invade and lay down bone resulting in growth plate fusion (91-93). More recent 
studies have questioned that apoptosis is the final mechanism through which chondrocytes die in 
the terminal hypertrophic zone, since terminal hypertrophic chondrocytes do not display a typical 
apoptotic appearance (94-96). Apoptotic cells undergo typical morphological changes like cell 
shrinkage with intact organelles and integrity of membranes, pyknotic nuclei by aggregation of 
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chromatin, fragmented DNA, partitioning of the cytoplasm and nucleus into membrane bound-
vesicles (apoptotic bodies) and absence of an inflammatory response (94;97-99). Roach et al 
reported autophagic vacuoles in terminal hypertrophic cells suggesting a role for autophagy 
in the final step of endochondral ossification (94;97;98;100). A third and oldest hypothesis is 
that terminal hypertrophic chondrocytes can transdifferentiate into osteoblasts (101-103). The 
mechanism by which terminal hypertrophic chondrocytes disappear at the chondro-osseus 
junction is believed to be related to the underlying cause of growth plate fusion.
Cell cycle regulators
The process of longitudinal bone growth requires precise regulation of chondrocyte proliferation 
which is regulated by intracellular and extracellular mechanisms. Extracellular mechanisms 
involve for example hormonal systems as described in the sections above. An important 
intracellular mechanism is the cell cycle which is controlled by orderly activation and inactivation 
of cyclin-dependent kinases (CDKs) and cyclin-dependent kinase inhibitors (CKIs). Cyclin-
dependent kinases control specific points of the cell cycle (104). Activation of the CDKs promotes 
progression of the cell cycle eventually resulting in cell division. CKIs can bind and inactivate these 
CDKs, thereby maintaining growth arrest. In mammals, two known families of CKIs have been 
identified, INK4 and the Cip/Kip family. The Cip/Kip family consists of p21Cip1 (p21), p27Kip1 
(p27), and p57Kip2 (p57) which can inhibit all G1/S-phase cyclin-CDK complexes and which are 
all expressed in the growth plate (105-109). Cip/Kip inhibitors appear to mediate the growth 
inhibiting and differentiation effects of different stimuli. For example a recent study suggests that 
the effects of PTHrP on both the rate and extent of chondrocyte proliferation are mediated through 
suppression of p57 expression (110). In addition, p27 expression is up-regulated during thyroid 
hormone-induced terminal differentiation of rat resting zone chondrocytes (111). Little is known 
about the exact role of cell cycle regulators in the regulation of skeletal growth.
Growth plate models and species differences
Studies on growth plate regulation and epiphyseal fusion are hampered by the fact that frequently 
used in vivo and in vitro animal models poorly represent the human situation. Mouse and rat for 
example do not fuse their growth plates at the end of puberty like humans (32;33). This indicates 
that rodents are not perfectly representative for studies on growth plate fusion, excluding the use 
of transgenic approaches. This is furthermore illustrated by the discrepancy in growth phenotype 
between ERa knock out mice and a male patient lacking functional ERa receptors (39;112). The 
patient did not fuse his growth plates and continued growing into adulthood. Gene ablation of the 
estrogen receptors in mice had only a marginal effect on longitudinal growth, which only became 
apparent in part of the long bones late in life. Other animal models occasionally used for studies 
on growth plate regulation are rabbits and piglets, however these are relatively expensive and 
few molecular biological tools are available for interventions. In vitro human models like primary 
cultures of human chondrocytes or chondrosarcomatous cells are limited in its representation of 
the in vivo situation and have other impairments like a rapid dedifferentiation in primary cultures, 
a high variability between donors and loss of differentiation capacity. A promising relatively new 
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human in vitro model is a model with Mesenchymal stem cells (MSCs). MSCs are multipotent cells 
with the ability to differentiate into several mesenchymal lineages including chondrocytes. They 
can differentiate from stem cells to proliferating chondrocytes to subsequently hypertrophic 
chondrocytes, in a similar fashion as observed in the human growth plate (113;114). MSCs were 
originally isolated from bone marrow (115), but they have also been isolated from other tissue 
sources such as fetal organs, placenta, umbilical blood and adipose tissue (113;116;117). The lack 
of representative animal models to study processes occurring in the human growth plate, has led 
to the realization that human based models are required to elucidate the molecular mechanisms 
involved in growth plate regulation and fusion.
Rationale and outline of this thesis
Estrogen is known to play an important role in longitudinal bone growth and growth plate 
maturation, but the mechanism by which estrogens exert their effect is not fully understood. In this 
thesis this role is further explored. Chapter 1 contains a general introduction to longitudinal bone 
growth and the regulation of the growth plate in respect to relevant topics further studied in this 
thesis. Estrogen can act through a genomic or a nongenomic pathway. Both pathways are explored 
in rats at the onset of maturation in chapter 2. Estrogen stimulates VEGF expression in uterus 
and bone, which is an important growth factor for chondrocyte differentiation and chondrocytes 
survival in the growth plate. In chapter 3 the effect of estrogen on VEGF expression in the growth 
plate was studied in the rat and human growth plate. Another effect of estrogen is that it accelerates 
growth plate senescence. Senescence is one of the postulated intrinsic mechanisms by which the 
growth plate matures and finally fuses. In chapter 4 we investigated senescence in relation to 
proliferation, by investigating a cell cycle inhibitor p27Kip1. In animal models, catch-up growth 
is suggested to be caused by delayed growth plate senescence. In chapter 5 this hypothesis was 
further tested in humans. 
With puberty estrogen levels increase, the growth plate matures and at the end growth ceases 
with epiphyseal fusion through mechanisms not yet completely understood.  In order to further 
explore growth plate maturation we subjected two growth plate tissues of the same patient, 
but with one year and one pubertal Tanner stage in between, to microarray analyses.  Gene 
expression patterns and transcription factor binding sides in relation to pubertal maturation 
were studied in a longitudinal study within this single patient in chapter 6. In addition, we 
collected extra prepubertal and pubertal growth plate tissues and studied these samples with 
microarray techniques as well in chapter 7. In chapter 8 the process of epiphyseal fusion and 
apoptosis was studied in human growth plates.
Animal models are frequently used but not fully representative for the human growth plate. 
Therefore we investigated a promising human in vitro model with multipotent mesenchymal 
stem cells (MSCs) that can differentiate into chondrocytes. MSCs can be isolated from various 
tissues. In chapter 9 we investigated the chondrogenic potential of MSCs from different origins 
and in chapter 10 we compared this model with the epiphyseal growth plate by analyzing gene 
expression patterns and pathways with micro-array analyses. Chapter 11 contains general 
conclusions and a discussion regarding the results.
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Abstract
Recently, both estrogen receptor (ER) α and β were detected in growth plate chondrocytes of rats 
before sexual maturation, implying a role for estrogen at this stage.
In this study, therefore, we investigated the effects of ovariectomy (OVX) or estrogen 
supplementation on parameters of longitudinal growth in 26-day-old rats, which were sexually 
immature at the start of the experiment. OVX caused an increase in body weight gain, tibial 
length and growth plate width due to an increased proliferating zone. This increase correlated 
with an increase in cell number, with a decrease in cell diameter and with increased proliferating 
cell nuclear antigen (PCNA) immunostaining compared with sham. Interestingly, the increase 
in proliferation was not caused by an increase in insulin-like growth factor-I (IGF-I) mRNA 
expression in the growth plate as assessed by real-time PCR. In contrast to OVX, 17β-estradiol 
(E2) supplementation (0.5 mg/21 days) of 26-day-old female rats caused a strong decrease in 
body weight gain, tibial length and growth plate width. The latter was explained by a reduction 
of the proliferating zone width, which correlated with a reduced number of PCNA-positive cells 
(not significant) and by a reduction of the hypertrophic zone width. In male rats supplemented 
with E2, similar effects were observed compared with the females. ER α and β immunostaining 
was found predominantly in late proliferating and early hypertrophic chondrocytes. OVX did not 
affect ER expression but E2 supplementation strongly decreased immunostaining for both ER α 
and β in both sexes. Besides E2, desoxyestrone (DE), an activator of nongenomic estrogen-like 
signaling (ANGEL) and 2-methoxyestradiol (2-MeO-E2), a tissue-selective naturally occurring 
metabolite of E2, were administered to female and male rats of the same age. Compared with 
E2, these compounds had less pronounced, though significant, effects on some parameters of 
longitudinal growth in both sexes, especially on growth plate characteristics. In conclusion, E2 
may exert effects on longitudinal growth before and at the onset of sexual maturation, despite 
very low endogenous serum levels at these stages. There may be a role for nongenomic signaling 
in body weight gain, tibial length and growth plate width but genomic signaling prevails.
Introduction
Recent findings in three male patients, one with an inactivating mutation in the estrogen receptor 
α (ERα) and β (ER β) and two with an aromatase p450 enzyme deficiency, have
established that estrogen modulates essential steps regarding growth during puberty, both in 
boys and girls (1-3). Estrogen can have both direct and indirect effects on the growth plate. It was 
shown that anti-estrogen lowers growth hormone (GH) secretion, while estrogen augments GH 
secretion, especially by increasing the secretory pulse mass (4-6). However, patients with Laron 
syndrome, who are resistant to GH due to a mutation in its receptor, do have a pubertal growth 
spurt, suggesting GH independent effects of estrogen as well (7). These effects may be mediated in 
the growth plate itself, since ER α and β have been demonstrated in growth plate chondrocytes of 
several species, including rabbit, rat and human (8-12).
In various mouse and rat models, effects of 17 β-estradiol (E2) on longitudinal growth have been 
described. These studies have, however, been mainly performed in animals that were sexually 
maturing or mature at the start of the experiment and are limited to a few reports. In 7-week-old 
sexually maturing female rats, ovariectomy (OVX) enhanced longitudinal growth rate (13). In 
contrast, high-dose E2 (4 mg/kg per day) strongly reduced tibial growth rate of 2-month-old 
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intact sexually mature male rats (14). In contrast to humans, rats do not fuse their growth plates 
at the end of sexual maturation, resulting in a continuation of longitudinal growth, albeit at a very 
low rate. At these stages, E2 still inhibited longitudinal growth as has been observed in 3-month-
old intact female rats (15).
Concomitant with longitudinal growth, growth plate thickness was increased after OVX, which 
was primarily explained by induced chondrocyte proliferation (13). Likewise, OVX enhanced 
proliferating cell nuclear antigen (PCNA) protein expression, a marker for cell proliferation, in 
growth plates from 14-week-old sexually immature rabbits (16). In the same study, serum IGF-I 
levels were elevated in the OVX animals compared with sham, suggesting an involvement of 
insulin-like growth factor-I (IGF-I) in the observed increase in chondrocyte proliferation (16). No 
studies had previously been performed in rats before and at the onset of sexual maturation.
Estrogen actions can be exerted through either a genomic (transcription activation) or a 
nongenomic pathway, which involves putative membrane-bound receptors and activation of 
the Src/Shc/ERK signal transduction route. Until now, it has been unclear to what extent the 
two pathways contribute to the regulation of longitudinal growth by E2. Furthermore, specific 
estrogen receptor modulators (SERMs) have been described which are known for their tissue 
selectivity. One of the best-studied SERMs is raloxifene, which prevents postmenopausal bone loss 
but has minor effects on other tissues, like breast and uterus (17). 
One example enabling distinction between genomic and nongenomic effects of estrogen is the 
synthetic compound desoxyestrone (DE), which has less than 1% binding affinity compared with 
E2 (18) and is believed to act exclusively through the nongenomic pathway. It has anti-apoptotic 
effects in cultured osteoblasts and osteocytes and is able to increase bone mineral density (BMD) 
and bone strength in both estrogenreplete and estrogen-deficient mice (19;20). 
Turner & Evans have recently described a naturally occurring metabolite of E2, 2-methoxyestradiol 
(2-MeOE2), which may well act as a SERM in rats. This compound strongly reduced growth plate 
thickness in 3-month-old intact female rats due to a reduced chondrocytes proliferation and 
hypertrophy but no effects were observed on various bone parameters, suggesting a tissue-
selective effect of 2-MeO-E2 (21). 
Recently, we demonstrated both ERs in tibial growth plates of female and male rats well before and 
during sexual maturation (1, 4 and 7 weeks of age), with no apparent regulation of expression by 
sexual maturation (12). Since endogenous levels of estrogen are very low before sexual maturation 
(22;23), we wondered whether the ERs in the growth plate are functional at this stage.
Furthermore, we wanted to know to what extent genomic and nongenomic actions of E2 might 
contribute to longitudinal growth. To achieve this, 26-day-old rats were either ovariectomized 
or intact female and male rats of the same age were supplemented with E2 (0.5 mg/21 days), DE 
or 2-MeO-E2 (both 5 mg/21 days). Three weeks later, halfway to sexual maturation, the effects 
on longitudinal growth were examined. Moreover, we investigated PCNA and ERα and β and the 
relative mRNA expression of IGF-I in the growth plate after OVX, using immunohistochemistry and 
real-time PCR respectively.




Female and male Wistar rats were obtained from Harlan (Broekman Instituut, Someren, The 
Netherlands). They were kept in a light- and temperature-controlled room (12 h light : 12 h 
darkness, 20–22 °C) with food and water available ad libitum. Experiments were approved by the 
local ethics committee for animal experiments.
Experiment 1
Twenty-four 26-day-old female Wistar rats were ovariectomized by the dorsal approach (n=11) 
or sham operated (n=13). During the experiment, body weight was measured weekly and after 
3 weeks the animals were killed using a fatal dose of pentobarbital sodium (Nembutal, Sanofi 
Sante Animale, Maassluis, Netherlands). Rats enter sexual maturation around day 30, and 
maturation takes about 4 weeks. This means that at the start of the experiment rats were still 
sexually immature, whereas at the end of the experiment they were halfway to sexual maturation. 
Approximately 50% of the animals from each experimental group (OVX: n=5; SHAM: n=6) were 
fixed in vivo (2% paraformaldehyde in 0.1 M phosphate buffer supplemented with 75 mM lysine 
monohydrochloride and 10 mM Na periodate) as described previously (24). Tibiae were isolated 
and fixed in the same fixative for 24 h. Next, they were decalcified in 15% EDTA, including 0.5% 
paraformaldehyde for 4 weeks and processed for paraffin embedding. Tibiae were cut in halves in 
a sagittal orientation, processed for paraffin embedding and 5 μm sections were cut mid-sagittally. 
From the other half (n=6), tibiae were collected and the growth plates were carefully excised, 
avoiding contamination with other cell types. The obtained growth plate material was frozen 
rapidly and stored at -80 °C until use. 
Experiment 2
Twenty-four female and 24 male 26-day-old Wistar rats were implanted with a slow-release 
pellet (Innovative Research of America, Saratosa, FL, USA) subcutaneously between the scapulae, 
releasing 0.5 mg of E2 (n=6), 5 mg of DE (n=6) or 5 mg of 2-MeO-E2 (n=6) over a 21-day period. A 
fourth group received a placebo pellet (n=6).
The doses of DE and 2-MeO-E2 were 10 times higher than that for E2, since they have a lower 
affinity for the receptor (18;25). During the experiment, body weight was measured weekly, and 
after 3 weeks the animals were killed using a fatal dose of pentobarbital sodium (Nembutal, Sanofi 
Sante Animale). All animals were fixed in vivo and tibiae were processed as mentioned in the first 
experiment.
Measurements
In both experiments, body weight gain (g), tibial bone length (cm), growth plate width (total, 
proliferating zone and hypertrophic zone: all in mm), ratio between proliferating and hypertrophic 
zone width (P/H ratio), the number of chondrocytes and cell diameter (μm) in each zone (except 
DE and 2-MeO-E2 treated animals), as well as wet weights of thymus (g) were determined. In 
the second experiment, uterus, testis and liver wet weight (g) were also measured. Values were 
expressed as means ± S.D.
PCNA and ER immunohistochemistry
The immunohistochemical protocol performed for both ERs has been published earlier (24). For 
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the detection of PCNA, growth plate sections were incubated in 10 mM citrate buffer (pH 6.0) at 
95 °C for 10 min followed by 30 min of cooling down. After blocking, sections were incubated 
overnight at 4 °C in 0.5% locking buffer with the mouse monoclonal PCNA antibody (Clone PC-01; 
Calbiochem, San Diego, CA, USA; 1:5000), the rabbit polyclonal ERα antibody (Clone MC-20: Santa 
Cruz Technologies, Santa Cruz, CA, USA; 1:50) or the goat polyclonal ERβ antibody (Clone Y-19; 
Santa Cruz; 1:50). After a number of secondary antibody steps, staining was visualized with AEC 
(0.2 mg/ml in acetate buffer pH 5.2 with 0.04% H2O2; Sigma) for 3 min. After counterstaining 
with hematoxylin, the sections were embedded in aquamount (BDH, Poole, Dorset, UK). Pictures 
of growth plate sections from rats in two consecutive experiments were taken with a Nikon DXM 
1200 digital camera using the same settings and the average number of positive cells in a fixed 
window was determined using Image-Pro-Plus software (Media Cybernetics Inc., Silver Springs, 
MD, USA). Next, mean values± S.D. were calculated and tested for significance (P<0.05) versus 
control groups, using the Student t-test. 
RNA isolation and cDNA synthesis
Total RNA was extracted from growth plate material according to Chomczynski & Sacchi (1987). 
Subsequently, RNA samples were treated with RNase-free DNase for 15 min at 37 °C to remove 
residual DNA contamination (Promega, Madison, WI, USA). The concentration of RNA was 
determined spectrophotometrically.
One microgram of RNA was denatured (10 min at 70 °C followed by 5 min on ice) and reverse 
transcribed in a 20 μl reaction containing first strand buffer (75 mM KCl, 3 mM MgCl2 and 50 mM 
Tris–HCl, pH 8.3), 5 mM DTT, 0.375 mM dNTPs, 200 ng of random hexanucleotides (all from Life 
Technologies, Breda, the Netherlands), 1 unit of RNasin (Promega) and 2.5 units of M-MLV reverse 
transcriptase (Life Technologies) at 37 °C for 60 min and denatured again at 70 °C for 10 min. A 
second addition of 1 unit of RNasin and 2.5 units of M-MLV reverse transcriptase was performed in 
each tube and the reaction was allowed to proceed at 37 °C for 30 min followed by inactivation of 
the enzymes by incubation at 70 °C for 10 min. Samples were diluted and stored until use at -20 °C.
Real-time PCR
Three microliters of cDNA were amplified in a total volume of 25 μl containing 1* buffer A, 3.5 mM 
MgCl2 (Applied Biosystems, Foster City, CA, USA), 0.2 mM dNTPs (Roche, Basel, Switzerland), 50 
pmol/ml of the forward and reverse primer (Eurogentec, Seraing, Belgium), 5 pmol/ml probe and 
5U/ml AmpliTaq Gold (Applied Biosystems). 
The probe sequences for the household gene, rat porphobilinogen deaminase (PBGD; 5’-CCA-
GCTGAC- TCT-TCC-GGG-TGC-CCA-C-3’) and rat IGF-I (5’-ACA-GGC-TAT-GGC-TCC-AGC-ATTCGG- 
A-3’) were labeled with the reporter dye FAM on the 5’ and with the quencher dye TAMRA on the 
3’ site. The primer sequences for rat PBGD were: forward (5’-ATG-TCC-GGT-AAC-GGC-GGC-3’) and 
reverse (5’-CAA-GGT-TTT-CAG-CAT-CGC-TAC-CA-3’); and for rat IGF-I: forward (5’-TCA-GTT-CGT-
GTGTGG- ACC-AAG-3’) and reverse (5’-TCA-CAGCTC- CGG-AAG-CAA-C-3’). The amplified products 
for PBGD and IGF-I were 135 and 117 bp long respectively.
For standardization, both PBGD and IGF-I primer sets were tested with different amounts of cDNA 
to determine the suitable amount of cDNA to be used in the quantitative analysis. The Taqman 
reaction included 40 thermal cycles consisting of 15 s at 95 °C and 1 min at 60 °C and was run 
on an ABI Prism 7700 Sequence Detector (Applied Biosystems). Finally, the Ct value (number 
of cycles to reach threshold value) was determined for all samples and mean values_S.D. were 
calculated for each experimental group.




We performed OVX in 26-day-old female rats and assessed several parameters concerning 
longitudinal growth 3 weeks later, which are summarized in Table 1.
At the start of the experiment, the rats were still sexually immature and 3 weeks later, they 
were halfway to sexual maturation. OVX caused significant increases in body weight gain (Fig. 
1). When examining longitudinal growth, both tibial length (Fig. 2A) and growth plate width 
(Fig. 2B) increased significantly compared with sham-operated rats. The wider growth plates 
in OVX animals were associated with an increased proliferating zone width, while the width 
of the hypertrophic zone was unaltered. The ratio between the width of the proliferating and 
the hypertrophic zone (P/H ratio) increased in the OVX animals (Table 1). The increase in the 
proliferating zone was associated with a significant increase in cell number with a decreased cell 
diameter compared with sham. Cell number and diameter were unchanged in the hypertrophic 
zone (Table 1). Representative HE-stained sections (Fig. 2C) from an OVX (b) and sham-operated 
(a) rat illustrate the results in Fig. 2B. To further address the increased proliferating zone width 
after OVX, PCNA immunohistochemistry and real-time PCR for IGF-I on cDNA from growth plate 
preparations were performed. Based on an analysis of two mid-sagittal growth plate sections from 
the sham (n=5) and OVX group (n=7), the number of PCNA-positive cells significantly increased 
after OVX compared with SHAM (Fig. 3A; 266_37 vs 181_49 cells; P=0.019). A representative 
picture of a PCNA-stained growth plate section of a sham-operated and an OVX rat is shown in 
Fig. 3B (a and b respectively). PCNA immunostaining was primarily found in the proliferating 
zone, although some positive cells were detected in the hypertrophic zone. Using real-time PCR 
on cDNAs from dissected growth plates (n=6), amounts of cDNA were adjusted for expression of 
the housekeeping gene PBGD. The difference between the expression levels of IGF-I and PBGD (Ct 
value) in each rat for the OVX versus SHAM rats did not reach significance (0.62_0.61 vs 0.36_0.79;
P=0.53), which was underscored by a near identical IGF-I expression level (OVX/SHAM ratio=0.83). 
Thymus wet weight of OVX rats was significantly increased compared with sham.
Estrogen supplementation experiment
As a mirror experiment, either E2 (0.5 mg/21 days), DE or 2-MeO-E2 (both 5 mg/21 days) was 
supplemented to 26-day-old female and male rats for 3 weeks (n=6). The effects of estrogen 
supplementation are summarized in Table 1. Compared with placebo rats, administration of E2 
via slow-release pellets caused a significant decrease in body weight gain in females and males 
(Fig. 1). Longitudinal growth was affected by E2, exemplified by a significant decrease in tibial 
length (Fig. 2A) and growth plate width (Fig. 2B) in both genders. In females, the reduced width 
of the growth plate was caused by a significant decrease of both the proliferating zone and the 
hypertrophic zone (Fig. 2B), with an unaltered P/H ratio compared with placebo. In males, 
however, the reduction of the hypertrophic zone width was more severe than of the proliferating 
zone, leading to significantly higher P/H ratio compared with controls (Table 1). In both sexes, 
the decrease in width of the proliferating and hypertrophic zone was associated with a significant 
decrease in cell number with unchanged cell diameter compared with placebo (Table 1). 
Representative HE-stained growth plate sections are shown in Fig. 2C (panels c–f). E2 tended to 
decrease the number of PCNA immunopositive cells in female (Fig. 3A; 40.8 vs 72.5 cells and Fig. 
3B: c and d) but not in male (Fig. 3A: 105.2 vs 88.0 cells and Fig. 3B: e and f) rats (n=6). In most 
of the growth plates studied, staining for PCNA seemed to be dominant in pre-hypertrophic and 
even hypertrophic chondrocytes, especially in the males (Fig. 3B: c–f). Due to large inter-animal 
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variation in expression levels, the results did not reach significance. Estrogen supplementation 
decreased thymus wet weight in females and males and increased uterus or decreased testis wet 
weight respectively. No effect was observed on liver wet weight (Table 1).
Supplementation of DE led to a number of significant effects (Table 1), albeit to a much lesser 
extent than E2. Body weight gain significantly decreased compared with placebo in both sexes 
(Fig. 1). Furthermore, in females there was a trend towards significance concerning decrease of 
tibial length (Fig. 2A). Despite an unaltered total growth plate width, the width of the proliferating 
zone was significantly reduced leading to a lower P/H ratio compared with placebo. In DE-
supplemented males, tibial length was significantly reduced (Fig. 2A), whereas at the level of the 
growth plate no changes were evident. When 2-MeO-E2 was supplemented, no effects were seen 
on body weight gain (Fig. 1) and tibia length (Fig. 2A) in females and males. However, at the level of
the growth plate, females had a significantly reduced proliferating zone width (Fig. 2B), leading 
to a reduced P/H ratio (Table 1), whereas in males the significantly reduced total growth plate 
width seemed to be associated primarily with a decreased width of the hypertrophic zone, which 
showed a trend towards significance (Fig. 2B). Due to the small changes in growth plate width, we 
did not determine the number of cells in the different zones in the DE and 2-MeO-E2 supplemented 
rats. DE and 2-MeO-E2 had no effect on thymus, uterus, testis or liver wet weight compared with 
placebo controls.
Figure 1
Effects of OVX and estrogen supplementation on body weight gain. Body weight gain was determined 3 weeks 
after OVX or E2, DE or 2-MeO-E2 supplementation of 26-day-old female and male rats. Values are given as 
means SD. *P<0.05 compared with sham; *P<0.05 and **P<0.001 compared with placebo.
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Figure 2 (page 38)
Effects of OVX and estrogen supplementation on tibia length and growth plate width. (A) Tibia length was 
measured 3 weeks after OVX or E2, DE or 2-MeO-E2 supplementation of 26-day-old female and male rats. 
(B) Total, proliferating zone and hypertrophic zone widths were determined 3 weeks after OVX or E2, DE or 
2-MeO-E2 supplementation of 26-day-old female and male rats. (C) Representative growth plate images of a 
sham-operated (a) and OVX rat (b) as well as female and male placebo controls (c and e respectively) and E2-
supplemented (d and f respectively) rats. The added lines in (a) indicate the borderlines between the growth 
plate and the epi- and metaphysis and the transition between proliferating and hypertrophic chondrocytes and 
were used to determine the width of the proliferating and hypertrophic zones. Bars represent 50 µm. Values 
are given as means_SD. *P<0.05 compared with sham; *P<0.05, **P<0.001 and † trend towards significance 
(P<0.1) compared with placebo.
Figure 3
Effects of OVX on PCNA staining in the growth plate. (A) After immunohistochemistry for PCNA, the number 
of positively stained chondrocytes was determined 3 weeks after OVX of 26-day-old female rats and in E2-
supplemented female and male rats by image analysis. Values are given as means_S.D. *P<0.05 compared with 
SHAM. (B) Representative growth plate images of a sham-operated (a), OVX rat (b), female placebo (c), female 
with E2 supplementation (d), male placebo (e) and male with E2 supplementation (f). Note the increased 
number of immunopositive nuclei in the growth plate of the OVX rat, predominantly in the proliferating zone 
(b) compared with sham (a). Bars represent 50 µm.
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Figure 4
Effects of OVX and E2 supplementation on ERα and β staining in the growth plate. Growth plate sections 
from the different animal groups were stained for ERα or β. Positive staining was predominantly found in 
late proliferating (P) and early hypertrophic (H) chondrocytes. No differences in staining intensity were seen 
between the female placebo (A), OVX (B) or male placebo (D). E2 reduced ERα and β staining in females 
(C) and males (E) in the growth plate, whereas it increased the expression in osteoblasts of the primary 
spongiosum (see arrows in C and E). Omission of the first antibody (F) resulted in absence of staining. S, stem 
cells. Bars represent 50 µm.
ERα and β expression in growth plates
Previously, we have demonstrated ER α and β protein expression in the growth plate of the rat 
(van der Eerden et al. 2002). To study whether the expression of the ERs is regulated by OVX 
or E2, supplementation immunohistochemistry was performed. Positive staining for ER α and 
β was predominantly detected in late proliferating and early hypertrophic chondrocytes. No 
differences in staining intensity were seen between the sham (data not shown), placebo (Fig. 4A 
and D) or OVX rats (Fig. 4B). In contrast, E2 supplementation caused a downregulation of ER α 
and β staining in growth plates of females and males (Fig. 4C and E respectively). In contrast, E2 
supplementation increased ERα and β staining in osteoblastic cells of the primary spongiosum 
(Fig. 4C and E). Negative controls, including pre-incubation with a corresponding peptide and 
omission of the first antibody (Fig. 4F), resulted in absence of staining. 
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Discussion
We recently found that in female and male rats before sexual maturation (1 and 4 weeks of age), 
both ER α and ER β were expressed in the tibial growth plate at the mRNA and protein level, 
implying that this tissue may be responsive to estrogens before sexual maturation (12). To assess 
this, we either ovariectomized or supplemented female and male rats with E2, DE or 2-MeO-E2 
at 26 days of age and analyzed several parameters of longitudinal growth and chondrocyte 
proliferation 3 weeks later. Rats usually enter sexual maturation around day 30, and maturation 
takes approximately 4 weeks, implying that rats were still sexually immature at the start of 
our experiments, while they were halfway to sexual maturation when the experiments were 
terminated. 
OVX of 26-day-old rats caused strong increments in body weight gain, tibia length and growth 
plate width over a 3-week period compared with sham. The increased growth plate width was 
explained by a widening of the proliferating zone, which was associated with an increased cell 
number as well as an increased number of PCNA immunopositive cells. In contrast to OVX, E2 
supplementation in female rats of the same age resulted in opposite effects: a dramatically 
reduced body weight gain, tibial length and growth plate width, the latter being caused by both a 
reduction in the proliferating zone and hypertrophic zone width. Concomitant with the reduced 
proliferating zone, E2 tended to decrease the number of PCNA positive chondrocytes as well, 
although this did not reach significance. In male rats, the parameters of longitudinal growth were 
similarly decreased compared with females. However, no reduction of PCNA-positive cells was 
observed. 
Turner and co-workers demonstrated increased longitudinal growth rates in ovariectomized 
7-week-old sexually maturing rats, whereas subsequent estrogen supplementation reversed this 
(13). The lowest effective dose of E2 was lower than in our study (1.5 vs 23 μg/day), but these rats 
were previously ovariectomized (13). Moreover, two reports in which intact 3-month-old female 
and 2-month-old sexually mature male rats received approximately 200 μg/day E2, demonstrated 
a substantial decrease in longitudinal growth (14;15). Our data extend previous data, claiming 
that as well as in sexually maturing or mature rats, E2 also inhibits longitudinal growth before 
and at the onset of sexual maturation. OVX of 26-day-old rats results in enhanced parameters of 
longitudinal growth, despite very low endogenous estrogen levels, suggesting that even in this 
period, E2 may have an inhibitory effect on growth. 
The change in tibial length after OVX or E2 supplementation coincided with changes in growth 
plate width. Estrogen removal in females caused an increase in proliferating zone width and 
therefore total growth plate width, whereas estrogen supplementation reduced the width of both 
the proliferating and hypertrophic zone in both genders. Moreover, the increased width of the 
proliferating zone after OVX paralleled the increased PCNA staining, whereas E2  supplementation 
did not significantly alter the number of immunopositive cells in the growth plate. In males, the 
immunostaining in the hypertrophic zone was quite high, especially in the E2- treated rats, which 
contributed to an absence of an effect of E2 on PCNA staining compared with placebo. In the 
E2-supplementation experiment, and to a lesser extent in the OVX experiment, PCNA-positive 
nuclei were abundantly observed in the pre- and hypertrophic zone. In a study by Aizawa and co-
workers, the same phenomenon has been described in rabbit growth plates (26). It appears that 
subtle changes in the fixation procedure as well as the fact that chondrocytes have a long G1 phase 
in relation to the S, G2 and M phase contribute to the relatively high number of PCNA-positive 
hypertrophic chondrocytes (26). In addition, we speculate that E2 may have a sexually dimorphic 
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effect on the cell cycle G1 phase duration in chondrocytes (27;28). The inhibitory effect of E2 on 
chondrocyte proliferation is well established. It has been shown that thymidine uptake is reduced 
following E2 administration in sexually maturing rats and PCNA staining is increased after OVX 
in sexually immature rabbits (13;16). In the latter study, besides increased PCNA staining, serum 
IGF-I levels were increased, suggesting that the proliferating effect of OVX was caused in part 
by serum IGF-I (16). In our study, we did not determine serum levels of IGF-I, since a dramatic 
decrease of total serum IGF-I did not affect body weight and longitudinal growth in liver-specific 
IGF-I knockout mice (29).  Instead, local effects of IGF-I seemed more important for longitudinal 
bone growth. Therefore, we quantified the amount of IGF-I mRNA in preparations from tibial 
growth plates using real-time PCR. We found no difference in relative IGF-I mRNA levels between 
OVX and sham. This suggests that the effects of E2 status on chondrocyte proliferation cannot be 
explained by influencing local IGF-I expression. However, we cannot exclude changes in expression 
levels of other members of the IGF family (IGF-II, IGF-I and II receptors and IGF binding proteins) 
in the growth plate caused by E2. Removal of E2 has no effect on the width of the hypertrophic 
zone, whereas E2 administration reduces both proliferating and hypertrophic zone widths. The 
reduced width of the hypertrophic zone may be a direct effect of E2 itself but it may also be 
secondary to an effect on chondrocyte proliferation. It was reported that estrogen reduces matrix 
synthesis, which has been shown to contribute to an age-related decline in longitudinal growth 
(30). This may be in line with our study, since OVX decreased the cell diameter in the proliferating 
zone, despite an increase in its width, indicating that matrix synthesis is downregulated when 
estrogen is deficient. In contrast, it has been shown that E2 stimulates 35S uptake by chondrocytes, 
implying increased chondrocyte differentiation (31;32). An explanation for a reduced width of 
the hypertrophic zone could be that estrogen causes the rate of apoptosis or vascular invasion to 
exceed the rate of cartilage matrix synthesis (21). We recently demonstrated that ER expression 
levels were relatively unaffected by endogenous estrogen levels (12). In this study, we found that 
OVX did not affect ER α or ER β expression. However, treatment with a medium dose of E2 caused 
a reduction in the expression levels of both receptors in male and female rats. From these findings, 
one may conclude that a substantial rise in endogenous estrogen levels is apparently required to 
elicit alterations in receptor expression in the rat growth plate. Interestingly, the raised E2 levels 
increased receptor expression in osteoblasts of the primary spongiosum. This suggests that E2 
can either down- or upregulate the expression of its own receptor, depending on the cell type.
From our data we cannot exclude effects of E2 on the somatotropic axis. It has been shown that 
estrogen augments GH secretion, especially by increasing the secretory
pulse mass (4;6). In addition, anti-estrogens lower the basal GH secretion (5). However, direct 
effects are also likely to occur since the P/H ratio increases strongly following OVX, whereas in 
dwarf rats (dw/dw), which have reduced GH levels to 5% of normal, the P/H ratio is similar to 
that in normal rats and this ratio is not affected by subsequent GH treatment (33). These results 
suggest that E2 inhibits longitudinal bone growth most likely by direct effects on chondrocyte 
proliferation and differentiation in female and male rats before sexual maturation. Since E2 
removal causes such dramatic effects on longitudinal growth, it seems evident that despite its 
low endogenous levels, E2 may play an important role in controlling longitudinal growth in these 
animals at this stage.
In analogy with E2 supplementation, we have used the synthetic compound DE, which, based on 
its lower binding affinity compared with E2, was administered at a
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dose 10 times higher than E2 (5 mg/21 days) (18). Despite the fact that supplementation of 
DE after OVX would result in more pronounced effects, we chose intact rats, since this mimics 
better the situation when it would be used clinically. DE was recently recognized as an activator 
of nongenomic estrogen-like signaling (ANGEL) and exhibits anti-apoptotic effects on osteoblasts 
and osteocytes in vitro (19). Moreover, DE increases BMD and bone strength in both estrogen-
replete and estrogen-deficient mice (20).
Although to a lesser extent than E2, DE decreased body weight gain in both sexes, tibial length 
(trend towards significance in females) and growth plate width (not significant in males). In 
addition, females had a decreased proliferating zone width combined with a reduced P/H ratio. 
However, despite a 10 times higher dose for DE compared with E2, no effects were found on wet 
weights of thymus, uterus and testis, whereas E2 severely affected these organs. This suggests that 
in the classical estrogen target tissues genomic effects are most important, whereas in bone and 
cartilage genomic and nongenomic pathways mediate the effect of estrogen. These results imply a 
role for genomic and nongenomic signaling in the regulation of body weight gain, tibia length and 
growth plate width, although genomic signaling prevails. 
In addition to DE, 2-MeO-E2 was administered at a similar dose used for DE, since this naturally 
occurring metabolite of E2 has a very low binding affinity compared with E2 (25). Our 2-MeO-E2 
supplementation experiment was comparable to that by Turner & Evans (21) using intact rats, 
but there were some differences. The rats in our study were sexually immature at the start of the 
experiment, whereas the female rats used by Turner & Evans were sexually mature (3 months). 
Moreover, we used slow-release pellets with a relatively low dose (230 μg/day), establishing 
relatively constant levels during the experiment, while Turner administered 2-MeO-E2 orally (20 
mg/day), not knowing precisely what amount the gastro-intestinal tract absorbs. Furthermore 
Turner & Evans demonstrated dramatically reduced longitudinal bone growth and growth plate 
width in the 3-month-old sexually mature intact female rats. Interestingly, no effects were found 
on radial bone growth and cancellous bone turnover or on uterus wet weight (21). Our results 
were less pronounced but a significant growth plate width reduction was observed in male rats, 
which was primarily explained by a reduction of the hypertrophic zone width (trend towards 
significance). Growth plate width in females did not alter but the proliferating zone width was 
significantly reduced and, subsequently, the P/H ratio. We found no effects of 2-MeO-E2 on body 
weight gain, tibial length and wet weights of thymus, uterus/testis or liver. From these results, we 
may conclude that, although not as pronounced as in an earlier study, effects of 2-MeO-E2 seem to 
be limited to the regulation of growth plate parameters only, suggesting that it might be used as a 
SERM in the future.
In conclusion, E2 may exert effects on longitudinal growth before and at the onset of sexual 
maturation, despite very low serum levels at these stages. There may be a role for nongenomic 
signaling in body weight gain, tibial length and growth plate width, explaining some of the effects 
on longitudinal growth, but genomic signaling prevails. DE administration in ovariectomized rats 
should provide more evidence on the relative contribution of genomic and nongenomic signaling 
in longitudinal growth.
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Abstract 
Longitudinal bone growth is regulated in the growth plate. At the end of puberty, growth velocity 
diminishes and eventually ceases with fusion of the growth plate through mechanisms not yet 
completely understood. Vascular Endothelial Growth Factor (VEGF) has an important role in 
angiogenesis, but also in chondrocyte differentiation, survival and the final stages of endochondral 
ossification. Estrogen has been shown to up-regulate VEGF expression in the uterus and bone of 
rats. In this study we investigated the relation between estrogen and VEGF production in growth 
plate chondrocytes both in vivo and in vitro. The expression of VEGF protein was down-regulated 
upon ovariectomy and restored upon estradiol supplementation in rat growth plates. In cultured 
rat chondrocyte cell line RCJ3.1C5.18 estradiol dose-dependently stimulated 121 kDa and 189 
kDa isoforms of VEGF but not the 164 kDa isoform. Finally, VEGF expression was observed at 
both protein and mRNA level in human growth plate specimens. The protein level increased 
during pubertal development supporting a link between estrogens and local VEGF production in 
the growth plate. We conclude that estrogens regulate VEGF expression in the epiphyseal growth 
plate although the precise role of VEGF in estrogen-mediated growth plate fusion remains to be 
clarified.
Introduction
Longitudinal growth occurs at the epiphyseal plate, a thin layer of cartilage entrapped between 
epiphyseal and metaphyseal bone, at the distal ends of the long bones (1). In the growth plate, 
immature cells lie toward the epiphysis, called the resting zone, with flat more mature chondrocytes 
in the proliferating zone and large chondrocytes in the hypertrophic zone adjacent to this. At the 
end of puberty longitudinal growth ceases with total replacement of avascular cartilage by highly 
vascularized bone eventually resulting in epiphyseal fusion. Estrogen is known to be an important 
hormone in the regulation of growth plate maturation and epiphyseal fusion; it regulates and can 
accelerate the programmed senescence of the growth plate, leading to proliferative exhaustion of 
chondrocytes and epiphyseal fusion (2;3). At a low concentration, estrogen is known to increase 
growth velocity, an effect possibly mediated through the GH-IGF-1 axis, while at a high concentration 
estrogen inhibits growth and promotes epiphyseal fusion in the long bones (4-6). 
A critical step in endochondral ossification is when blood vessels enter from the primary 
spongiosum and osteoblasts invade from the bone marrow to lay down trabecular bone (7;8). 
Vascular Endothelial Growth Factor (VEGF) is a potent mediator of angiogenesis but has also 
been shown to modulate chondrocyte differentiation and survival, osteoblast differentiation and 
osteoclasts recruitment (9-11). VEGF is expressed by growth plate chondrocytes and osteoblasts 
in different species including the human (12-15). Human VEGF is present in 6 different proteins, 
VEGF-A, -B, -C, -D, -E and -F, where VEGF-A has been shown to be expressed in the growth plate 
and also believed to be most important in the regulation of longitudinal bone growth. VEGFA 
has six alternatively spliced isoforms: VEGF121, VEGF145, VEGF165, VEGF183, VEGF189, and 
VEGF206 (16). The receptors involved in VEGF-A signalling are VEGFR-1 (also fms-like tyrosine 
kinase receptor 1) and VEGFR-2 (also kinase insert domain-containing receptor, KDR) with almost 
all responses being mediated through the second receptor which has also been detected at the 
chondro-osseous junction in the mouse growth plate (11;14;17).   Inactivating VEGF in mice and 
monkeys resulted in impaired trabecular bone formation and expansion of the hypertrophic 
zone indicating inhibition of cartilage resorption (14;18). In addition, Vegfa conditional knockout 
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mice driven by a col2a1 promotor showed delayed invasion of blood vessels into the primary 
ossification center and delayed removal of terminal hypertrophic chondrocytes together with 
massive cell death in chondrocytes throughout the growth plate demonstrating the importance 
of VEGFA for chondrocyte survival (9).  In vitro VEGF expression can be up-regulated by factors 
known to be important in the regulation of longitudinal bone growth like FGF, TGF-beta and IGF-
1 (13). Rat studies showed that in uterus and bone tissue, VEGF expression is upregulated by 
estrogen (19;20). In humans, bone growth and estrogen levels increase in parallel during earlier 
phases of puberty while at the end of puberty growth ceases with a total replacement of cartilage 
by bone resulting in fusion of the growth plate. 
We hypothesized that estrogens have the capacity to stimulate local VEGF production in growth plate 
chondrocytes and that this could be a possible mechanism involved in the process of growth plate 
maturation and fusion in humans. To address this, we performed in vivo studies in ovariectomized 
rats supplemented with estradiol and also in vitro studies in cultured rat chondrocytes exposed to 
estradiol and assessed chondrocyte specific expression of VEGF. In addition, we measured VEGF 
expression in growth plate specimens obtained from humans in different pubertal stages.
Material and Methods
Animals and study protocol
Female Sprague-Dawley rats were purchased from Scanbur BK AB (Sollentuna, Sweden). The 
animals were housed in a temperature- and humidity-controlled room with a 6:00 a.m. to 6:00 p.m. 
light cycle and allowed a soy-free diet containing 0.7% of calcium and 0.5% of phosphorus (R70; 
Lactamin AB, Kimstad, Sweden) and tap water ad libitum. All procedures were approved by the 
ethics committee at Göteborg University and conformed to the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals. The animals were randomly divided into three groups: 
sham operation + vehicle treatment (sham, n = 12), OVX + vehicle treatment (OVX, n = 10) and OVX 
+ 17β-estradiol treatment (E2, n = 11). At 12 weeks of age (body weight, 251 ± 2 g), the rats were 
either sham-operated or OVX under isoflurane anesthesia (Baxter Medical AB, Kista, Sweden), and 
small silastic implants were placed subcutaneously in the cervical region. The silastic implants 
were prepared as previously described, releasing 2.5 μg/day of E2 (21). Vehicle-treated animals 
received an empty implant. 17β-estradiol was obtained from Sigma Chemical. After 6 weeks of 
treatment, the animals were killed by excision of the heart under isoflurane anesthesia, and the 
right proximal tibia was fixed in 4% paraformaldehyde, decalcified, and embedded in paraffin. 
Uterus size, correlating with estrogen levels, was smaller in the ovariectomized rats and slightly 
larger in the estrogen-supplemented animals compared to sham indicating supra-physiological 
levels of estrogen in the estrogen treated group. Study details were previously described (22;23).
Patients and tissue preparation
Human proximal and distal femur growth plate tissues were collected from 12 girls at different 
pubertal stages who were undergoing surgery for different medical indications (Table 1). One 
fetal sample was collected from a female donor of 23 weeks gestational age. The study protocol 
was approved by the Local Medical Ethics Committees of the Leiden University Center, Leiden, 
the Netherlands and the Karolinska University Hospital, Stockholm, Sweden. Informed consent 
was obtained from all patients and their parents. Epiphyseal samples were either directly frozen 
in liquid isopentane and stored at –80ºC or fixed in 10% formalin, decalcified and embedded in 
paraffin. All tissue samples were processed in the same way.
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Immunohistochemistry
All tissues were cut in 5 um sections and mounted on histological glass slides (Superfrost plus), 
dried at 37°C overnight and heated at 60°C for 1 hour before immunohistochemical treatment. 
Immunohistochemistry was performed as previously described (24) with the modification that 
antigen retrieval was achieved by incubating with 0.1% trypsin (Invitrogen) for 10 minutes at 
37°C. Anti-VEGF antibody was obtained from Santa Cruz Inc. (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA) and used in a 1:200 dilution for rat tissues and 1:50 dilution for human tissues. 
Secondary anti-rabbit biotinilated antibody (Jackson Immunoresearch lab, West Grove, PA, USA) 
was used in a 1:1000 dilution, followed by incubation with avidin-biotin Vectastain ABC reagent 
according to manufactures instructions (Vector laboratories, Burlingame, California, USA). Digital 
images were collected employing a Nicon Eclipse E800 microscope equipped with an Olympus 
DP70 digital camera. 
Image analysis
Images of the central two thirds of the rat growth plates were captured in three visual fields. All 
pictures were taken in a 200X magnification with a 2040x1536 resolution and further analyzed 
in Image Pro Plus 5.0® software. Pictures were converted into grey scale-8 mode and inverted 
in order to obtain correct optical density (OD) values in immuno-positive areas. An automatic 
bright objects counting was performed to identify the number of immuno-positive objects above 
the defined thresholds. Threshold level for cell size was defined as objects with an area over 12 
μm2 and 20 μm2 in the proliferative and hypertrophic zone respectively. The total optical density 
of the immuno-positive objects was calculated automatically, a function referred as Density sum in 
the Image Pro Plus software. The analyzed areas were measured in mm2 and results are expressed 
as number of positive cells/mm2, protein expression (OD arbitrary unit)/mm2 and protein 
expression (OD arbitrary unit)/per cell. Data are presented as mean +/- SEM.
RNA isolation
Bone was removed from all epiphyseal samples and 40 μm thick sections were cut with a cryostat. 
Every fifth section was followed by a 5 μm thick section which was studied with Haematoxylin 
staining to ensure lack of bone contamination. Total RNA isolation was performed with an 
optimized method for RNA extraction from cartilage as described by Heinrichs et al. (25) except 
that the protocol was started by homogenizing the sections in 1 ml guanidine thiocyanate solution. 
RNA samples from bladder and prostate tissue was obtained from Gentaur molecular products 
(Gentaur molecular products, Brussel, Belgium). RNA extraction was followed by purification with 
a RNeasy kit according to the manufacturers protocol (Qiagen) and quality and integrity of each 
sample were checked with the Agilent 2100 Bioanalyzer. 
Real-Time RT-PCR (qPCR)
RNA was reverse transcribed into cDNA using a First Strand cDNA Synthesis kit for qPCR (Roche 
Diagnostics Gmbh, Mannheim, Germany) according to the manufacturer’s instructions. Expression 
of VEGFA and VEGFR-2 (KDR) mRNA was quantified by real-time PCR using the Bio-Rad iCycler 
with SYBR Green. QuantiTect Primer Assays were purchased from Qiagen (Qiagen Benelux B.V., 
Venlo, the Netherlands) and used according to the manufacturer’s protocol. Threshold cycles were 
estimated and averaged for the triplicates. Relative amounts of mRNA were normalized to β2-
microglobulin expression in the same sample to account for variability in the initial concentration 
and quality of total RNA and in the efficiency of the reverse transcription reaction.
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Western Blotting
Nontransformed clonal rat chondrogenic cells RCJ3.1C5.18 (C5.18 cells) were differentiated for 10 
days (26) and subsequently treated 24 hours with a dose-range of 17β-estradiol. Cells were lysated 
and the protein concentration was measured by the Bradford protein assay (Bio-Rad Laboratories 
AB, Sundbyberg, Sweden). Proteins were separated on acrylamide gels (Bio-Rad Laboratories) 
and transferred to PVDF membrane. Three different isoforms of VEGFA were detected employing 
anti-VEGF rabbit Ab (1:1500; sc-152, Santa Cruz Biotechnology Inc., Santa Cruz, CA).  Secondary 
goat anti-rabbit antibody was peroxidase labelled and used in a 1:10000 dilution (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA). The resulting bands were confirmed by comparing the size 
of the protein in the cell extract with known molecular weight markers. The antigen-antibody 
complexes were then detected by chemiluminescence. After films had been developed, blots were 
stained with Coomassie Blue to ensure equal loading of total protein. Density measurements were 
normalized per density of Coomassie blue staining (27). Each experiment was repeated at least 
three times.
Statistics 
The human sections were blinded and a relative staining intensity was scored (score 0 to 3) for the 
proliferative and hypertrophic zone of each growth plate. Scores were displayed in a scatterplot 
and a linear regression analyses was performed to calculate significance. The same was done for 
the qPCR results.
For the rat data, 6 growth plate sections for every animal were analysed by Image analysis 
protocol described above and means were calculated in terms of VEGF positive cells/um2 and 
VEGF expression (OD arbitrary unit)/per cell for each animal. Significance was calculated by one 
way ANOVA followed by Fisher’s protected least significance difference test.
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Results
VEGF protein expression in the rat growth plate
Sham-operated rats were used as an internal control confirming abundant VEGF expression in 
the growth plates,  both in the proliferative and hypertrophic zone (figure 1A). Pre-incubation 
of the primary antibody with recombinant VEGF abolished the staining in both proliferative and 
hypertrophic chondrocytes (figure 1C). Staining was analysed by a computerized method for the 
proliferative and hypertrophic zone (see Methods section).
To reveal any possible regulation of VEGF expression by estrogens we analyzed the number of 
VEGF-expressing chondrocytes in rats upon ovariectomy and 17β-estradiol supplementation. 
Ovariectomy resulted in a significant decrease in the number of VEGF positive cells in the 
proliferative zone (1173±93 vs. 1556±100 cells/mm2 in sham-operated animals; p<0.01), an 
effect completely restored by 17β-estradiol replacement (1713±81 vs. 1173±93 cells/mm2 in 
vehicle alone; p<0.001; figure 2A). A similar trend was observed in hypertrophic chondrocytes, 
albeit not statistically significant (figure 2C). The level of VEGF per cell (expressed as OD arbitrary 
units/cell) did not differ significantly between the groups in the proliferative zone (figure 2B). 
However, in the hypertrophic zone ovariectomy resulted in a significant decrease in the level of 
VEGF per cell  (35747±1989 vs. 43240±1900 in sham-operated animals; p<0.01), an effect which 
was not restored by estradiol supplementation (36601±1615 vs. 35747±1989 in vehicle alone; 
p=0.74; figure 2D). 
VEGFA isoform expression in cultured chondrocytes
In order to distinguish between direct and systemic effects of estrogen on VEGF expression we 
performed experiments in the rat chondrogenic cell line RCJ3.1C5.18 (C5.18 cells) which can be 
differentiated into hypertrophic chondrocytes (26). The cells were differentiated for 10 days and 
then treated with 17β-estradiol for 24 hours. Estradiol dose-dependently stimulated expression 
of VEGF-121 and VEGF-189 while VEGF-164 expression was not affected (figure 3). VEGF-189 was 
suppressed by low estradiol concentrations and increased by high concentrations. 
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Figure 1. VEGF immunohistochemistry staining.
VEGF protein expression was detected in the rat growth plate (panel A, 100x magnification) 
and the human pubertal growth plate (panel B, 100x magnification). Panel Ai and Bi show 5x 
enlargements of the proliferative zone in panel A and B. Panel Aii and Bii show 5x enlargements of 
the hypertrophic zone in panel A and B. Pre-incubation of the primary antibody with recombinant 
VEGF abolished the staining in both proliferative and hypertrophic chondrocytes (panel C, 400x). 
Panel D shows a negative control for the human growth plates. Bars indicate 100 µm.
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Figure 2. Quantification of VEGF staining in the proliferative and hypertrophic zone.
VEGF staining was quantified with a computerized method for the proliferative zone. Panel a. shows 
a significant decrease in the amount of positive cells/mm2 growth plate after ovariectomy which was 
completely restored by 17β-estradiol. Staining intensity per cells (OD arbitrary unit/cell), showed 
no difference between all groups (panel b.). The hypertrophic zone shows the same trend as the 
proliferative zone, there were however no statistically significant differences (panel c.). Staining 
intensity per cells (OD arbitrary unit/cell) showed a significant decrease after ovariectomy in the 
hypertrophic zone, but no restoration with estrogen supplementation (panel d.).  Data are presented 
as mean ±SEM. *p<0.05, ** p< 0.01, *** p< 0.001.
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Figure 3. VEGFA isoform Western blot analysis in chondrocyte culture 
Panel a illustrates that 17β-estradiol directly stimulated expression of isoforms VEGF 189, 
VEGF 164, and VEGF 121. The isoforms VEGF-121 and VEGF-189 showed a very strong 
response, VEGF-164 in contrast just a marginal response. In panel b, the expression levels are 
calculated as a percentage of the VEGF expression in non-treated control.
a.
b.
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VEGF protein and mRNA expressions in human growth plates
Growth plate biopsies were obtained from girls at different stages of pubertal development. To 
verify how VEGF is distributed in the human pubertal growth plate, we analyzed VEGF expression 
levels in these rare tissue samples. Out of 13 collected growth plates we analyzed 6 human 
growth plates for VEGF protein expression and 9 for VEGF mRNA expression (see table 1). In 
all these human growth plates VEGF protein was detected in both proliferative and hypertrophic 
zone chondrocytes (figure 1B). When the relative staining intensity was scored (score 0 to 3), 
a significant increase in VEGF expression with progression of puberty was found in both the 
proliferative (p=0.022) and hypertrophic zone (p=0.017) (figure 4 panel a and b). Negative 
controls showed no staining (data not shown). 
Studies of mRNA levels with qPCR confirmed VEGF expression in pubertal as well as fetal human 
growth plates albeit expression of VEGF mRNA in the prepubertal growth plate was approximately 
200 fold lower compared to the expression in prostate and bladder tissue (positive controls). The 
threshold cycles for VEGF expression were subtracted from the β2-microglobulin threshold cycles 
in order to calculate the delta Ct (ΔCt). Average values for the different groups were calculated 
and compared to the prepubertal growth plate. The fetal growth plate showed a 4.2 fold higher 
expression of VEGF compared to the prepubertal growth plate. The pubertal growth plate samples 
(n=6) showed on average a 1.6-fold higher expression of VEGF mRNA compared to the prepubertal 
growth plate (n=2) but in contrast to VEGF protein expression, we did not find a significant 
correlation between VEGF mRNA levels assessed by qPCR and the stage of pubertal development 
(p=0.183, R=0.238). The VEGF receptor, VEGFR-2, was also expressed at mRNA level in all our 
growth plate samples analyzed. Similarly to VEGF, the average VEGFR-2 mRNA level was 1.6-
fold higher in pubertal girls (n=6) compared to prepubertal (n=2), but there was no statistically 
significant correlation with pubertal progression (p=0.585, R=0.045) likely due to high variation 
between samples and low number of patients. 
Patient Diagnosis Bone age (yr) Puberty Experiment
1 leg length difference distal femur 9 B1-2 IHC
2 hip luxations, femur head resection proximal femur 12 B2 qPCR, IHC
3 leg length difference distal femur 12 B2 IHC
4 leg length difference distal femur 14 B2-3 IHC
5 hip luxations, femur head resection proximal femur 13 B3 qPCR, IHC
6 cerebral palsy, femur head resection
proximal 
femur 15 B4 IHC
7 osteosarcoma in tibia distal femur 8 B1 qPCR
8 Upper limb amputation of the leg distal femur 9 B1 qPCR
9 tall stature distal femur  10 B2 qPCR
10 tall stature distal femur 12 B3 qPCR
11 tall stature distal femur 15 B4 qPCR
12 hip luxations, femur head resection proximal femur 14 B4 qPCR
13 fetal, selective abortion distal femur 23 weeks Fetal qPCR
Table 1. Patients information and human tissues
Table showing diagnosis of each patient, location of growth plate, age given in years, Tanner pubertal breast stage (B1-
B5) and experiment in which growth plate sample is used (IHC and/or qPCR). IHC indicates immunohistochemistry. 
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Figure 4. Scatterplot of VEGF expression in the human growth plate
Relative intensity of VEGF protein expression was scored for each growth plate and 
plotted in relation to the pubertal stage for the proliferative zone (panel a.) and the 
hypertrophic zone (panel b.). R square values were respectively 0.766 (p= 0.022) for 
the proliferative zone and 0.794 (p= 0.017) for the hypertrophic zone.
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Discussion
Our in vivo and in vitro data demonstrate that estradiol directly stimulates the expression of 
VEGF in rat growth plate chondrocytes. Furthermore, we confirmed that VEGF is expressed in the 
human pubertal growth plate and that the VEGF protein level increases with pubertal progression 
supporting a link between estrogens and local VEGF production in the growth plate. 
VEGF was previously detected mostly in hypertrophic chondrocytes of human growth plate samples 
by immunohistochemistry (15). We observed VEGF expression not only in the hypertrophic 
zone, but also in the proliferative zone, which is in line with the observations of Horner et al who 
studied VEGF protein expression in neonatal human growth plate cartilage (Horner 1999 J. Anat). 
VEGF mRNA was also detected in the proliferative zone of murine growth plate cartilage (Cramer 
and Pfander 2004). VEGF expression in proliferating chondrocytes and the significant change 
in expression with alternating estrogen levels were observed in both human and rat growth 
plates in our study. This slight divergence in results could be due to technical issues attributed to 
immunohistochemistry such as antigen retrieval or type of antibody.
We confirmed our immunohistochemistry data by Q-PCR analysis. mRNA expression of VEGF 
and the VEGFR-2 receptor was, to our knowledge for the first time, detected in adolescent and 
pubertal human growth plates. VEGF mRNA was previously detected in the fetal growth plate by 
others (Petersen 2002 and Garcia-Ramirez 2000). Expression of VEGFR-2 was earlier detected 
at the chondro-osseous junction in mice (14), in epiphyseal cartilage of pigs (28), in the avian 
growth plate (29) and in hypertrophic chondrocytes of the fetal growth plate (30). In contrast to 
protein levels, mRNA did not reveal a significant increase in VEGF expression with progression 
of puberty. This discrepancy in results could be due to a difference between mRNA and protein 
expression, a difference in tissue preparation for RNA extraction when the surrounding bone was 
removed or alternatively due to a change in morphological organization of the growth plate during 
progression of puberty (e.g a decreased hypertrophic layer).
This is the first report demonstrating a link between estrogens and VEGF expression in the 
epiphyseal growth plate. In vivo treatment of rats with 17β-estradiol increased the number 
of growth plate chondrocytes expressing VEGF. In line with this, in the hypertrophic zone of 
ovariectomized animals the number of VEGF positive cells/mm2 growth plate was decreased. In 
addition, in vitro data in a rat chondrocytic cell line showed a dose-dependent stimulatory effect 
of estradiol on the expression of VEGF-121 isoform. VEGF-189 was suppressed by low estradiol 
concentrations and stimulated by higher concentrations. This might counterbalance the slight 
concomitant increase of VEGF 121 thereby protecting the growth plate when exposed to low 
concentrations of estradiol. Our growth plate findings are in line with previous reported effects of 
estrogens on VEGF expression in bone, uterus and breast cancer tissues (20;31;32). 
Systemic estrogen levels increase with puberty eventually resulting in epiphyseal fusion by the end 
of puberty (33), presumably due to acceleration of growth plate senescence through proliferative 
exhaustion of chondrocytes (3). From our results obtained in the rat we hypothesized that estrogen 
not only accelerates senescence of the growth plate, but also stimulates chondrocytes to secrete 
VEGF which might contribute to the process of epiphyseal fusion. VEGF protein was detected in 
human pubertal growth plates and indeed, the expression level significantly increased during 
pubertal progression. This observation in humans supports our findings in rats and strengthens 
our hypothesis that estrogens stimulate VEGF expression in the growth plate.
A 200 fold lower VEGF mRNA level in the growth plate was observed compared to the prostate 
or bladder tissues. We believe that observed stimulation of VEGF expression by estrogens in 
avascular growth plate chondrocytes can substantially affect the growth plate.  Indeed, VEGF 
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has an important role in chondrocyte differentiation, chondrocyte survival and endochondral 
ossification (9-11). Inhibition of VEGF showed in several studies dramatic effects on the growth 
plate, like expansion of the hypertrophic zone and delayed removal of terminal hypertrophic 
chondrocytes (9;14). Conversely, one might speculate that an increase in expression leads to a 
smaller hypertrophic zone, a more rapid removal of terminal hypertrophic chondrocytes and 
eventually epiphyseal fusion. Reports on an increase in VEGF expression has to our knowledge not 
been published before.
Estrogen levels were higher in the estrogen-supplemented rats compared to the sham-operated 
rats. Uterus size, correlating with estrogen levels, was small in ovariectomized rats compared 
to sham-operated animals and slightly larger in the estrogen-supplemented animals indicating 
supra-physiological levels of estrogen in the estrogen treated group (22;23). Serum levels of 
estradiol were not measured in patients from whom growth plate tissue samples were collected. 
However, serum levels of estradiol are well known to positively correlate with the stage of pubertal 
development (34). 
The collection of human samples is small and consists of a variability of disorders. However, 
human growth plate samples are extremely difficult to obtain. We believe that even though patients 
suffered from diverse disorders, the underlying mechanism of epiphyseal maturation and fusion 
will be the same for all growth plates. Eventually longitudinal growth stops in all patients, with only 
few exceptions, at the end of puberty. The human data are in line with both in vivo and in vitro rat 
data thereby strengthening our conclusion that estrogen stimulates VEGF expression in the growth 
plate. Estrogen levels were not analyzed in these patients and our assumption of different levels 
of estrogen exposure is based on the fact that tissue samples were obtained from girls in different 
pubertal stages.
In summary, we demonstrated that VEGF protein expression in the growth plate is elevated by 
estrogens in vivo in ovariectomized rats and in vitro in a rat chondrocytic cell line. Our findings 
are supported by human expression studies in girls in different pubertal stages. From this we 
conclude that estrogens stimulate VEGF expression in the growth plate although the exact role of 
VEGF in estrogen-mediated growth plate fusion remains to be clarified. 
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Abstract
p27/Kip1, a cyclin-dependent kinase inhibitor, negatively regulates proliferation of multiple cell 
types. The goal of this study was to assess the role of p27 in the spatial, temporal and conditional 
regulation of growth plate chondrocyte proliferation. p27 mRNA expression was detected by 
real-time RT-PCR in both proliferative/resting and hypertrophic zones of the mouse growth plate 
at levels approximately 2-fold lower than in the surrounding bone.  To determine whether this 
expression is physiologically important, we studied skeletal growth in 7-wk-old mice lacking a 
functional p27 gene.  In these mice, body length was modestly increased compared to wild-type 
littermates.  In the proximal tibiae, proliferation of growth plate chondrocytes was increased but 
tibial length was not significantly greater than controls.  p27 ablation had no measurable effect on 
growth plate morphology, including the number of proliferative or  hypertrophic chondrocytes, 
suggesting that p27 is not necessary for the cessation of proliferation and terminal differentiation 
of chondrocytes as they exit the proliferative zone. Treatment with dexamethasone in vivo 
inhibited longitudinal bone growth similarly in p27-deficient mice and controls indicating that 
p27 is not required for the inhibitory effects of glucocorticoid on growth plate function. p27-
deficient mice had increased width of the femoral diaphysis, suggesting that p27 acts normally to 
inhibit periosteal bone growth.  In conclusion, our findings suggest that p27 has modest inhibitory 
effects on growth plate chondrocyte proliferation but is not required for the spatial or temporal 
regulation of proliferation or the conditional regulation by glucocorticoid. 
Introduction
Longitudinal bone growth occurs at the growth plate, a thin layer of cartilage located between 
the epiphysis and the metaphysis, at the ends of the long bones. Bone elongation occurs by a 
process called endochondral ossification, in which chondrocytes undergo the sequential steps of 
proliferation, hypertrophic differentiation, and apoptosis. The chondrocytes and the surrounding 
cartilage matrix are then replaced by bone tissue. 
This process of longitudinal bone growth requires precise regulation of chondrocyte proliferation. 
First, chondrocyte proliferation is regulated spatially within the growth plate; the proliferation 
rate varies with distance along the long axis of the bone. In the resting and uppermost proliferative 
zone, proliferation is slow. Proliferation increases in the mid proliferative zone and then slows 
again in the lower proliferative zone and finally ceases in the hypertrophic zone (1). Second, 
chondrocyte proliferation varies temporally; the proliferation rate of chondrocytes declines 
with increasing age (2-5) causing longitudinal bone growth to slow and eventually stop. Third, 
chondrocyte proliferation is regulated conditionally, in response to conditions elsewhere in the 
body (1). Some of the extracellular signaling mechanisms that regulate proliferation are known. 
For example, spatial regulation involves parathyroid hormone-related protein (PTHrP) and 
Indian hedgehog (Ihh) and conditional regulation involves circulating IGF-1 and glucocorticoids 
(6, 7). However, the final portion of the pathway is not understood, that is, how the cell cycle of 
chondrocytes is modulated temporally, spatially, and conditionally.
One of the suggested mechanisms is through orderly activation and inactivation of cyclin-
dependent kinases and cyclin-dependent kinase inhibitors that control the cell cycle. Progression 
of the cell cycle is promoted by activation of cyclin-dependent kinases. Cyclin-dependent kinase 
inhibitors play important roles in maintaining growth arrest and cell differentiation by binding 
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and inactivating these cyclin-dependent kinases. In mammals two known families of cyclin-
dependent kinase inhibitors have been identified, INK4 and Cip/Kip. The Cip/Kip family includes 
p21, p27 and p57, which can act on most cyclin/cyclin-dependent kinase complexes and also on 
some kinases unrelated to cyclin-dependent kinases, essential for G1 progression and S1 entry 
(8). Different Cip/Kip inhibitors appear to mediate the growth-inhibiting effects of different 
stimuli. For example, p21 and p57 expression is increased in cells containing damaged DNA, and 
p21 expression is also increased in terminally differentiated cells (9). p27 expression, on the other 
hand, increases in response to extracellular anti-proliferative signals while proliferative signals 
repress p27 expression (10). Cells grown in the presence of antiproliferative factors, like cAMP or 
rapamycin, have elevated levels of p27 mRNA (11, 12).
Previous studies suggest that p27 may regulate growth plate chondrocyte proliferation 
and differentiation (13,14). p27 has been detected immunohistochemically in hypertrophic 
chondrocytes in fetal and early postnatal mice (15, 16). p27 has also been detected in cultured rat 
resting zone chondrocytes where its expression is upregulated during thyroid hormone-induced 
terminal differentiation (13). Targeted disruption of p27 in mice causes multiorgan hyperplasia 
and increased body weight with all tissues proportionally enlarged and containing more cells (14, 
17-19). Kiyokawa et al. (17) reported an increased size and width of tibiae and femora in p27-
deficient mice compared to wild-type mice. However, beyond this, little is known about the role of 
p27 in regulating skeletal growth. 
The current study was designed to explore the role of p27 in the spatial, temporal, and conditional 
regulation of growth plate chondrocyte proliferation. First, we measured p27 expression in the 
mouse growth plate using real time PCR. Second, we assessed growth plate structure, chondrocyte 
proliferation, longitudinal bone growth and cortical width in p27-deficient mice. Third, we 
determined whether p27 mediates the effects of a hormonal modulator of longitudinal bone 
growth by administering a glucocorticoid to p27-deficient mice.
Materials and Methods
Animals
Heterozygous p27+/- mice from a mixed C57BL/6J and 129 background were provided by Dr. Jack 
Pledger (H Lee Moffitt Cancer Center, University of South Florida College of Medicine, Tampa, 
USA). In these mice, originally generated by Matthew Fero and colleagues, the entire coding region 
for p27 has been replaced by a neomycin resistance cassette (10). The mice were bred in our 
animal facility to obtain p27-/- and p27+/+ mice. Mouse colonies were maintained in a pathogen 
free environment and fed standard rodent chow (Zeigler Bros, Gardners, PA) with water ad 
libitum. Animal care was in accordance with the Guide for the Care and Use of Laboratory Animals 
(National Research council (1996). The protocol was approved by the Animal Care and Use 
Committee, National Institutes of Child and Human Development, National Institutes of Health.
Mouse genotyping
At three weeks of age, 5 mm of the tail end was excised under local anaesthesia, and genomic 
DNA was extracted using the DNeasy Tissue Kit (Qiagen, Valencia, CA). Genotypes were analysed 
by the polymerase chain reaction (PCR). p27 deletions were confirmed by the presence of a 600 
bp fragment unique to the mutant genotype amplified with primer p27 KO1 (CCT TCT ATG GCC 
TTC TTG ACG) and primer P27 KO2 (TGG AAC CCT GTG CCA TCT CTA T) (sequences provided by 
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Matthew Fero, Fred Hutchinson Cancer Research Center, Seattle, Washington). The PCR reaction 
mixture (Invitrogen, Carlsbad, CA) contained 5% DMSO. PCR reactions were performed under the 
following conditions: 94 ˚C for 3 min, followed by 40 cycles of 94 ˚C for 1 min, 61 ˚C for 45 s and 72 
˚C for 45 s, and ending with primer extension at 72 ˚C for 5 min. Wild-type alleles were confirmed 
by the presence of a 190 base-pair fragment amplified with the primers p27 WT1 (GAT GGA CGC 
CAG ACA AGC) and p27 WT2 (CTC CTG CCA TTC GTA TCT GC) (Dr. Jack Pledger, H Lee Moffitt Cancer 
Center, University of South Florida College of Medicine, Tampa, USA., personal communication). 
The DNA was amplified with PCR conditions as follows: 94 ̊ C for 3 min, followed by 12 cycles of 94 
˚C for 20 s, 64 ˚C for 30 s (subtracting 0.5 ˚C every cycle) and 72 ˚C for 35 ˚C, followed by 25 cycles 
of 94 ˚C for 20 s, 58 ˚C for 30 s and 72 ˚C for 35 s, and ending with 72˚C for 2 min.
Animal procedures and tissue processing
To assess p27 expression in growth plate, five 5-wk-old wild-type C57BL/6J mice and two 5-wk-
old mice homozygous for p27 deletion were sacrificed by cervical dislocation. Proximal tibial 
growth plates were rapidly excised, embedded in OCT compound (Electron Microscopy Sciences, 
Hatfield, PA) and stored at –80 ºC for subsequent processing. 
To analyze the skeletal phenotype of p27 deficiency, mice were separated in 4 groups by their 
genotypes and sex: p27+/+ female (n = 9), p27+/+ male (n = 10), p27-/- female (n = 9), p27 -/- male (n 
= 10). At 7 weeks of age, mice were sacrificed by inhalation of carbon dioxide. 7 weeks was chosen 
because previous studies (17, 20) demonstrated a significant difference in weight between wild-
type and p27-deficient mice beginning at this age. Furthermore, at 7 weeks of age mouse growth 
plates are still active.  200 µl 5-Bromo-2’-deoxy-uridine (BrdU, 10 mg/ml, Sigma-Aldrich, St. 
Louis, MO) was administered i.p 7 h and 2 h before sacrifice. The animals were weighed, and body 
length (nose-base of tail and total length including tail) was determined (21). Heart, liver, spleen 
and kidney were excised and weighed. Tibiae and femora were excised, separated from adjacent 
muscle, and their lengths were measured using a digital vernier caliper.  The left femora were fixed 
overnight in 10% phosphate buffered formalin and preserved in 70% alcohol for microcomputed 
tomography.  The left tibiae were prepared for histological analysis by fixing overnight in 10% 
phosphate buffered formalin, decalcifying in 10% EDTA, and embedding in paraffin. 
To assess the effect of dexamethasone in the absence of p27, 3-wk-old mice were divided into a 
p27+/+ (7 males, 10 females) and a p27-/- group (6 males, 5 females). The animals were all injected 
subcutaneously with 20µg dexamethasone once a day, five times a week for four weeks. Body 
weight and body length was measured weekly. BrdU was administered as before. After sacrifice, 
tibiae and femora were excised and measured. Measurements were compared to non-treated 
controls.
Isolation and reverse transcription of RNA
Frozen longitudinal sections (40 µm) of proximal tibial growth plates from 5-week-old mice were 
mounted on Superfrost Plus slides (Histoserv, Germantown, MD). Slides were thawed 2 min, fixed 
in 70% ethanol and 95% ethanol, stained in eosin, washed in 100% ethanol and dehydrated in 
xylene (each step for 60 s, at room temperature). Standard precautions against RNases were 
employed. Using an inverted microscope and a scalpel, from each section, four different zones were 
separated: epiphyseal bone, resting plus proliferative zone, hypertrophic zone, and metaphyseal 
bone. The division between bone tissue and growth plate tissue was readily distinguished visually. 
To avoid cross-contamination between the resting/proliferative zone and the hypertrophic 
zone, the boundary segment of cartilage containing the lower proliferative zone and the upper 
hypertrophic zone was discarded. For each zone, approximately 16 sections from a single animal 
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were pooled prior to RNA isolation.  RNA isolation was performed as previously described 
except that we scaled down the procedure to use one fifth of each volume and omitted the final 
precipitation with LiCl (22). RNA concentration was assessed and integrity was confirmed using 
a Bioanalyzer 2100, RNA Pico Chips, and version A.02.12 of the Bio Sizing software according to 
manufacturers instructions (Agilent Biotechnologies, Inc., Palo Alto, CA). 
Reverse transcription was accomplished by mixing the entire RNA solution generated, 100 ng 
random hexamers , and 10 µmol deoxynucleoside triphosphate (dNTP) (Invitrogen).  The samples 
were denaturated for 5 min at 65 C then placed on ice. 4 µl of 5x First strand buffer (Invitrogen), 
0.1 M DTT (Invitrogen) and 40 U RNase out (Invitrogen) was added to the mixture followed by 
2 min incubation at 42 C. 200 U Superscript III Reverse transcriptase (Invitrogen) was added 
followed by a 10 min incubation at 25 C and a one hour of incubation at 50 C. Afterwards samples 
were heated at 70 C for 15 min to inactivate reverse transcriptase.
Real-time RT-PCR
Expression of p27 mRNA was quantified by real-time quantitative PCR using the ABI prism 7300 
Sequence Detection System (Applied Biosystems, Foster City, CA) with specific, FAM- labeled 
probes. The oligonucleotide primers and probes for p27 mRNA and 18S ribosomal RNA were 
supplied by Applied Biosystems; assays 4319413E and Mm00438168_m1, respectively. PCR 
reactions were performed with the cDNA solution, TaqMan Universal PCR Master Mix, p27 or 
18S primers and probes (Applied Biosystems, Foster City, CA) , according to the manufacturer’s 
instructions, using the following thermal cycling conditions: one cycle at 50 °C for 2 min and 95 °C 
for 10 min, followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C. Each sample, which represents 
a single region from a single animal, was assayed in triplicate. The efficiencies of the p27 and 18S 
PCR reactions were determined using serial dilutions of whole growth plate cDNA.
Quantitative Histology
Longitudinal 5 µm sections of the proximal tibial growth plate were obtained near the center of 
the formalin-fixed, decalcified bone, mounted on Superfrost Plus slides (Histoserv, Germantown, 
MD) and stained with Masson Trichrome. All histological measurements were performed in the 
central two-third of the growth plate sections. Height was measured at three points parallel to the 
chondrocyte columns, and results were averaged. The number of proliferative and hypertrophic 
cells was counted in 15 intact columns per growth plate, and counts were averaged. The terminal 
hypertrophic chondrocyte was defined as the cell in the last lacuna that was not invaded by 
metaphyseal blood vessels (5). Height of 10 lacunae per animal were measured and results were 
averaged. We only measured lacunae with a sharp boundary, which indicates that the lacunar wall 
is perpendicular to the plane of section and thus the section had been made near the center of the 
lacuna. 
BrdU labeling and detection
In tissues sections from animals injected with BrdU, labeled cells were visualized with a commercial 
kit (BrdU staining kit, Zymed, San Francisco, CA.), using the kit protocol except that the trypsin was 
diluted 1:6 with reagent 1B. Labeled and unlabeled cells were counted in 20 chondrocyte columns 
per animal in the central two-third of the growth plate sections and averaged. 
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Microcomputed tomography (micro-CT)
Excised and fixed femora from wild type and p27 knock out mice were scanned using a MicroCAT 
II scanner (Imtek, Inc., Knoxville, TN). Each femur was immobilized on the sample table using 
plastic foam. The scanning conditions were as follows: resolution 50 µm, voxel size 30 micron, 80 
kVp, 500 mA and 720 projections over 360 degrees. After scanning, 3-dimensional images of the 
whole femora were reconstructed and used to measure total length (most proximal to most distal 
point), shaft width (measured at mid-shaft), cortex width (measured at mid-shaft at 0, 90, 180 and 
270 degrees and averaged), bone volume and bone mineral density.
Statistics
Data were presented as mean ± SEM. 
For the real-time PCR data, triplicate threshold cycle values were averaged and then the relative 
amounts of p27 mRNA were normalized to an endogenous control, 18S ribosomal RNA, in the same 
sample to account for variability in the initial concentration and quality of total RNA and in the 
efficiency of the reverse transcription reaction.  This normalization was calculated as described 
by Pfaffl et al.(23).  To analyze differences between tissues, relative expression values were log 
transformed to achieve a normal distribution , and analyzed by ANOVA followed by Holm-Sidak 
comparisons between adjacent regions. 
Phenotypic comparisons between wild-type and p27-deficient groups were made by two-way 
ANOVA with sex and genotype as independent variables. One mouse was eliminated from the 
micro CT-data because of a fractured femur. For the dexamethasone administration experiment, 
comparisons between wild-type and p27-deficient mice were made using a Generalized Linear 
Model using 3 independent variables: genotype, sex, and treatment.
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Results
Expression of p27 mRNA in the growth plate and surrounding bone
In the wild-type mouse growth plate, p27 mRNA expression was assessed by real-time PCR. p27 
mRNA was detected in both resting/proliferative zone and in hypertrophic zone at similar levels. 
However the concentration of mRNA (normalized to 18S ribosomal RNA concentration in the 
same sample) in both regions of the growth plate was approximately 2-fold lower than in the 
surrounding bone ( Fig. 1). As a negative control we measured the expression of p27 mRNA in two 
p27-deficient mice. In both mice the p27 mRNA expression was undetectable in growth plate and 
surrounding bone tissue. To confirm the accuracy of the dissection, we analyzed mRNA expression 
for type X collagen and type I collagen. As expected, type X collagen was primarily expressed in the 
hypertrophic cartilage and type I collagen was primarily expressed in the bone (Fig. 1). 
Growth phenotype of p27-deficient mice 
Ablation of p27 in mice had a mild positive effect on body size measured at 7 weeks of age (Table 
1, ANOVA using sex and genotype as independent variables). p27-/- mice had an increased body 
weight compared to p27+/+ littermates. Weight of the spleen, heart, liver, and kidney were also 
significant increased in p27-/- mice.
Ablation of p27 increased the body length, suggesting greater longitudinal growth of the vertebrae, 
but did not significantly affect the length of the tibia or femur. Width of the femur mid-shaft was 
significantly increased in p27-/- compared to wild-type mice (Table 1). This increase in shaft width 
did not result in an increase in mid-shaft cortical thickness or in overall femoral bone density, 
measured by micro CT-scan. 
Growth plate morphology and proliferation in p27-deficient mice
p27 deficiency had no discernable effect on tibial growth plate morphology (Fig. 2). Total growth 
plate width, the number of proliferative and hypertrophic cells per intact column, and the height 
of the terminal hypertrophic cell did not differ significantly between p27-deficient and wild-type 
mice (Table 2). However growth plate chondrocyte proliferation, assessed by BrdU-labeling index, 
was greater in p27-deficient than in wild-type mice (Table 2). 
Dexamethasone-induced growth inhibition in p27-deficient mice
Treatment of 3-wk-old mice with dexamethasone for 4 weeks caused a significant decrease in total 
body weight, tibial length, and femoral length but not in body length when compared to untreated 
controls (Table 3). This decrease was observed in both wild-type and p27-deficient mice. The 
magnitude of this growth inhibition did not significantly differ with the genotype (P = NS for body 
weight, tibial length, and femoral length, and body length). Therefore dexamethasone appeared to 
have a similar effect on wild-type and p27-deficient mice.
75Regulators of growth plate maturation
4
Figure 1 
Relative mRNA expression (mean ± SEM) of type X collagen, type I collagen, and p27 in proximal tibial 
growth plate and surrounding bone of 5-wk-old mice. Using an inverted microscope and a scalpel, epiphyseal 
bone, resting plus proliferative zone, hypertrophic zone, and metaphyseal bone samples were isolated from 
longitudinal sections of proximal tibiae from 5 wild-type mice. For each zone of each animal, approximately 
16 sections were pooled prior to RNA isolation and reverse transcription. mRNA expression was measured 
by real-time PCR using oligonucleotide primers and TaqMan probes. All samples were run in triplicate. The 
mRNA content of each gene was normalized to 18S ribosomal RNA content in the same sample and, for ease 
of comparison, multiplied by 106. Statistical significance was assessed by ANOVA, followed by Holm-Sidak. P 
values shown are not corrected for multiple comparisons.
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Table 1. Body and organ size of wild-type and p27-deficient mice .
             Males              Females  Both sexes
          p27+/+           p27-/-           p27+/+           p27-/-  p27
-/- vs p27+/+ 
(ANOVA)  
   Mean  SEM    Mean   SEM    Mean   SEM   Mean   SEM P
weight (g) 22.3±  0.465 26.6±  1.087** 19.4±  0.504 21.8±  0.729* <0.001
spleen weight (g) 0.063±  0.004 0.102±  0.007** 0.066±  0.006 0.083 ±  0.007 <0.001
heart weight (g) 0.148±  0.01 0.191±  0.008** 0.133±  0.006 0.141 ±  0.009 0.005
liver weight (g) 1.3±  0.054 1.90±  0.12** 1.05±  0.049 1.29±  0.066* <0.001
kidney weight (g) 0.16±  0.007 0.226±  0.018** 0.126±  0.007 0.149 ±  0.008 <0.001
body length without tail (cm) 9.3 ±  0.1 9.6 ±  0.1 9.0 ±  0.1 9.4 ±  0.2* 0.003
body length with tail (cm) 16.6 ±  0.1 17.1 ±  0.1* 16.1 ±  0.1 16.3 ±  0.2 0.025
tibia length (mm) 17.38 ±  0.19 17.51 ±  0.1 16.82 ±  0.21 17.05 ±  0.11 NS
femur length (mm) 14.49 ±  0.14 14.42 ±  0.12 13.85 ±  0.19 14.07 ±  0.13 NS
femur shaft width (mm) 1.62±  0.03 1.84±  0.05** 1.63±  0.02 1.79±  0.05** <0.001
femur cortex width (mm) 0.226±  0.011 0.254±  0.015 0.247±  0.007 0.251 ±  0.007 NS
bone density/volume 26.26 ±  1.29 27.44 ±  1.3 21.21 ±  1.25 23.96 ±  1.16 NS
mean ± SEM
* , p <0.05
** , p<0.01
Figure 2 
Representative photomicrographs of proximal tibial growth plates of p27+/+ (A) and p27-/- (B) mice at 7 weeks 
of age.  Longitudinal 5 µm sections were obtained near the center of the formalin-fixed, decalcified bone and 
stained with Masson Trichrome. No differences were observed between the two genotypes.  e, epiphyseal 
bone; p, proliferative zone; h, hypertrophic zone; m, metaphyseal bone.
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Table 2. Growth plate characteristics of wild-type versus p27-deficient mice.
             Males             Females       Both sexes
           p27+/+             p27-/-            p27+/+             p27-/-  
 -/- vs+/+ 
(ANOVA)  
height growth plate 0.361 ±  0.01 0.371 ±  0.011 0.343 ± 0.007 0.343 ±  0.009 NS
proliferating cells/intact 
column 11.4 ±  0.5 11.7 ±  0.3 11.0 ±  0.3 11.3 ±  0.3 NS
hypertrophic cells/intact 
column 3.9 ±  0.2 3.6 ±  0.1 3.9 ±  0.1 3.8 ±  0.1 NS
height terminal 
hypertrophic cell 0.0222±  0.0005 0.0221± 0.0006 0.0215±  0.0006 0.0217±  0.0006 NS
# positive BrdU cells/
intact column 2.7 ±  0.1 3.6 ±  0.2** 2.5 ±  0.2 3.1 ±  0.2** 0.001
% positive BrdU cells/
intact column 24 ±  1 31 ±  2** 23 ±  2 28 ±  2** 0.002
mean ± SEM
** = p < 0.01
Table 3. Effect of dexamethasone treatment on body and bone growth in wild-type and p27-deficient mice
p27-/- p27+/+
              Males† %‡ Females† % ‡ P § Males†     % ‡       females† % ‡ P §
weight (g) -3.7 ± 0.6 -16.6 -2.7 ± 0.7 -13.9 < 0.001 -5.3 ± 1.3 -19.9 -3.5 ± 1.5 -15.6 < 0.001
body length 
without tail (cm) -0.08 ± 0.10 -1.1 0.04 ± 0.13 -1.09 NS -0.28 ± 0.16 -3.1 -0.23 ± 0.21 -2.1 NS
tibia length (mm) -1.1 ± 0.3 -6.2 -0.8 ± 0.2 -4.5 < 0.001 -1.1 ± 0.2 -6.5 -0.6 ± 0.4 -3.7 < 0.001
femur length (mm) -0.8 ± 0.2 -5.6 -0.5 ± 0.2 -3.3 < 0.001 -1.1 ± 0.2 -7.5 -0.7 ± 0.2 -4.9 < 0.001
† dexamethasone-treated minus untreated controls (mean ± SEM) 
‡ % change = 100* (dexamethasone-treated minus untreated controls)/untreated controls
§ dexamethasone-treated vs. untreated controls (males and females combined)
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Discussion
p27 mRNA was detected in the growth plates of 5-wk-old mice by real-time PCR. The p27 mRNA 
levels in growth plate were approximately two-fold lower than levels in the surrounding epiphyseal 
and metaphyseal bone tissue. 
The expression of p27 mRNA was not significantly greater in the hypertrophic zone than in the 
resting/proliferative zone. This finding does not support the hypothesis that upregulation of p27 
is involved in terminal differentiation of growth plate chondrocytes (13, 14, 24). Earlier studies 
using immunohistochemistry reported p27 expression primarily in hypertrophic chondrocytes 
of fetal mouse long bones. This divergence in results could be due to a difference between mRNA 
and protein expression, to developmental changes in p27 expression, or to the poor quantitative 
nature of immunohistochemistry (15, 16). The current study is the first to assess the expression 
of p27 in the growth plate using a quantitative method and the first to assess expression in the 
growth plate beyond the neonatal period.
In tissues from p27-/- mice, we did not detect p27 expression, which indicates that our real-time 
PCR assay was specific for p27 mRNA. The observed p27 expression in the growth plate is unlikely 
to be due to contamination from the surrounding bone because measurement of type I and type X 
collagen mRNA levels suggests that the microdissection was quite accurate. The surrounding bone 
tissue consists of several different cell types, and this study does not determine the level of p27 
expression in different bone cells.
To determine whether the p27 expression in the growth plate is physiologically important, we 
studied skeletal growth in p27-deficient mice. p27-deficient mice had a slightly greater body 
length than wild-type mice, presumably reflecting greater growth of the vertebrae. In long bones, 
p27 ablation was associated with a modestly increased rate of chondrocyte proliferation. The tibial 
and femoral lengths were not significantly different from those of wild-type littermates, suggesting 
that the increase in growth plate chondrocyte proliferation had begun shortly before 7 weeks of 
age, the time when the differences in body size are beginning to manifest (17, 20). Alternatively 
the lack of difference in bone length despite an increase in growth plate chondrocyte proliferation 
might reflect a decrease in matrix production rate or an increase in apoptosis of non-terminal 
chondrocytes. Taken together, our findings indicate that p27 has a mild inhibitory effect on the 
normal proliferation of proliferative zone chondrocytes. Kiyokawa et al also mentioned a positive 
effect of p27 ablation on bone length in mice although the actual bone length was not presented 
in that paper (17). The magnitude of the effect on skeletal growth in different studies may depend 
on  genetic background. Previous studies in other backgrounds (coisogenic 129S4 mice) show an 
approximately 30% greater weight in p27-deficient than wild-type mice (10, 14, 17) whereas we 
observed only a 19% (male) and 13% (female) difference at 7 weeks of age. Nonetheless, the small 
magnitude of the effect suggests that p27 is not necessary for the normal growth deceleration that 
occurs with age. The absence of skeletal growth deceleration would allow continued growth at 
fetal rates, which would be expected to have yielded a dramatic increase in bone length.
There was no discernable effect of p27 deficiency on growth plate morphology. In particular, 
the number of proliferative chondrocytes and the number of hypertrophic chondrocytes per 
column were unaffected. One previous study mentioned that the overall growth plate height was 
unaffected by p27 ablation but that the proliferative zone of p27-/- mice appeared larger in some 
sections. However, in that study, no supporting quantitative data were reported (14). The BrdU-
labeling index was increased in the proliferative zone of p27-/- compared to p27+/+ mice, whereas 
the number of chondrocytes in the proliferative zone was the same in p27-/- and p27+/+ mice. This 
difference may occur because the number of proliferative chondrocytes depends not only on the 
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number of cells being generated per column but also on how far down the column the cells undergo 
terminal differentiation into hypertrophic chondrocytes. Therefore, it is possible to have an effect 
on proliferation rate and not on number of proliferative chondrocytes.  Our findings indicate that 
p27 is not necessary for the cessation in proliferation and for the terminal differentiation that 
occurs near the boundary between the proliferative and hypertrophic zones. Thus, p27 is not 
critical for the spatial regulation of growth plate chondrocyte proliferation. 
We next hypothesized that p27 might mediate the growth-suppressing effects of glucocorticoids and 
thus play an important role in the conditional regulation of growth plate chondrocyte proliferation. 
The growth-inhibiting effects of glucocorticoids are the result of a decrease in proliferation and 
possibly an increase in apoptosis (25). The growth-inhibiting effects of glucocorticoids in other 
cell types may be mediated in part by p27 (26). Thus, p27-deficient murine embryonic fibroblasts 
are partially resistant to the growth-inhibitory effects of glucocorticoids (27). However in our 
experiment, dexamethasone administration slowed longitudinal bone growth in p27-deficient mice 
and wild-type mice to a similar extent. Thus, p27 does not appear to be necessary for the decreased 
proliferation of growth plate chondrocytes induced by excess glucocorticoid in mice. 
p27 affected not only the process of longitudinal bone growth but also radial growth of the 
diaphyseal cortex. p27-/- mice showed a greater diaphyseal width of the femur. This finding is 
consistent with a previous report (14). In contrast to the overall shaft width, we found that the 
cortical thickness (from endosteal to periosteal surface) was not increased. Similarly, overall 
femoral bone density, which is highly dependent on cortical thickness, was not affected by p27 
ablation. Taken together these data suggest that periosteal bone growth is increased in the absence 
of p27, but that endosteal resorption may also be increased, thus negating any effect on cortical 
thickness. The increase in diaphyseal width might be caused by increased mechanical load due to 
increased body weight or to a direct effect of p27 on periosteal growth. 
We choose to study the role of p27 in the regulation of longitudinal growth because of the suggestion 
from previous studies (13:14) that it may regulate growth plate chondrocyte proliferation and 
differentiation. Other cell cycle regulators may also be important in the regulation of longitudinal 
growth. For example, mice lacking p57 have altered cell proliferation and differentiation, leading 
to endochondral bone ossification defects with incomplete differentiation of hypertrophic 
chondrocytes (28). Also p21CIP1/WAF1 might play a role in skeletal growth since it is shown to be 
expressed in both the proliferative and hypertrophic zones in the growth plate of mice, rats and 
pigs (29, 30).
In conclusion, our findings suggest that p27 is expressed in the growth plate. p27 ablation modestly 
increases growth plate chondrocyte proliferation, the process of longitudinal bone growth, 
and periosteal bone growth. However, p27 does not appear to be required for the inhibition of 
chondrocyte proliferation that occurs during hypertrophic differentiation, with increasing age, 
or in response to glucocorticoid excess. Thus, our findings suggest that p27 negatively modulates 
growth plate chondrocyte proliferation, but it is not required for spatial, temporal, or conditional 
regulation of chondrocyte proliferation in the growth plate.
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After a period of growth inhibition, the linear growth rate usually exceeds the normal range. This 
phenomenon, known as catch-up growth, was first described more than 40 years ago by Prader 
et al (1). It has been observed in humans and other mammals, after a wide variety of growth-
inhibiting conditions, including malnutrition, Cushing syndrome, hypothyroidism, growth 
hormone deficiency, and many other systemic diseases (2).
Tanner proposed the hypothesis that catch-up growth is regulated by a central nervous system 
mechanism that compares the individual’s actual body size to an age-appropriate set point 
and then adjusts the growth rate accordingly (3). However, this hypothesis is not supported by 
observations that transient growth inhibition within a single growth plate is followed by local 
catch-up growth in rabbits (4). This local catch-up growth suggests a mechanism intrinsic to the 
growth plate. Evidence from animal studies suggests that catch-up growth is due, in large part, to 
a delay in growth plate senescence. Growth plate senescence refers to the normal, programmed 
changes that occur in the growth plate over time. With increasing age, there is a decrease in the 
linear growth rate, the chondrocyte proliferation rate, the height of the growth plate, and the 
number of cells in each growth plate zone (5). 
Animal studies suggest that growth plate senescence is not a function of time per se, but of cell 
proliferation (6). In particular, growth plate chondrocytes may have a finite proliferative capacity 
that is gradually exhausted, causing growth to slow and eventually to stop (6;7). Conditions 
that suppress growth plate chondrocyte proliferation conserve the proliferative capacity of the 
chondrocytes, thus slowing senescence. Consequently, after transient growth inhibition, growth 
plates retain a greater proliferative capacity, are less senescent, and, hence, show a greater growth 
rate than expected for age, resulting in catch-up growth. 
However, the relationship between catch-up growth and delayed growth plate senescence has 
only been studied in rabbits (6) and rats (8). Thus it is not known whether catch-up growth is 
caused by delayed growth plate senescence in humans. Testing this hypothesis in humans is more 
difficult because most of the known hallmarks of growth plate senescence require microscopic 
examination of the growth plate. In children, we are restricted to indirect measures of growth plate 
senescence, including bone age and linear growth rate. Bone age assesses the degree to which the 
embryonic cartilaginous skeleton has been transformed into the adult bony skeleton. Bone age 
has been used as a surrogate marker for growth plate senescence (9) on the basis of 2 lines of 
evidence. First, the determination of bone age is based partly on the thickness of the radiolucent 
bands between the epiphyses and metaphyses, and thus bone age depends in part on growth 
plate height, a structural marker of senescence (7). Second, bone age is inversely associated with 
the remaining linear growth potential. This association is the basis for most height prediction 
methods (10). Thus bone age is associated with a functional marker of senescence, the decline in 
growth potential of the growth plates. 
If catch-up growth in humans is indeed due to delayed growth plate senescence, and if bone age 
is a marker for growth plate senescence, then catch-up growth should be associated with delayed 
bone age. Abundant clinical data support this association. A delayed bone age is observed in 
essentially all conditions that impair growth, including nutritional, endocrine, rheumatologic, 
gastrointestinal, heart, lung, and kidney disease (11). Thus multiple conditions, which span the 
breadth of pediatric medicine, are all associated with growth inhibition, bone age delay, and, if the 
condition resolves, catch-up growth. This broad association supports the hypothesis that catch-up 
growth in humans is due, at least in part, to delayed growth plate senescence. 
Linear growth rate can also be used as a marker for growth plate senescence. With age, the linear 
growth rate declines dramatically. The human fetus grows at a rate of over 100 cm/y. By birth, 
the linear growth rate has decreased to 50 cm/y, and in later childhood to 5 cm/y. In humans, this 
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decline is briefly interrupted by the pubertal growth spurt, after which the growth rate declines 
to zero. Animal studies suggest that this decline in growth rate is due to a mechanism intrinsic to 
the growth plate (4). 
We propose that the linear growth rate in prepubertal children can be used to test the hypothesis 
that catch-up growth in children is due to delayed growth plate senescence. If catch-up growth is 
due solely to a delay in growth plate senescence, then the linear growth rate of a child experiencing 
catch-up growth should be equal to the growth rate of a normal younger child. Thus the growth 
curve during catch-up growth should represent a simple time shift of the normal growth curve of a 
younger child (Figure 1, A). A steeper curve would suggest that other (or additional) mechanisms 
besides delayed senescence are responsible for the catch-up growth. 
As a first test of this approach, we examined catch-up growth in children with celiac disease placed 
on a gluten free diet. We reanalyzed data from an earlier study (12) using a new mathematical 
approach designed to test our hypothesis. A total of 28 prepubertal children, consisting of 9 boys 
(chronological age [CA] 3.9 ± 3.0 years, bone age [BA] 3.6 ± 2.5 years, height standard deviation 
score SDS for CA 21.3 ± 1.1, BMI SDS 20.1 ± 1.0, mean ± SD) and 19 girls (CA 3.9 ± 3.4 yr, BA 3.2 ± 
2.7 yr, height SDS for CA 21.4 ± 1.0, BMI  SDS 20.7 ± 1.1), from the Netherlands with celiac disease 
were included in this study. The following inclusion criteria were used: (1) symptoms and small 
intestinal biopsy typical for celiac disease, (2) no signs of puberty, and (3) no other known diagnoses 
or treated diseases. Height was measured 0.5, 1, 2, 3, 6, 12, 18, 24, 30, 36, and 50 months after 
introduction of a gluten-free diet with standard equipment. The study was approved by the hospital 
ethical committees, and informed consent was obtained from parents and/or patients. 
The height at initiation of treatment was used to determine the baseline height age, defined as 
the age at which the median height for normal children was equal to the child’s baseline height. 
For each child we then calculated the baseline growth delay, defined as the chronological age at 
initiation of treatment minus the height age at initiation of treatment. The growth delay for each 
child was calculated only once, using the data from the baseline visit. For each subsequent data 
point, we calculated the adjusted age, defined as the chronological age at that visit minus the 
baseline growth delay. Use of the adjusted age rather than the chronological age allowed us to 
assess whether growth was normal for a younger child, that is, whether the child’s growth curve 
represented a simple time shift of the normal growth curve. We therefore calculated the child’s 
height SDS for adjusted age. A similar analysis was done using initial bone age instead of height 
age. Our hypothesis predicts that the height SDS for adjusted age would remain close to 0 SDS 
over time (Figure 1, B, dashed curve). An increasing SDS for adjusted age (Figure 1, B, solid curve) 
would indicate that the growth rate was increased even for adjusted age, which would not be 
consistent with the delayed senescence hypothesis.
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Figure 1 
Theoretical catch-up growth curves predicted by the delayed senescence hypothesis. A, The delayed 
senescence hypothesis predicts that the height curve during catch-up growth (dashed line) should represent 
simple time-shift of normal (50 percentile, solid line) height curve. B, Therefore the delayed senescence 
hypothesis also predicts that, during catch-up growth, height should remain normal for a younger child 
(based on initial height age). Consequently, the height SDS for adjusted age should remain close to 0 (curve b). 
If the height SDS for adjusted age increases over time, this would indicate that the child’s growth rate is rapid 
even for a younger child (curve a). Curve a would be inconsistent with the delayed senescence hypothesis.
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The height SDS for chronological age (Figure 2, A) at onset of gluten-free diet was 21.5, and in the 
following 36 months this value increased to 20.6 SDS,12 indicating that the linear growth rate was 
greater than normal for CA. Thus these children experienced catch-up growth.
However, height SDS for adjusted age on the basis of initial height age remained very close to 0 
SDS (Figure 2, B), and height SDS for adjusted age on the basis of initial bone age did the same 
(Figure 2, C), although with a wider 95% confidence interval (SEM 0.23-0.34) compared with the 
analysis with height age (SEM 0.02-0.19). Both analyses indicate that the growth rate was normal 
for a younger child based on initial height age and bone age. Specifically, at baseline, the height 
age was 0.7 ± 0.8 years less than the CA, and the BA was 0.7 ± 1.0 year (mean ± SD) less than the 
CA. Subsequently, the children grew at a rate that was normal for a child 0.7 years younger than 
chronological age. The larger SEM values for the analysis with BA probably reflect the subjective 
nature and lower precision of BA measurement compared with height measurement. Because 
linear growth and bone maturation reflect longitudinal bone growth at the growth plate, the data 
imply that growth plate function was appropriate for a younger child.
These findings are therefore consistent with the hypothesis that catch-up growth is due to 
delayed senescence of the growth plate. Indeed, if the height SDS for adjusted age had increased or 
decreased over time, it would have implied that mechanisms other than growth plate senescence 
were involved. Although the actual data match the predictions of the delayed senescence 
hypothesis well, they do not provide a definitive proof of the hypothesis; it is possible that the 
catch-up growth is due to a completely different mechanism that happens to produce a growth 
curve that is a time-shift of the normal curve. For example, the neuroendocrine hypothesis, that 
catch-up growth is regulated by a central nervous system mechanism, does not predict any specific 
growth pattern, and therefore the current findings neither support nor refute that hypothesis. It 
is also possible that a gluten-free diet does not fully reverse the growth inhibition, or compliance 
with a gluten-free diet was not fully accomplished, and thus the observed catch-up growth curve 
was artifactually dampened. 
Indeed, anecdotal observations of individual children have shown catch-up growth curves that 
appear too steep to be consistent with a delayed senescence mechanism alone (3;13). These 
observations suggest that an additional mechanism may contribute to human catch-up growth in 
some conditions, although it is possible that these individual cases might instead reflect individual 
confounding factors, for example, a pubertal growth spurt superimposed on catch-up growth.
We conclude that the pattern of catch-up growth during recovery from celiac disease is consistent 
with the hypothesis of delayed growth plate senescence. Analogous studies could be performed in 
children experiencing catch-up growth after other conditions. The delayed senescence hypothesis 
predicts that the time course of catch-up growth will vary dramatically with the age of the subjects 
studied. In infancy, the normal grow rate declines rapidly. Thus delayed growth plate senescence 
should produce a markedly increased growth rate in infants, and catch-up growth should occur 
over a brief time course. Conversely, in older children, the hypothesis predicts that catch-up growth 
should occur gradually, over years. Perhaps in the future, the resolution of noninvasive imaging 
methods will improve to the point where the histologic markers of growth plate senescence can 
be assessed in humans. Until then, we may have to extrapolate from animal studies, relying on 
bone age and linear growth rate to provide indirect tests of the delayed senescence hypothesis in 
children.
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Figure 2 
Height SDS for chronological age (A) and for adjusted age (B and C) after institution of a gluten-free diet for 
celiac disease. A, Before initiation of the gluten-free diet, the average height SDS for chronological age (CA) was 
negative, indicating short stature. On the gluten-free diet, the height SDS increased, indicating catch-up growth
B, Age was adjusted for height age (HA) at diagnosis. C, Age was adjusted for bone age (BA) at diagnosis. The 
upper and lower curves in each panel represent 95% confidence interval of the mean. In both B and C the 
height SDS for adjusted age remained close to 0, indicating that growth was normal for a younger child.
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Abstract
In late puberty, estrogen is responsible for the deceleration of growth by stimulating growth 
plate maturation. The mechanism of action is largely unknown. We obtained pubertal growth 
plate specimens of the same girl at Tanner stage B2 and B3, which allowed us to address this 
issue in more detail. Histological analysis showed that progression of puberty coincided with 
characteristic morphological changes associated with growth plate maturation, such as decreases 
in total growth plate height (p=0.002), height of the individual zones (p<0.001) and an increase 
in intercolumnar space (p<0.001). Microarray analysis identified 394 genes (72% upregulated, 
28% downregulated) changing with progression of puberty. Overall changes in gene expression 
were small (average 1.38-fold upregulated and 1.36-fold downregulated genes). The 394 genes 
mapped to 13 significantly changing pathways (p<0.05) in majority belonging to extracellular 
matrix, cell cycle and cell death, all related to growth plate maturation. We next scanned the 
upstream promoter regions of the 394 genes for the presence of evolutionarily conserved binding 
sites for transcription factors implemented in growth plate maturation such as Estrogen Receptor, 
Androgen Receptor, Elk1, Stat5b, CREBP and Runx2. High quality motif sites for Runx2 (87 genes), 
Elk1 (43 genes) and Stat5b (31 genes), but not estrogen receptor, were evolutionarily conserved, 
indicating their functional relevance across primates.
In conclusion, our data suggest a role for Runx2, Elk1 and Stat5b in growth plate maturation 
and provides suggestive evidence that the effect of estrogen on growth plate maturation is not 
mediated by activating genomic estrogen signalling in growth plate chondrocytes. 
Introduction
Longitudinal growth occurs at the epiphyseal growth plate, a thin layer of cartilage entrapped 
between epiphyseal and metaphyseal bone at the distal ends of the long bones. In the normal 
growth plate, immature cells are located towards the epiphysis, called the resting zone, with 
mature chondrocytes in the proliferating zone, which hypertrophy in the hypertrophic zone 
adjacent to this (1). At the beginning of puberty longitudinal growth rate first increases, but with 
progression of puberty, growth rate is decelerating due to growth plate maturation, and at the 
end of puberty the growth plate eventually disappears due to epiphyseal fusion.  The molecular 
mechanisms underlying these distinct phases of growth plate activity during puberty are largely 
unknown but a role for estrogen has been suggested (2;3).
Endocrinological observations suggest that at the beginning of puberty relatively low levels of 
estrogen initiate the growth spurt. With progression of puberty, estrogen levels further increase 
which drives growth plate maturation and finally growth plate fusion. The most compelling 
evidence for a role of estrogen is provided by clinical observations in a patient with an inactivating 
mutation in the estrogen receptor alpha and in patients with a mutation in the aromatase gene 
resulting in lack of estrogen. These patients did not experience a growth spurt, and lack growth 
plate maturation and fusion (4;5). Furthermore, from clinical observations it is known that high 
levels of estrogen inhibit longitudinal bone growth (6). 
The mechanism by which estrogens exert these effects on growth plate activity is not fully 
understood. It has been postulated that estrogen accelerates the senescent decline of the growth 
plate (7). Senescence is a term for the structural and functional changes over time in the growth 
plate, such as a gradual decline in the overall growth plate height, proliferative zone height, 
hypertrophic zone height, size of hypertrophic chondrocytes, proliferation rate and column 
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density (7). It is believed that the growth plate fuses when senescence reaches a critical point in 
the growth plate. Recent evidence indicates that senescence might occur because stem-like cells 
in the resting zone have a finite proliferative capacity, which is exhausted gradually. This process 
is accelerated by estrogen (8;9). 
Estrogen induces cell responses by activating the so-called genomic signaling pathway involving 
the nuclear estrogen receptor alpha (ERa) and beta (ERb) or of a non-genomic signaling pathway 
involving membrane bound receptors like GPR30 resulting in activation of adenylyl cyclase and 
MAPKs (10-13). ERa, ERb and GPR30 are all expressed in human growth plate chondrocytes 
(14;15). Their expression is not limited to the stem-like cells of the resting zone, which are the 
main target cells of estrogen action based on the senescence hypothesis, but is more broadly 
distributed in the growth plate. It is still largely unknown whether the pubertal phenomena in 
relation to growth rate are caused by direct effects of estrogen on chondrocytes or by indirect 
effects via, for example, activation of the Growth Hormone/IGF-I axis. 
During puberty both sex steroids, growth hormone (GH) and IGF-1 levels increase (16). It is well 
known that GH and IGF-1 can increase growth velocity as well as accelerate bone maturation 
measured by a decrease in growth plate height in children (17;18). Also receptors for GH and IGF-
1 are present on human chondrocytes (19), indicating that both hormones can have direct effects 
on the growth plate. Stimulation of the GH-receptor activates an intracellular signal transduction 
cascade eventually converging to the transcription factor Stat5b (20). Likewise, IGF-1 signalling 
results in the activation of signalling routes involving for example the transcription factor Elk1 
(21). The exact contributions of these hormones in growth plate maturation and epiphyseal fusion 
still need to be clarified.
Alternatively, estrogen may regulate, either directly or indirectly, the expression of paracrine 
regulators of growth plate activity such as Parathyroid hormone-related peptide (PTHrP) and 
Indian hedgehog (Ihh). These secreted growth factors coordinate endochondral ossification by 
regulating chondrocyte proliferation and differentiation as well as osteoblast differentiation 
(22;23). PTHrP signals, amongst others, via activation of the cyclic AMP response element binding 
protein (24). Both factors have been identified in the postnatal growth plate and have been 
postulated to play a role in growth plate fusion (25). 
In the growth plate, the transcription factor Runx2 plays an important role in the regulation 
of chondrocyte hypertrophy and the associated changes in the extracellular matrix (26). The 
expression and activation of this transcription factor is in part regulated by PTHrP and Ihh (27). 
Studies on the regulation of growth plate activity during puberty are hampered by the lack of easy 
accessible and representative animal models. For example, rodents do not fuse their growth plates 
at the end of sexual maturation and discrepancies exist between human and mouse models with 
respect of the role of ERa in growth plate regulation (28-30). In addition, human growth plate 
specimens are very difficult to obtain. 
 We were fortunate to obtain growth plate samples of a single patient at two different stages of 
puberty. The growth plate tissues are genetically identical and from the same anatomical location. 
In this study we have performed a morphological analysis of these growth plate specimens 
complemented with a detailed microarray and bioinformatic analysis and identified 394 
differentially expressed genes which were representative for processes that occur during growth 
plate maturation. We subsequently searched the promoter regions of these genes for evidence 
of involvement of hormones and paracrine factors in their expression regulation during growth 
plate maturation. Assuming that the regulation of processes such as growth plate maturation is 
conserved across primates, we identified functional transcription factor binding sites as those 
motif sites with a better evolutionary conservation than sites occurring by chance, related to 
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phylogenetic footprinting (31).  More specifically, we searched the promoter regions of genes that 
were differentially expressed in the two growth plate specimens for evidence of direct effects of 
estrogen, androgen, GH, IGF-I, PTHrP and Runx2 on their expression. 
Material and Methods
The study was approved by the local medical ethical committee and informed consent was 
obtained. Two epiphyseal growth plate samples, from the left and right proximal femur were 
obtained from the same girl with a 1 year interval. In this period the girl progressed from early 
(Tanner B2) to a progressed stage of puberty (Tanner B3). The patient suffered from cerebral palsy 
and underwent resection of her femur head twice because of painful luxations. She did not use 
any long-term medication. Both epiphyseal samples were longitudinally cut with a bone saw and 
pieces were covered by Tissue-Tek (Sakura Finetek Europe B.V., Zoeterwoude, the Netherlands), 
directly frozen in liquid isopentane and stored at –80ºC or fixed in 10% formalin, decalcified with 
EDTA and embedded in paraffin.
Histological analysis
Paraffin embedded samples were cut into longitudinal 5 mm thick sections using a Reichert Jung 
2055 microtome (Leica, Rijswijk, The Netherlands). The sections were mounted on glass slides and 
stained with Haematoxylin. Total height was measured at three points parallel to the chondrocyte 
columns, height of each zone was measured at 10 different places for each zone and results were 
averaged. The space between columns in the proliferative and hypertrophic zone was measured 
at 20 different places. 
RNA isolation
Bone was removed from both epiphyseal growth plate samples and 40 μm thick sections were 
cut with a cryostat. Every fifth section was followed by a 5 μm thick section which was studied 
with Hematoxylin staining to ensure lack of bone contamination. Total RNA isolation was 
performed with an optimized method for RNA extraction from cartilage as described by Heinrichs 
et al. (32) except that the protocol was started by homogenizing the sections in 1 ml guanidine 
thiocyanate solution. RNA extraction was followed by purification with a RNeasy kit according to 
the manufacturers protocol (Qiagen) and quality and integrity of each sample were checked with 
the Agilent 2100 Bioanalyzer.
Microarray
RNA was tested by capillary electrophoresis on an Agilent 2100 bioanalyzer (Agilent) and high 
quality was confirmed. 100 ng of total RNA was then amplified and labeled using the GeneChip 
Two-Cycle cDNA Synthesis Kit (Affimetrix) and the MEGAscript T7 Kit (Ambion). The labeled 
cRNA was further used for the hybridization to Affymetrix Human Genome U133 PLUS 2.0 Array 
Genechips and hybridized according to Affymetrix manufacturer’s protocol. RNA was extracted 
from two different sections of each growth plate. A Custom CDF Version 11 with Entrez based 
gene definitions was used to annotate the arrays (33). The Raw fluorescence intensity values 
were normalized applying quantile normalization using a commercial software package SAS JMP7 
Genomics, version 3.1, from SAS (SAS Institute, Cary, NC, USA). Gene annotation was obtained 
through the Affymetrix NetAffx website (http://www.affymetrix.com/analysis/index.affx). The 
quality control, normalisation and statistical modelling were performed by array group correlation, 
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mixed model normalisation and mixed model analysis respectively. For the presence/absence 
analysis for a single-array, GeneChip® Operating Software version 1.4 (GCOS) from Affymetrix 
was used. Analysis of differential gene expression was based on loglinear mixed model of perfect 
matches (34). A false discovery rate of a=0.05 with FDR-correction for multiple testing was used 
to make a selection of most differentially expressed genes. These affected genes were further 
investigated to identify pathways that are likely to be affected by differential expression. Pathways 
were generated either from the KEGG database (Kyoto Encyclopedia of Genes and Genomes, http://
www.genome.ad.jp/kegg/pathway.html) or from manual annotation. The selection of affected 
genes were also analysed with a genome wide analysis of gene sets defined by the Gene Ontology 
(GO) Consortium and classified as GO-terms (35). In this analysis, an enrichment of affected 
genes within a GO-term suggests that this GO-term is affected by maturation of the growth plates. 
Analyses were done with the Gene Ontology Tree Machine program (http://bioinfo.vanderbilt.
edu/gotm). The raw and normalized data are deposited in the Gene Expression Omnibus database 
(http://www.ncbi.nlm.nih.gov/geo/; accession No. GSE-18338).
Reverse transcription- Polymerase Chain Reaction (RT-PCR)
RNA was reverse transcribed into cDNA using First Strand cDNA Synthesis kit for qPCR (Roche 
Diagnostics Gmbh, Mannheim, Germany) according to the manufacturer’s instructions. Expression 
of collagen 3A1 (COL3A), CDKN1B (p27Kip1), dolichyl-phosphate mannosyltransferase 
polypeptide 1 (DPM1), Thrombospondin 4 (THBS4), and ribosomal protein L15 (RPL15) mRNA 
was quantified by real-time PCR using the Bio-Rad iCycler with SYBR Green. QuantiTect Primer 
Assays for each of these genes were purchased from Qiagen (Qiagen Benelux B.V., Venlo, the 
Netherlands) and used according to the manufacturer’s protocol. Threshold cycles were estimated 
and averaged for the triplicates. Relative amounts of mRNA were normalized to β2-microglobulin 
expression in the same sample to account for variability in the initial concentration, quality of 
total RNA and in the efficiency of the reverse transcription reaction. Delta Ct was calculated by 
extracting the threshold cycle for β2-microglobulin from the threshold cycle for the gene of interest 
followed by calculation of the change in delta Ct with progression of puberty.
Transcription factor binding sites
Upstream regions of 5000nt were downloaded from the 394 genes that changed with progression 
of puberty.  The promoter regions were scanned for six transcription factor binding motifs selected 
from Jaspar 3.0 (36) and Transfac 7.0 (http://www.gene-regulation.com). The motifs were (see 
supplemental table 1): estrogen receptor (Jaspar MA0112), androgen receptor (Jaspar MA0007), 
Elk-1 (Transfac M00025), CREB (Jaspar MA0018), Runx2 (Jaspar MA0002) and STAT5B (Transfac 
M00459). A selection was made of the fraction of the highest scoring positions as potential 
regulatory sites. Two types of randomization controls were included. Firstly, we scanned the 
5,000nt upstream regions of 100 sets of 394 randomly chosen genes for the six motifs mentioned 
above (random genes). Secondly, we scanned the 5,000nt upstream regions of the 394 differentially 
expressed genes for 100 versions of the six motifs with randomized columns (random motifs).
Because we expected that meaningful binding sites may be distinguished from spurious high 
scoring hits by their evolutionary conservation, we assessed the conservation of each of the 
binding sites across nine primate genomes. For this purpose the phastCons (37) primates 
conservation track was downloaded from the UCSC Genome Browser download page (38) and the 
average conservation score for all positions aligned with the motif were calculated.




Histology of the samples showed a clear decrease in overall height of the growth plate at the 
more progressed stage of puberty (figure 1). This was confirmed by quantitative measurements 
showing a significant decrease in the average height of the growth plate, and a significant decrease 
in the height of the resting, proliferative and hypertrophic zone at Tanner stage 3.  The mean space 
between columns was increased in the more matured growth plate. These data are summarized 
in table 1.
Gene expression microarray analysis
RNA of both growth plate samples was amplified, labelled and subjected to Affymetrix microarray 
analysis (HG-U133 Plus 2) in duplicate. The technical and biological reproducibility was good, 
with correlations above 0.97. The raw and normalized data are deposited in the Gene Expression 
Omnibus database (http://www.ncbi.nlm.nih.gov/geo/; accession no. GSE-XXXX). Presence and 
Absence analysis for each probe set was employed by using the GeneChip® Operating Software 
version 1.4 (GCOS) from Affymetrix. On average 5043 genes were present; with progression of 
puberty the number of genes present in the growth plate increased slightly (5069 vs 5016) (table 2). 
The microarray data was validated by quantitative PCR for 5 randomly chosen genes. Similar 
trends in gene expression (up- or downregulation) were found in qPCR and microarray analysis for 
all genes (Figure 2).  THSB4 showed a more pronounced increase in expression in the microarray 
results compared to the qPCR results.
Analysis with a loglinear mixed model of perfect matches and a false discovery rate of a=0.05 
and a Bonferroni-correction for multiple testing revealed 460 affymetrix probe IDs changing 
in expression, of which 330 were upregulated and 130 were downregulated. Using BioMart 0.7 
(39) these probes were mapped to 394 genes changing with maturation of the growth plate (see 
table 2 supplemental data). The overall changes in gene expression were small; on average 1.38-
fold increase for upregulated and 1.36-fold decrease for down regulated genes. Cytokine-like 1 
was the most upregulated gene showing a 6.48 fold increase in expression and the most affected 
downregulated gene, pannexin 3, showed a 2.02 fold decrease in expression level. 
The 394 differentially expressed genes were further investigated with Fisher’s exact tests using SAS 
and the KEGG database. 111 of the 394 genes could be mapped to 13 enriched pathways (p<0.05) 
(Table 3). Several of the differentially expressed genes were present in more than one of the above 
pathways. These pathways were mostly related to the extracellular matrix, cell communication 
and metabolism. We studied these genes independently for their up or down regulation (see 
table 3 supplemental data). Most genes, 89 out of 111, were upregulated in the growth plate with 
progression of puberty. In addition, differentially expressed genes were further investigated with 
the Gene Ontology Tree Machine. This revealed 49 different Gene Ontology terms (GO terms) 
relatively enriched (p<0.01). Enriched GO terms were related to the extracellular matrix, cell cycle, 
cell growth and ligase activity (see figure 1 supplemental data). 
102 Regulators of growth plate maturation
Figure 1: Histology of growth plate Tanner 2 and Tanner 3.
Panel A and B; pictures of growth plate of patient in Tanner stage 2 in respectively 40x and 100x 
magnification. Panel C and D; pictures of growth plate of patient in Tanner stage 3 in respectively 40x and 
100x magnification. The more mature growth plate (Tanner stage 3) shows a decrease in total growth plate 
height, a decrease in height of each separate zone and an increase in the mean space between columns. RZ 
means resting zone, PZ means proliferative zone and HZ means hypertrophic zone. Bars indicate 200μm.
Table 1: Quantitative Histology growth plate Tanner stage 2 and 3.
Tanner stage 2 Tanner stage 3 P-value
Total height (mm) 0.16 ± 0.01 0.097 ± 0.012   0.002
Height resting zone (mm) 0.073 ± 0.003 0.037 ± 0.009 <0.001
Height proliferative zone (mm) 0.047 ± 0.003 0.033 mm ± 0.004 <0.001
Height hypertrophic zone (mm) 0.024 ± 0.003 0.016 ± 0.003 <0.001
Intercolumn space (mm) 4.87*10-4 ± 0.34*10-4 7.52*10-4 ± 0.45*10-4 <0.001
Table showing measurements of total height, height of each individual zone and intercolumn space of the 
growth plate in Tanner stage 2 and the more progressed growth plate in Tanner stage 3.
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Figure 2: RT-PCR validation of microarray data.
Correlation between RT-PCR and microarray results for (A) collagen 3A1 (COL3A), (B) Thrombospondin 
4 (THBS4), (C) CDKN1B (p27Kip1), (D) ribosomal protein L15 (RPL15), (E) dolichyl-phosphate 
mannosyltransferase polypeptide 1 (DPM1). Results are expressed as changes with progression of puberty 
(value Tanner B3- Tanner B4) for both the RT-PCR (delta Ct = Ctgene of interest- Ctβ2-microglobulin) and microarray 
results (least square means). Similar trends in gene expression (up- or downregulation) were found in qPCR 
and microarray analysis for all genes, however THSB4 showed a more pronounced increase in expression in 
the microarray results compared to the qPCR results.
Table 2: Number of expressed and non-expressed genes.
Absent Present Unknown
Growth plate Tanner 2 10255 5016 5555
Growth plate Tanner 3 10118 5069 5639
Table showing the number of genes absent or present in each of the growth plate. In the column defined as 
unknown is the number of genes not consistent in the present/absent analysis.
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Table 3: Pathways significantly changing with progression of puberty. 
pathway genes found total genes
pathway
% p.
1 Proteasome 9 23 39 ***
2 Cholera_Infection 10 30 33 ***
3 Oxidative_phosphorylation 20 89 22 ***
4 N_Glycan_biosynthesis 9 27 33 **
5 ATP_synthesis 9 28 32 **
6 Adherens_junction 14 60 23 **
7 Aminosugars_metabolism 6 17 35 **
8 Regulation_of_autophagy 6 17 35 **
9 Ribosome 9 35 26 **
10 ECM_receptor_interaction 14 67 21 **
11 Cell_cycle 15 84 18 *
12 Cell_Communication 13 74 18 *
13 Ubiquitin_mediated_proteolysis 7 32 22 *
      *= p < 0.05, **= p < 0.01, ***= p < 0.001
 Table showing the 13 significant pathways associated with pubertal maturation of the growth plate.
Table 4: Top 0.001% genes with a transcription factor binding site for 6 motifs; Estrogen receptor, 
Elk-1, STAT5B, RunX2, Androgen receptor and CREB. 
Motif no. genes % of 394 
genes
p-value average conservation 
score 




49 13 0,25 0,19 73 27
Elk-1 43 9 <0,01 0,33 70 30
STAT5B 31 8 0,04 0,25 81 19
RunX2 87 22 <0,01 0,23 76 24
Androgen 
receptor
46 12 0,07 0,22 80 20
CREB 44 11 0,16 0,20 75 25
Number and percentage of genes plus the average conservation score containing an transcription factor 
binding site for each of the 6 motifs. Results are presented for the top 0.0001% of sites and 0.001% of sites. 
For each motif is the percentage given of genes going up and down in expression.
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Transcription factor binding sites
We next scanned the promoter regions of the 394 differentially expressed genes for the presence of 
conserved transcription factor binding sites. We limited our search to transcription factor binding 
sites which are activated by hormones and paracrine factors that have previously been implicated 
in growth plate maturation: Estrogen response elements (EREs) and androgen response elements 
(ARE) for activity of sex-steroids, Stat5b for GH (20),  Elk-1 for IGF-I (21), Cyclic AMP response 
element (CREB) for PTHrP (24) and Runx2 for growth plate hypertrophy (40). We limited 
our analysis to the top 0.001% of the highest scoring motifs and determined the evolutionary 
conservation score of these sites. We found 215 genes with one or more transcription factor binding 
motif using the cut off of 0.001% of the top scoring motifs. The motifs and genes are listed in table 
4 of the supplemental data. As a control, a similar analysis was performed using 100 sets of 394 
randomly chosen genes. In addition, the promoter regions of the 394 genes were screened with 
randomized motifs for each transcription factor binding site and their evolutionary conservation 
score was also determined. These randomizations were used to calculate the statistical confidence 
score (p-value). The data are summarized in table 4. 
We found 87 genes with a transcription factor binding site for RUNX2, 76% of genes going up 
and 24% going down in expression. The average evolutionary conservation score of the motif 
was significantly higher (p<0.01) compared to the findings in randomly chosen genes. Likewise, 
evolutionary conservation of the ELK-1 (49 genes) and STAT5B (31 genes) binding sites in the 
panel of 394 genes associated with growth plate maturation was significantly higher than random. 
We subsequently repeated the statistical analysis of the conservation score by including the top 
0.01, top 0.1, top 1 and top 10% of the highest scoring sites in the analysis. By including up to 
10% of the highest scoring sites of ELK-1 and STAT5B, the evolutionary conservation score was 
still significantly higher than for the controls. Significance for RUNX2 was lost by increasing the 
number of motif sites from the top 0.001 to the top 0.01 % (data not shown).
In marked contrast, the average evolutionary conservation scores of EREs (49 genes), AREs (46 
genes) and CREB (44 genes) in the set of 394 genes were not significantly higher than in the 
randomly chosen controls.
In summary, the highest scoring motif sites for RUNX2, Elk-1 and STAT5B were also the most 
conserved across primates, suggesting that the presence of these motifs may play a functional role 
in the regulation of expression of the genes related to growth plate maturation. Conversely, high 
scoring ER, AR and CREBP motif sites were not better conserved than those in random gene sets, 
suggesting that their presence is coincidental.
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Discussion 
In the present study we compared gene expression levels in two epiphyseal growth plate samples 
obtained from one girl at early and mid puberty (Tanner stage 2 and 3) with a 1 year interval. 
Maturation of the epiphyseal growth plate in mid puberty is associated with a multitude of 
changes in morphology and expression levels of genes associated with the extracellular matrix, 
cell death, cell communication and metabolism. In the panel of 394 genes changing with growth 
plate maturation we found evidence, based on the evolutionary conservation of the highest scoring 
transcription factor binding sites, for regulation of expression by the transcription factors RUNX2, 
ELK-1 and STAT5B. 
Histological experiments and measurements showed a clear decrease in total growth plate height 
with maturation. This is in line with the observations in rabbits, where growth plate height 
gradually declines with age and even more rapidly under the influence of estrogen (7). In humans 
it is known and widely used for assessing skeletal maturation that radiographically the epiphyseal 
width varies in different stages and declines in its progress toward maturity. In the more mature 
growth plate, columns were more widely spaced with more intervening extracellular matrix. These 
changes are described as senescence of the growth plate and confirm earlier results in rabbits 
and rats (7;41). Histological observations and measurements were in line with the microarray 
results, showing significant changes in the extracellular matrix compartment with maturation 
of the growth plate.The ECM receptor interaction pathway changed significantly with 14 out of 
67 genes affected in this pathway. Associated with the extracellular matrix are the aminosugars 
metabolism pathway and the N-Glycan biosynthesis pathway, both changing significantly 
with maturation. The ECM is composed of a variety of macromolecules like proteoglycans and 
polysaccharides (glycosaminoglycans) that are secreted locally and assembled into an organized 
network (42;43). Most genes in these three pathways are upregulated with maturation suggesting 
an increase in pathway activity and extracellular matrix production. In addition to the pathway 
and morphology data, the GO term analyses also showed many enriched GO categories that are 
involved and associated to the extracellular matrix, which strengthens our findings. Blanchard 
et al demonstrated previously that estrogens and testosterone stimulate proteoglycan synthesis 
in vitro in male and female human epiphyseal chondrocytes, consistent with our results (44). 
Besides extracellular matrix pathways, also cell death pathways were enriched in the differentially 
expressed gene sets, e.g. proapoptotic and anti-apoptotic genes, but also genes involved in the 
regulation of autophagy. Apoptosis and autophagy are closely related and there is an overlap 
in signaling proteins (45;46). Previously, we found no signs of classical apoptosis in the human 
growth plate with pubertal maturation and epiphyseal fusion (47). The results of this study are in 
line with this and suggestive for a non-classical and perhaps intermediate mechanism of different 
types of cell death. 
The overall change in gene expression levels in growth plate chondrocytes with progression of 
puberty was unexpectedly small, particularly since puberty is associated with dramatic changes 
in growth velocity and hormone levels like sex steroids, Growth Hormone and IGF-I (48-50). Our 
microarray data is in line with the histological changes observed with growth plate maturation 
providing support that the differentially expressed gene set is representative for the changes that 
occur during growth plate maturation. We hypothesized that analysis of the promoter regions of 
these genes may provide clues for transcription factors and signaling pathways that are involved 
in growth plate maturation. More specifically the promoter regions were analyzed for the presence 
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of evolutionarily conserved binding sites for Estrogen and Androgen Receptors, ELK-1 for IGF-I, 
STAT5b for GH, CREB for PTHrP and RUNX2 for growth plate hypertrophy.
Despite strong clinical and experimental evidence for the role of sex steroids and in particular 
estrogen in growth plate maturation, the potential EREs and also AREs in the promoter regions of 
the 394 genes were not conserved in other primate species. Although these motif sites may still be 
functional in human, the fact that they are uniquely human makes this less likely since sequences 
conserved along species are more likely to have functional roles (37).  Thus, estrogen may not 
have a direct genomic effect in pubertal growth plate maturation. This contrasts with findings of 
Windahl et al., who previously detected an ERE-mediated response in the hypertrophic zone of 
mice (51). This discrepancy might be explained by a species difference, as illustrated before by the 
divergent phenotypes of the ERα knockout mice and man with respect to growth plate regulation. 
Our data does not exclude a role for non-genomic estrogen signalling in growth plate maturation 
nor for an indirect effect of estrogen. Likewise, no enrichment was found for CREB binding sites 
which are activated by intracellular cAMP levels via for example PTHrP. 
Interestingly, the high scoring ELK-1, STAT5b and RUNX2 motif sites were conserved across 
primates. ELK-1 and STAT5b are activated by, amongst others, IGF-I and GH for which receptors 
are present in growth plate chondrocytes. In animal models local effects of GH and IGF-1 on growth 
plate chondrocytes have been established (52;53). Besides the increase in levels of estrogen, also 
the levels of GH and IGF-I increase significantly with the progression of puberty. In addition, it is well 
known that GH-treatment accelerates growth as well as growth plate maturation, either directly 
or indirectly via IGF-I. Our conservation analysis of the transcription factor binding motifs in the 
promoters of differentially expressed genes supports a direct role for GH and IGF-I in growth plate 
maturation, resulting in activation of STAT5b and ELK-1 mediated gene transcription, respectively. 
The effect of estrogen on the activity of the GH/IGF-I axis is well appreciated, demonstrated by 
increasing GH levels in patients with oral estrogen treatment (54;55). This may suggest that effects 
of estrogen on growth plate maturation might be mediated, at least in part, by GH and/or IGF-I.
Runx2 plays an important role in chondrocyte maturation and is involved in the production of 
bone matrix proteins (56). Our results are in line with this hypothesis, since we found many genes 
changing with maturation of the growth plate in puberty that contained evolutionarily conserved 
transcription factor binding site for Runx2. Previous studies have shown that Runx2 can mediate 
actions of estrogen in an osteoblastic cell line and that selective estrogen receptor modulators 
like tamoxifene and raloxifene can increase Runx2 promotor activity in an osteosarcoma cell 
line (57;58). This provides an additional mechanism by which estrogen can indirectly influence 
growth plate maturation. 
While the changes in growth plate morphology are in line with the senescence hypothesis, our 
data do not allow testing the proposed effect of estrogen on the depletion of stem-like cells in the 
growth plate with progression of puberty. 
The major limitation of our study is the small sample number. However these growth plate samples 
are unique and enable a longitudinal analysis within one patient, therefore excluding genetic 
confounders. Adult height is determined for 80-90% by genetic factors (58;59). Including additional 
patients would therefore result in increasing variability, which would complicate all subsequent 
analysis. To the best of our knowledge, no other microarray studies have been performed on human 
growth plate tissues. The observed changes in gene expression and subsequent pathway analysis 
were fully in line with morphological changes that were characteristic for growth plate maturation 
in animal studies. In addition, microarray data were confirmed by qPCR. This strengthens our 
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confidence that the set of 394 genes is representative for changes in growth plate maturation and 
that our findings are biologically relevant. However, additional studies have to be done in a larger 
number of samples and with more pubertal stages to confirm our findings. 
In conclusion, maturation of the epiphyseal growth plate in mid-puberty is associated with 
morphological changes in line with the senescence theory. This was corroborated by a multitude 
of changes in gene expression. Thirteen pathways were affected with maturation, several related 
to the extracellular matrix, the cell cycle, and programmed cell death. Evolutionary conservation 
of binding sites provides evidence for a direct role for GH, IGF-I and RUNX2 in growth plate 
maturation. We did not find support for direct genomic effects of estrogen, suggesting that the well 
appreciated role of estrogen in growth plate maturation might perhaps be indirect by modulating 
GH, IGF-I and RUNX2 activity.
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Abstract
In puberty growth velocity first accelerates, followed by a phase of deceleration and eventually 
cessation of growth with fusion of the epiphyses. Little is known about the exact mechanisms 
underlying the pubertal growth spurt, growth plate maturation and epiphyseal fusion. In this study, 
human growth plate specimens were collected during distinct phases of puberty. High quality RNA 
was isolated, amplified, labelled and subjected to Affymetrix microarray analysis (HG-U133 Plus 
2).  We compared growth plate tissue from the distal femur and proximal tibia and found no great 
difference between expression patterns of these two growth plates from different anatomical 
locations. Secondly, we performed a cross-sectional microarray study with female tibial growth 
plate specimens obtained at different stages of pubertal development (prepuberty, early puberty 
and more progressed puberty). Progression of puberty is associated with many, however mostly 
small, changes in gene expression that occurred most frequently late in puberty. Pathway analysis 
revealed 11 pathways, associated with the extracellular matrix homeostasis, hormonal pathways 
and programmed cell death, changing with maturation of the growth plate. Significance in this 
comparison was lost when the results were corrected for multiple testing, probably due to the 
small sample size. Power calculations revealed that at least 5 growth plates are needed in each 
group to detect a 1.5 fold difference. For the first time we show a developmental regulation of the 
gene expression pattern in the human epiphyseal growth plate with most alterations occurring 
during late puberty. However more future studies are needed to validate our findings.
Introduction
Longitudinal growth occurs at the epiphyseal growth plate, a thin layer of cartilage entrapped 
between epiphyseal and metaphyseal bone, at the distal ends of the long bones (1). Epiphyseal 
chondrocytes are under tight control of a variety of hormones and growth factors acting directly 
or indirectly on the growth plate (2). At onset of puberty, the levels of various hormones, including 
sex steroids, increase in circulation. Sex steroids induce the external signs of puberty (secondary 
sex characteristics) and the accompanying rise in growth velocity, called the pubertal growth 
spurt. Typically, pubertal growth consists of a phase of acceleration, followed by a phase of 
deceleration, and the eventual cessation of growth with the fusion of the epiphyses. One of the 
important hormones regulating pubertal bone growth in both males and females is estrogen. 
Estrogen levels increase about 10-fold along with a 1.5 to 3-fold increase in GH and IGF-1 secretion 
in puberty (3;4). 
In puberty, humans gain on average 27.5-31 centimeters in height, accounting for approximately 
17% of adult height (5). The dramatic effects on growth velocity during distinct phases of puberty 
are a reflection of the activity of the growth plate which consequently undergoes substantial 
changes over time. Little is known about the exact mechanisms underlying the pubertal growth 
spurt, growth plate maturation and epiphyseal fusion. Most previous studies studying growth 
plate regulation have used animal models, which poorly represent characteristic growth patterns 
of human during puberty. 
In chapter 6 we investigated gene expression levels during pubertal growth plate maturation 
within one patient. This revealed a multitude of changes in gene expression. In addition, 13 
pathways changed with maturation. Several of these pathways were related to the extracellular 
matrix. An increase in matrix / cell ratio is a typical characteristic of a maturing growth plate. 
These analyses were, however, based on one single patient. In order to validate these findings in 
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a larger population we have started collecting human growth plate specimens. Human growth 
plate specimens become occasionally available during surgical procedures for diverse medical 
indications.  These medical indications are founded in various diseases, some related to growth 
others. These specimens were processed for histology and for RNA extraction. In this study, we 
report preliminary results of the microarray analysis of human growth plate specimens collected 
during distinct phases of puberty.
Material and Methods
Patients and tissue preparation 
Human proximal tibia growth plate tissues were collected from patients at different pubertal 
stages, undergoing surgery for different medical indications (Table 1). The study protocol was 
approved by the Local Medical Ethics Committees of The Leiden University Center, Leiden, the 
Netherlands and The Karolinska University Hospital, Stockholm, Sweden. Informed consent was 
obtained from all patients and their parents. Epiphyseal samples were embedded in Tissue-Tek 
(Sakura Finetek Europe B.V., Zoeterwoude, the Netherlands) and frozen in liquid isopentane or 
immediately fixed in 10% formaldehyde for 24hrs, decalcified in 10% EDTA and embedded in 




1 elective abortion f tibia fetal RNA Leiden fetal
2 constitutional tall stature f distal 11:06 B1 paraffin Stockholm pt2
3 leg length difference f distal 9:06 B1 paraffin Stockholm pt22
4 Osteosarcoma f distal 8 B1 RNA Leiden GP1234
5 Upper limb amputation of the leg, tibia f proximal 9 B1 RNA Leiden GP_t_8
6 Upper limb amputation of the leg, femur f distal 9 B1 RNA Leiden GP_f_6 
7 Chondroid osteosarcoma, Rothmund Thompson S f distal 12 B1 RNA Leiden GP1142
8 leg length difference f distal 9:06 B1-2 paraffin Stockholm pt23
9 hip luxations, femur head resection f proximal 12:05 B2 paraffin/RNA Leiden GS 3
10 leg length difference f distal 12:08 B2 paraffin Stockholm pt19
11 constitutional tall stature f distal 13:07 B2 paraffin Stockholm pt25
12 constitutional tall stature f distal 12:01 B2 paraffin Stockholm pt30
13 Tall stature f distal 10:06 B2 RNA Stockholm GP 12h
14 leg length difference f distal 14:02 B2-3 paraffin Stockholm pt17
15 Tall stature f distal 11:05 B2-3 RNA Stockholm GP 10h
16 hip luxations, femur head resection f proximal 13:05 B3 paraffin/RNA Leiden GS 7
17 leg length difference f distal 13:08 B3 paraffin Stockholm pt15
18 Tall stature f distal 12 B3 RNA Stockholm GP 22h
19 cerebral palsy, femur head resection f proximal 15:01 B4 paraffin Leiden GS 8
20 leg length difference f distal 13:03 B4 paraffin Stockholm pt8 
21 femur head resection f proximal 14:00 B4 RNA Leiden 5233
22 Tall stature f distal 15:07 B4 RNA Stockholm GP 21h
23 cerebral palsy, femur head resection f proximal 17:00 B5 paraffin Leiden GS 9
24 leg length difference f distal 1:00 B5 paraffin Stockholm pt31
25 CHD, femur head resection m proximal 13:01 G1 RNA Leiden GS 13
26 Marfan m distal 12:03 G1 paraffin Stockholm pt 5
27 cerebral palsy, AIS, femur head resection m proximal 10 G1/B1 RNA Leiden GP6
28 cerebral palsy, femur head resection m proximal 16:10 G2 RNA Leiden GP25
29 leg length difference m distal 12:06 G3 paraffin Stockholm pt 24
30 leg length difference m distal 15:04 G3-4 paraffin Stockholm pt 26
31 leg length difference m distal 14:08 G4 paraffin Stockholm pt 18
32 47XYY m distal 14 G4-5 paraffin Stockholm pt 27
sample                 diagnosis                                              sex     location    age (yr:m)   Tanner      parafin/RNA         origin            code
                                                                                                                                 in fumer 
Table 1
Patients information. Samples #4 and 5 are derived from the same patient. Samples #8 and 15 are derived from the same patient
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Microarray analyses
100 ng of total RNA was amplified and labeled using the GeneChip Two-Cycle cDNA Synthesis 
Kit (Affymetrix, Santa Clara, CA) and the MEGAscript T7 Kit (Ambion, Austin, TX). The labeled 
cRNA was further used for the hybridization to Affymetrix Human Genome U133 PLUS 2.0 Array 
Genechips and hybridized according to Affymetrix manufacturers protocol. In a first approach we 
compared growth plate tissue from the distal femur and proximal tibia to investigate the influence 
of location on gene expression profiles. In this analysis samples #4 and #5 were used.
In a second approach we performed a cross-sectional microarray study with growth plate 
specimens obtained at different stages of pubertal development. To minimize the variability 
we only included growth plate specimens from the female sex derived from the proximal tibia. 
The samples were divided in 3 different groups: 1. prepubertal (pt #3 and #4); 2. early puberty 
(defined as Tanner stage B2 and B2-3, pt #12 and #14); 3. more progressed stage puberty (defined 
as Tanner stage B3 and B4 pt #17 and #20). A genewise linear model was fitted to the six arrays 
using the R package Limma to test differences between the three stages of puberty. Because of 
the limited power due to the small sample size, no adjustment was made for multiple testing, but 
attention was focused on the patterns in the uncorrected P values. Differentially expressed genes 
were further investigated as previously described with a global test in order to identify pathways 
that are likely to be affected by growth plate maturation (6). 
Thirdly, a power calculation was performed to see how many growth plate specimens are needed 
to ensure that with 80% probability a 1.5 fold change can be detected at 5% level of significance 
after correction for multiple testing. 
Besides the growth plate samples used in the experiments described in the above table 1 also 
contains additional growth plate samples not just yet, but available for future experiments.
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Results
Proximal vs distal femoral growth plate expression
The expression profiles of distal and proximal femoral growth plate were largely overlapping. 
Most genes showed a small non-significant change (<1.4 fold). Only eight genes were showing 
a more than 2-fold difference. Figure 1 shows a volcano plot of all genes. From this we conclude 
that growth plates from different anatomical locations are similar in gene expression pattern. 
Subsequently, they can be used together in one comparison studying other parameters like 
pubertal maturation.  
Pubertal maturation 
Because of the small sample size (n=2 in each group) attention was focused on the patterns in the 
uncorrected P values. This revealed 605 genes changing from prepuberty to early puberty, while 
1275 genes changed from early to late puberty and as many as 2362 genes changed from prepuberty 
to late puberty. Many genes were changing in more than one comparison (Figure 2). Significance 
was lost when results were corrected for multiple testing. The changes in expression level were 
mostly in a small range. The most affected upregulated gene (matrilin-1) showed a 32 fold change 
in expression from prepuberty to late puberty. The most affected downregulated gene showed a 11 
fold change in expression level from prepuberty to late puberty (TCDD-inducible poly(ADP-ribose) 
polymera). The percentage of probes, out of the genes changing with maturation, with ≥2 fold change 
are shown in table 2. Results indicate that most alterations occurred during late puberty with 48.6% 
of genes increasing in expression level and 51.4% of genes decreasing in expression level. 
Power calculation
Although the expression of many genes tended to change with progression of puberty, in this 
limited analysis none of these changes reached significance after correction for multiple testing. 
This was due to the small sample size, the biological variability between the specimens and 
the unexpectedly low levels of fold change. Based on this first analysis, we performed a power 
calculation to determine the number of growth plate specimens needed to ensure that with 80% 
probability a 1.5 fold change at 5% level of significance after correction for multiple testing can 
be detected. 
In this analysis the total number of genes has to be considered, given that including many genes 
which are not involved in the regulation of growth during puberty makes it more difficult to flag 
the genes that do play a role. The variance of the expression levels between the samples also has to 
be considered. If a given gene naturally varies very much between individuals, it will consequently 
be hard to detect a signal. To get an idea of the amount of variability we might expect, we computed 
the variance for each gene in our data. We found that the mean variance was around 0.2, but 
variances above 0.8 did also occur. 
In Figure 3 we plotted the required sample size (in each group) as a function of the variance. 
The red line is based on testing 200 genes, the black line on testing 1000 genes. From this can be 
concluded that about 5 growth plates in each group are needed to detect a fold change of 1.5 when 
the variance is 0.2. 
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Figure 1. Proximal vs distal femoral growth plate expression. 
In this figure the gene expression levels of the tibial growth plate versus the femoral growth plate is plotted. 
On the x-axis is written the fold-difference which can be calculated by 2x-value. On the y-axis the –log10(p-
value) which indicates the level of significance. The higher these value the more significant and values above 
the dashed line are significant without correction for multiple testing. Expression profiles were largely 
overlapping. Most genes showed a small non-significant change (x<0.5= fold change< 1.4 fold). Only eight 








Fold difference of femoral vs tibial growth plate (2x-value) 
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Table 2
        Percentage of probes ≥2 fold change
prepuberty to early puberty 0.4%
early puberty to late puberty 2.0%
prepuberty to late puberty 3.1%
Percentage of probes with a ≥2 fold change between the different groups of pubertal maturation.
A pathway-based analysis with a global test for all genes revealed 11 pathways changing 
significantly from early to late puberty (table 3). Affected pathways associated with the 
extracellular matrix homeostasis, hormonal pathways and programmed cell death. Significance 
was lost when the results were corrected for multiple testing.
Figure 2: Venn diagram of significantly different genes in each group.
This figure shows the number of genes significantly different in each of the 3 comparisons between the 
different groups. It also shows the number of genes significant in more than one comparison.









Regulation of autophagy 0.518 0.046 0.005
N-Glycan biosynthesis 0.879 0.403 0.006
RNA polymerase 0.767 0.195 0.016
Peptidoglycan biosynthesis 0.266 0.053 0.020
Lysine degradation 0.631 0.151 0.026
Biosynthesis of steroids 0.802 0.262 0.026
Terpenoid biosynthesis 0.749 0.358 0.028
Apoptosis 0.658 0.106 0.034
Complement + coagulation cascades 0.677 0.199 0.042
Fc epsilon RI signaling pathway 0.749 0.314 0.047
GnRH signaling pathway 0.715 0.168 0.049
Affected pathways and p-values for each comparison.
Figure 3: Required number of growth plates for different standard deviation scores. 
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Discussion
A limited microarray analyses of 6 human growth plate samples at prepuberty, early puberty 
and advanced puberty revealed a large number of changes in gene expression with progression 
of puberty. Changes in expression levels were on average small and most alterations occurred 
during late stage of puberty. Furthermore, the variations in gene expression in between growth 
plate samples isolated from different patients at an identical stage of pubertal development were 
relatively large. Given the high impact of genetic composition on growth and final height this is 
not surprising. 
A number of pathways changed with progression of puberty. Affected pathways were associated 
with extracellular matrix homeostasis, hormonal pathways and programmed cell death which 
have all been implicated in growth plate maturation. None of the identified changes reached 
significance when the statistical analyses were corrected for multiple testing. This was due to 
small sample size, large variation between specimens at the same developmental stage and overall 
small changes in gene expression levels.
The overall small change in gene expression levels in growth plate chondrocytes with progression 
of puberty was unexpected, since puberty is associated with dramatic changes in growth velocity 
which is mediated by the activity of growth plate chondrocytes. This is exemplified by the pubertal 
growth spurt, which accounts for approximately 17% of final height (3-5). In addition, puberty is 
related to a large increase in expression of hormones like sex steroids, Growth Hormone and IGF-I. 
These hormones have been postulated to regulate the changes in growth plate activity in part by 
exerting direct effects on growth plate chondrocytes. Of these hormones, estrogen demonstrates 
the most dramatic changes particularly in girls who were subject of the present study and is 
postulated to be the driving factor of the growth spurt, growth plate maturation and fusion. This 
might indicate that gene expression in the human growth plate is not as sensitive to circulating 
estrogen levels as was expected. 
Estrogen accelerates the senescent decline (7). Senescence is a term for the structural and 
functional changes over time in the growth plate. Stem-like cells in the resting zone have a finite 
proliferative capacity, which is gradually exhausted resulting eventually in epiphyseal fusion 
(8;9). Based on this hypothesis, cells that are most sensitive to estrogen are growth plate stem 
cells. These cells are located in the resting zone of the growth plate adjacent to the epiphyseal 
bone and form a minority in the growth plate. By removing the bone from the cartilage by micro 
dissection, it is likely that many of the growth plate stem cells are removed as well. Likewise, to 
prevent contamination of the RNA prepartions with cells of the metaphyseal bone, large parts 
of the terminal hypertrophic cell layer will be sacrificed as well. Our growth plate RNA samples 
are therefore enriched in proliferating and early hypertrophic cells. If stem cells are indeed 
most responsive to estrogen by changes in gene expression it is likely that such an effect will be 
missed in our experiment. Micro dissection with a laser for example, which allows a more precise 
selection of cell types for RNA isolation than manual micro dissection, might be considered as 
an alternative approach. Our findings do not support nor contradict the senescence hypothesis. 
A suggested biological marker for growth plate senescence is loss of DNA methylation and this 
cannot be detected by gene expression microarray analysis (10).
Although the analysis of the microarray data did not reveal findings that could withstand 
correction for multiple testing, it was remarkable that genes changing over time could be mapped 
to pathways like ‘regulation of autophagy’ and ‘apoptosis’. Chondrocyte death is presumed to be a 
characteristic of growth plate maturation and fusion. In a previous study we studied apoptosis in 
a collection of growth plate tissues together with a unique growth plate specimen in the process 
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of epiphyseal fusion (11). In this study we were not able to detect any signs of autophagy and/
or classical apoptosis with pubertal maturation morphologically nor at the protein level. We did 
observe early signs of necrosis and signs of hypoxia. The results from this microarray study are 
indicative for more cell death markers in late stages of puberty. Results do not identify the exact 
mechanism since both pathways contain many genes, and also overlapping genes, suggestive for 
some sort of programmed cell death which might be a combination of autophagy, apoptosis and 
perhaps a third kind of cell death like necrosis. 
The exact mechanism through which chondrocytes disappear during epiphyseal fusion in humans 
still needs to be clarified. By increasing the power of the analysis by including new growth plate 
specimens, microarray analysis may shed more light on the process of chondrocyte death during 
the advanced stages of puberty. Alterations in genes associated with hormonal pathways are in 
line with a rat study, reporting an increase in sex steroid synthesis in sexually maturing rats (12).
A number of growth plates in our collection were derived from pathological conditions. We believe 
that it is a safe assumption that the underlying mechanism of epiphyseal maturation and fusion is 
the same for all growth plates regardless of the underlying disease of each patient since eventually 
longitudinal growth stops in all patients by the end of puberty and all patients undergo growth 
plate maturation as a function of puberty.
Power calculations showed that 5 growth plates in each group are needed to detect a fold change of 
1.5 with an overall variance of 0.2. Unfortunately, we did not have that many growth plates derived 
from female tibias. Differences in genetic background were omitted in the longitudinal analysis 
of the 2 growth plate samples from one patient as described in chapter 6. Comparing data from 
this longitudinal analysis with the present cross-sectional study did not show a perfect match in 
respect to individual genes. However, results of pathway analysis are more in agreement with the 
longitudinal study. Both analyses showed changes in pathways associated with the extracellular 
matrix and programmed cell death. In addition, the longitudinal study confirmed extracellular 
matrix changes on protein level. 
Our microarray results are promising and contain a great amount of data; however more samples 
are needed to validate our findings. With a larger collection, results could serve as a database and 
clarify multiple research questions involving the growth plate. In addition, we now have a large 
collection of paraffin embedded tissues on which studies can be performed on protein expression.
In conclusion, for the first time we show a developmental regulation of the gene expression pattern 
in the human epiphyseal growth plate. Most alterations occurred during late puberty suggesting 
that the affected pathways may be involved in the regulation of human epiphyseal growth plate 
maturation and fusion. However, more future studies are needed to validate our findings.
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Abstract
By the end of puberty, growth ceases and epiphyseal fusion occurs through mechanisms not 
yet completely understood. Human growth plate tissues were collected in various pubertal 
stages including a unique late pubertal growth plate, which was about to fuse. Apoptosis was 
studied by TUNEL (terminal deoxynucleotidyl transferase (TdT)-mediated deoxy-UTP nick 
end labeling) staining, immunolocalization of pro- and anti-apoptotic proteins and electron 
microscopy. Morphological analyses of the fusing growth plate revealed disorganized, large 
chondrocytes surrounded by a border of dense, cortical-like bone. In the unfused growth plates, 
few chondrocytes were TUNEL-positive. In contrast, the fusing growth plate contained no single 
TUNEL-positive cell. Anti-apoptotic (Bcl-2 and Bcl-XL) and pro-apoptotic (Bax, Bad and cleaved 
caspase-3) proteins were detected in all growth plate zones without change in intensity during 
pubertal progression. Expression of anti-apoptotic proteins was found in the fusing growth plate 
but of the pro-apoptotic proteins only Bad was detected. Electron microscopy revealed no typical 
signs of apoptosis or autophagy in any of the growth plates. In contrast, morpohological signs of 
hypoxia as well as necrosis were observed. We conclude that classical apoptosis is not likely to be 
involved in the process of human growth plate fusion.
Introduction
Longitudinal growth occurs at the epiphyseal plate, a thin layer of cartilage entrapped between 
epiphyseal and metaphyseal bone, located at the distal ends of the long bones. The epiphyseal plate 
consists of three principal layers with immature cells lying toward the epiphysis, called the resting 
zone, more mature flat chondrocytes in the proliferating zone and the hypertrophic zone adjacent 
to this. Stem-like cells in the resting zone have a finite proliferative capacity that is gradually 
exhausted which consequently results in fusion of the growth plate at the end of puberty (1). At the 
chondro-osseous junction site of the growth plate, a nowadays generally accepted hypothesis is 
that terminally hypertrophic chondrocytes die by undergoing apoptosis leaving behind a scaffold 
of cartilage matrix for osteoblasts that invade and lay down bone resulting in growth plate fusion 
(1, 2). Apoptotic cells in general show typical morphological changes like cell shrinkage, intact 
organelles and integrity of membranes, pyknotic nuclei by aggregation of chromatin, fragmented 
DNA, partitioning of the cytoplasm and nucleus into membrane bound-vesicles (apoptotic bodies) 
and absence of an inflammatory response (3, 4). The Nomenclature Committee on Cell Death 
suggested to describe apoptosis at a biochemical level as a caspase-dependent process (5). 
Apoptosis in growth plate chondrocytes has been reported in many in vivo and in vitro studies 
performed in different species applying mostly the TUNEL (Terminal deoxynucleotidyl transferase 
(TdT)-mediated deoxy-UTP nick end labeling) technique to label fragmented DNA (6-8). Additional 
studies in animals show that apoptosis-regulating proteins are predominantly expressed in the 
proliferative and hypertrophic zones with an increase of pro-apoptotic factors by age (7, 9). Others 
have questioned apoptosis as the final mechanism through which chondrocytes die in the terminal 
hypertrophic zone. Ahmed et al. hypothesized non-apoptotical mechanisms to be involved and 
described morphological changes distinct from classical apoptosis (10). In addition, Roach et al. 
re-examined microscopic pictures of hypertrophic chondrocytes of in vitro cultured chick growth 
plates and hypothesized that terminal hypertrophic chondrocytes not only die through apoptosis 
but some also go through transdifferentiation to endochondral osteoblasts (11). In later studies 
Roach et al studied rabbit growth plates and described chondrocytes with condensed chromatin, 
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suggestive of apoptosis, but the ”morphology of the cytosol” was unlike that of necrotic, apoptotic, 
or normal cells (12, 13). In 2004, they came up with the name chondroptosis instead of apoptosis 
to describe the appearance of these cells (14). This study also reported autophagic vacuoles in the 
chondroptotic cells, suggesting a role for autophagy in the process of cell death of the terminal 
hypertrophic cell. Autophagy and autophagosomes were also observed in avian hypertrophic 
chondrocytes and in chondrocytes of newborn mice (15, 16).
Previous studies focusing on the fate of growth plate chondrocytes have been performed mostly 
in different animal models. It is uncertain whether the chick growth plate is comparable to the 
human, and studies in rodents are limited by the fact that growth plate fusion does not occur 
during sexual maturation in rats and mice. The only studies done in human tissues are not 
very extensive involving TUNEL analyses performed in spinal growth plates and slipped capital 
femoral epiphysis growth plates (6, 17, 18). To resolve this issue, we decided to jointly collect 
human growth plate tissue samples obtained during epiphyseal surgery performed in children at 
different stages of development. When analyzing all these samples of human growth plate tissues, 
we were lucky to discover that in one of the patients, a 17-year-old late pubertal female, the 
growth plate was captured just when it was in the process of undergoing epiphyseal fusion. This 
growth plate tissue can be considered as unique since epiphyseal fusion is a rapid process which 
is extremely difficult to capture. This specific human tissue specimen is therefore like a snapshot 
of epiphyseal fusion and could help us to better understand how growth plate fusion occurs 
and the underlying mechanisms involved. Using these tissues, we here aimed to describe the 
morphological characteristics of a fusing human growth plate and possible mechanisms involved 
in the process of human epiphyseal fusion and discuss these in relation to previous published data 
obtained in different animal models.
Figure 1: X-ray of patient #13. Complete luxation of the right hip.







(yr:m) Tanner TUNEL Bcl-2 Bcl-XL Bax Bad Casp3
1 constitutional tall stature f distal 11:6 B1 0 x x x x x
2 leg length difference f distal 9:6 B1 0 x x x x x
3 leg length difference f distal 9:6 B1-2 0 x x x x 2
4 hip luxations, femur head resection f proximal 12:5 B2 0 1 2 1 1 2
5 leg length difference f distal 12:8 B2 1 x 3 x 2 2
6 constitutional tall stature f distal 13:7 B2 0 x x x x x
7 constitutional tall stature f distal 12:1 B2 0 2 x x x x
8 leg length difference f distal 14:2 B2-3 0 x 2 1 2 2
9 hip luxations, femur head resection f proximal 13:5 B3 0 2 2 2 2 1
10 leg length difference f distal 13:8 B3 0 x 1 1 x 0
11 cerebral palsy, femur head resection f proximal 15:1 B4 0 2 2 1 2 1
12 leg length difference f distal 13:3 B4 0 x x x x x
13 cerebral palsy, femur head resection f proximal 17:0 B5 0 2 2 0 2 0
14 leg length difference f distal 12:1 B5 0 x x x x x
15 Marfan m distal 12:3 G1 0 x x x x 1
16 leg length difference m distal 12:6 G3 0 x x x x x
17 leg length difference m distal 15:4 G3-4 0 x x x x x
18 leg length difference m distal 14:8 G4 0 x x x x x
19 47XYY m distal 14:0 G4-5 0 x x x x x
Table 1: IHC Total growth plate staining
TUNEL and histology staining for Bcl-2, Bcl-XL, Bax, Bad and caspase-3 were scored from 0 to 3 for each patient (Pt). 0 indicating 
no staining in the growth plate and 3 indicating many positive chondrocytes throughout the growth plate. x indicates that no 
staining was performed. Age is given in years and months (yr:m)
Methods
Patients and tissue preparation
Human proximal and distal femur growth plate tissues were collected from 14 girls and 5 boys at 
different pubertal stages who were undergoing surgery for different medical indications (Table 
1). The study protocol was approved by the Local Medical Ethics Committees of The Leiden 
University Center, Leiden, the Netherlands and The Karolinska University Hospital, Stockholm, 
Sweden. Informed consent was obtained from all patients and their parents. No patient used any 
continuous medication. Patient #13, the patient with a growth plate in the process of epiphyseal 
fusion, was mostly wheelchair bound and mentally retarded. Because of frequent painful hip 
luxations hip replacement surgery was performed. Figure 1 shows an X-ray of her right hip where a 
complete luxation can be observed. All tissue samples were processed in the same way. Specimens 
were immediately fixed in 10% formaldehyde overnight, decalcified in 10% EDTA for 5 days and 
then embedded in paraffin.
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Immunohistochemistry
Immunohistochemistry was performed as previously described (19) with the following 
modifications. After antigen retrieval by incubating with trypsin (Invitrogen) for 10 minutes at 
37°C, the sections were additionally treated with 5 mg/ml hyaluronidase (Sigma-Aldrich, Inc, 
Steinheim, Germany) for 30 min at 37°C. Anti-Collagen-X antibody was from Quartett (Berlin, 
Germany) and used in a 1:100 dilution. Anti-Bcl-2 antibody was from Upstate (#06-474 Upstate 
Biotechnology, Lake Placid, NY, USA) and used in a 1:300 dilution. Anti-Bax antibody (P19) and 
anti-Bad antibody (C-20) were purchased from Santa Cruz Inc., (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA) and respectively used in a 1:300 and 1:200 dilution. Anti-Bcl-XL antibody was 
purchased from Transduction Laboratories (Becton Dickinson AB, Stockholm, Sweden) and used 
in a 1:100 dilution. Anti-cleaved-caspase 3 primary antibody was purchased from Cell Signaling 
Technology (In Vitro Sweden AB, Stockholm, Sweden) and used in a 1:50 dilution. Secondary 
anti-rabbit biotinilated antibody (Jackson Immunoresearch lab, West Grove, PA, USA) or anti-
mouse biotinilated antibody (DAKO, Glostrup, Denmark) were respectively used in a 1:1000 and 
1:300 dilution, followed by incubation with avidin-biotin Vectastain ABC reagent according to 
manufactures instructions (Vector laboratories, Burlingame, California, USA). Digital images were 
collected employing a Nicon Eclipse E800 microscope equipped with an Olympus DP70 digital 
camera.
Apoptosis assay (TUNEL)
Apoptotic cells were identified by terminal deoxynucleotidyl transferase (TdT)-mediated 
deoxy-UTP nick end labeling (TUNEL) immunohistochemistry according to instructions for 
the TdT-FragEL™ DNA fragmentation kit (Oncogene Research, Boston, MA) with the following 
modifications. The sections were treated with 5 μg/ml proteinase K for 15 min (20-22). Control 
experiments showed that when pre-treating sections with distilled water instead of TdT, all cells 
were negative, whereas pretreatment with DNase enabled labeling of all cells.
Tartrate-resistant acid phosphatase (TRACP) staining 
TRACP staining was performed using a combination of solutions that include naphtol–AS BI 
phosphate, dimethylformamide, tartaric acid, acetate buffer, vermoal buffer, sodium nitrite, and 
pararoseaniline pH 5.2. Tissue sections were deparaffinized, rehydrated, and incubated with the 
reactive solution for 30 min as described in detail previously (23).  After washing with distilled 
water, the tissue sections were counterstained with Mayer’s hematoxylin.  
Transmission electron microscopy (TEM)
Small tissue pieces were cut out from blocks of paraffin embedded bone/cartilage tissue and 
the paraffin was dissolved in Xylene at 60°C. The tissue was re-hydrated in alcohol into distilled 
water and fixed in 2% glutaraldehyde + 0.5% paraformaldehyde in 0.1M sodiumcacodylate buffer 
containing 0.1M sucrose and 3mM CaCl2, pH 7.4, 24 hours at 4°C. Specimens were rinsed in 0.15 
M sodiumcacodylate buffer containing 3mM CaCl2, pH 7.4 postfixed in 2% osmium tetroxide in 
0.07 M sodiumcacodylate buffer containing 1.5 mM CaCl2, pH 7.4 at 4°C for 2 hour, dehydrated in 
ethanol followed by acetone and embedded in LX-112 (Ladd, Burlington, Vermont, USA). Semithin 
sections were cut and stained with toluidine blue and used for light microscopic analysis. Ultrathin 
section were cut and contrasted with uranyl acetate followed by lead citrate and examined in a 
Tecnai 10 transmission electron microscope at 80 kV. Digital images were captured by a MegaView 
III digital camera (Soft Imaging System, GmbH, Münster, Germany).




Figure 2a and c show representative pictures of an early pubertal female growth plate (patient 
#4) at 40x (a) and 100x (c) magnification. Figure 2b and d show pictures of the late pubertal 
patient (patient #13) with ongoing fusion of her growth plate stained with H&E at respectively 
40x and 100x magnification. As expected, early pubertal growth plate chondrocytes were found 
to be organized in parallel columns maturing from resting to proliferative and then to large 
hypertrophic cells. In the late pubertal patient, growth plate remnants were found at the site where 
in less mature bones the epiphyseal plate is located. These remnants were small and surrounded 
by dense cortical-like bone. Chondrocytes within these growth plate remnants were disorganized 
and no columns could be found. In addition, the cells were very large with big lacunae and some of 
them were fused together. In order to study in more detail the interface of the fusing growth plate, 
immunohistochemistry for collagen type X and TRACP staining were performed. The unfused 
growth plates showed expectedly positive staining for collagen type X in the hypertrophic zone 
(Figure 2e). However, the growth plate remnant with large hypertrophic-like cells did surprisingly 
not show any positive staining (Figure 2f).  TRACP staining, a marker for osteoclasts, was seen at 
the chondro-osseus junction of prepubertal growth plates (Figure 2g), as well as in early pubertal 
growth plates (data not shown). However, at the interface of the growth plate remnant no TRACP 
staining could be detected (Figure 2h).
Transmission electron microscopy
To allow comparative electron microscopic studies of cell death characteristics, small pieces 
were cut out from paraffin blocks containing growth plate tissues from the patient with ongoing 
epiphyseal fusion. For comparative analysis, three younger pubertal female growth plates (patients 
#4, 9 and 11) were processed in a similar way.
The fusing growth plate was found to be entirely surrounded by a border of very dense, cortical-
like bone clearly isolating the growth plate from any vessels or osteoclasts (figure 3f). In contrast, 
in nonfusing growth plates, there was a small distinct border between loosely packed collagen 
type II in the cartilage matrix and collagen type I in the bone matrix (figure 3e). Collagen type 
I contains thick fibers compared to the very thin collagen type II fibers and therefore these two 
types of collagen could easily be distinguished. There were no signs of classical apoptosis in the 
fusing growth plate; e.g. no apoptotic bodies or patched chromatin and proteins could be found 
(figure 3b, d). In addition, no typical signs of inflammation were found although we did observe 
some signs of early necrosis like empty vacuoles (see arrows figure 3b). Additionally we observed 
signs of hypoxia, e.g. patchy distributed chromatin and defect plasma cell membranes. No double-
membrane autophagosomes, like typically seen in cells undergoing autophagy, were found in the 
fusing growth plate.
In early-pubertal and mid-pubertal growth plates (figure 3a, c), we observed normal chondrocytes 
with non-pyknotic nuclei containing homogenous dense chromatin without signs of DNA 
fragmentation. We specifically focused on the terminal hypertrophic chondrocytes that were 
about to be incorporated into the newly formed bone. In these cells some chromatin condensation 
was seen, but this was clearly different from what normally is seen in cells undergoing classical 
apoptosis. Cell membranes were intact and the cytoplasm mostly empty. No autophagosomes 
could be found and no sign of necrosis was present.
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Figure 2. H&E staining of sectioned human growth plates. 
In early pubertal patients, growth plate chondrocytes were organized in parallel columns; (patient#4; panel 
a. 40x and panel c. 100x magnification). In a late pubertal patient, the growth plate was diminished to a small 
remnant surrounded by dense cortical-like bone (patient #13; panel b. 40x and panel d. 100x magnification). 
All unfused growth plates stained positive for collagen type X in the hypertrophic zone (patient #2; panel 
e. 100x magnification) while the fusing growth plate did not show any staining (patient #13; panel f. 100x 
magnification). Panel g. shows positive TRACP staining in an early pubertal growth plate, indicated by arrows 
(patient #2, 100x magnification) while the fusing growth plate stained negative (patient #13; panel h. 100x 
magnification). Bars in all figures indicate 200μm.
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Figure 3
TEM images from the proximal femur epiphyseal growth plate in a mid-pubertal patient (patient #9; left 
panels, a, c, and e) and the late pubertal patient with a fusing growth plate (patient #13; right panels b,d, and 
f). In the mid-pubertal patient, hypertrophic zone chondrocytes displayed a normal morphology (a) and at a 
higher magnification dense chromatin was found in the cell nucleus (c). In contrast, the fusing growth plate 
displayed a patchy chromatin pattern (b and d). At high power magnifications of the interphase between 
cartilage and bone matrix, a distinct border between loosely packed cartilage matrix collagen type II (Coll-II) 
and bone matrix collagen type I (Coll-I) was found in the mid-pubertal patient (e) while in the fusing growth 
plate, the border was thicker and the bone matrix collagen type I more dense (f). Bars: a, b = 5µm; c, d = 2µm; 
e, f = 1µm.
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Figure 4
TUNEL and immunohistochemistry staining of prepubertal, pubertal and fusing growth 
plates (100x and inserts 200x magnification). Panel a: TUNEL analysis patient #4, left 
insert showing positive cells in surrounding bone marrow. Panel b: TUNEL analysis 
fusing growth plate (patient #13). Panel c+d: Bcl-2 staining patient #4 and fusing 
growth plate. Panel e+f: Bcl-XL staining patient #10 and fusing growth plate. Panel g+h: 
Bax staining patient #4 and fusing growth plate. Panel i+j:  Bad staining patient #3 and 
fusing growth plate. Panel k+l: cleaved caspase-3 patient #3 and fusing growth plate. 
Bars indicate 100 µm.
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TUNEL analysis
In all female (2 prepubertal and 12 pubertal) and male (5 pubertal) subjects, very few growth plate 
chondrocytes stained positive or showed an apoptotic-like morphology when applying the TUNEL 
method (figure 4a). The staining intensity was scored (0 to 3 points; 0 indicating no staining 
and 3 indicating many positive cells throughout the growth plate) and the results are shown in 
table 1, ranked according to pubertal stages. It is important to point out that when evaluated by 
experienced scientists in the field, most TUNEL-positive cells indeed were considered to have 
a viable appearance, as indicated by a complete absence of apoptosis-related morphological 
changes, and should therefore be considered as non-specifically stained. In the fusing growth 
plate, no single TUNEL-positive cell was detected (figure 4b). In contrast, the surrounding bone 
marrow was abundantly stained with the TUNEL technique and could therefore serve as an 
internal positive control as previously described (21, 24). Negative controls showed no staining.
Anti-apoptotic proteins
Bcl-2 staining was detected in cells throughout the whole growth plate in patients with non-fused 
growth plates (n=4, table 1) (figure 4c). When the relative staining intensity was scored (score 0 to 
3), a possible tendency towards increased expression was found during maturation (table 1). The 
fusing growth plate did show some staining for Bcl-2 (score 2; figure 4d).
Bcl-XL, another anti-apoptotic factor, was also localized in cells throughout the whole growth plate 
(n=6, table 1, figure 4e). No change in percentage positive cells or staining intensity was seen during 
maturation. Also in the fusing growth plate some cells stained positive for Bcl-XL (score 2; fig 4f).
Pro-apoptotic proteins and caspase 3
Staining for Bax, a proapoptotic factor, was seen in chondrocytes throughout the whole growth 
plate (n=5, table 1, figure 4g). No change in staining intensity or percentage Bax positive cells was 
seen during pubertal development. Interestingly, in the fusing growth plate no staining for Bax 
could be detected (figure 4h).
Staining for Bad, another proapopotic factor, was found throughout the whole growth plate (n=5, 
table 1, figure 4i). No change in staining intensity or percentage of positive cells was seen during 
development. Some staining for Bad proteins was observed in the fusing growth plate (score 2; fig 
4j), unfortunately with abundant background staining.
Cleaved caspase 3, an effector caspase in the apoptotic cascade, was seen throughout the whole 
growth plate in all pubertal stages (n= 8, table 1) with no change during maturation (figure 4k). In 
the fusing growth plate, no staining for cleaved caspase 3 was detected (figure 4l). 
Negative controls showed no staining for all analyzed pro- and anti-apoptotic proteins.
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Discussion
Based on well established morphological and histological criteria of apoptosis, we could not detect 
any signs of classical apoptosis in human terminal hypertrophic growth plate chondrocytes. These 
findings were also confirmed by electron microscopy. In a unique tissue specimen of a late pubertal 
fusing human growth plate, we found clear evidence that chondrocyte apoptosis is not likely to be 
involved in the end phase of growth plate fusion in humans. In contrast, signs of hypoxia and early 
necrosis were present in the fusing growth plate.
This is the first detailed study of apoptosis in the human pubertal growth plate which includes 
expression levels of pro- and anti-apoptotic proteins together with morphological analysis based 
on light and electron microscopy. Our study includes the characterization of a unique tissue sample 
from a growth plate in the process of undergoing fusion where we made the novel observation that 
the chondrocytes were markedly enlarged, disorganized, and surrounded by a border of dense, 
cortical-like bone. No morphological signs of classical apoptosis were found in this fusing growth 
plate. Our findings are in agreement with earlier studies describing terminal hypertrophic zone 
chondrocytes at the chondro-osseous junction to have a morphology which is not typically seen in 
cells undergoing classical apoptosis (11, 14, 25, 26). However, it is important to point out that all 
these previous studies were performed in animal growth plates; avians or rodents that do not fuse 
their growth plates by the end of sexual maturati.
The mechanism by which terminal hypertrophic chondrocytes disappear during endochondral 
ossification is believed to be related to the underlying cause of eventual growth plate fusion. 
However, these two events involving the epiphyseal growth plate might as well be two different 
and independent processes. In this paper we compared both. Interestingly, we found some signs 
of early apoptosis and also some signs of necrosis such as empty vacuoles in the fusing growth 
plate, suggesting that fusing growth plate chondrocytes appear in a sort of intermittent stage 
between apoptosis and necrosis. Importantly, no signs of inflammation were observed around the 
fusing growth plate. Erenpreisa and Roach also reported signs of necrosis in dark chondrocytes 
of the embryonic chick growth plate (26), however such dark chondrocytes were not found in our 
human growth plate tissue samples. To our knowledge, no other signs of necrosis have previously 
been reported in the growth plate. Interestingly, Shapiro et al. has reported that the morphology 
of terminal hypertrophic chondrocytes suggest autophagy, a type II programmed cell death, to 
occur in the growth plate (16). However, we did not see any double membrane structures like 
autophagosomes suggestive for autophagy, but only vesicles with a single membrane that we 
interpreted as vacuoles. 
Apoptosis is the most widely accepted and described mode of cell death through which terminal 
hypertrophic chondrocytes disappear and are replaced by bone (27). Most studies relay on TUNEL 
technique only, which often overestimates the number of apoptotic nuclei, as it labels not only 
fragmented DNA but also DNA in the process replication and repair. In many studies TUNEL 
positive chondrocytes were observed not only in the hypertrophic layer where cells are assumed 
to die prior to being incorporated into the newly formed bone, but in all zones of the growth 
plate (6, 17, 18). When re-evaluating pictures of growth plate chondrocytes positive for TUNEL 
staining, a high diversity of results could be found. Cell morphology is not always complementing 
TUNEL positivity and when data are presented, cells often do not look like cells in the process 
of undergoing apoptosis, but as healthy viable cells without showing signs of cell shrinkage and 
pyknotic nuclei (6, 17, 18). Thus, the TUNEL method is very sensitive and it requires precise 
temporal control of each step (28) and must be verified by other techniques like EM or molecular 
markers of apoptosis.
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Molecular markers of apoptosis include cleavage of caspases and often regulation of pro- and anti-
apoptotic proteins of the Bcl-2 family (29). In the current study we are the first to investigate 
these proteins in the human postnatal growth plate and we found that they are indeed expressed 
throughout the whole growth plate. We did not observe any caspase-3 cleavage, the effector 
caspase of apoptosis in the fusing growth plate. Moreover, in the fusing growth plate we observed 
clear expression of the anti-apoptotic proteins Bcl-2 and Bcl-XL and a possible down-regulation 
of the pro-apoptotic protein Bax. Thus, all three approaches including TUNEL technique, analysis 
of cell morphology by electron microscopy and molecular markers by immunohistochemistry 
altogether suggest that there is no classical apoptosis occurring in the fusing human growth plate.
A novel and clear observation was that the fusing human growth plate is surrounded by a border 
of very dense thick bone, shelling the growth plate remnant. There are no vessels seen in or 
surrounding the fusing growth plate. Moreover, there were some signs of hypoxia in the fusing 
growth plate like patchy distributed chromatin. From these findings one can hypothesize that this 
border of dense bone is functioning as a physical barrier for oxygen and nutrients to reach the 
fusing growth plate resulting in hypoxia and eventually cell death in a non-classical apoptotic way 
through necrosis or a mixture of apoptosis and necrosis. White et al. recently demonstrated by 
light microscopy bridging bone in the center of a distal human tibial growth plate obtained from a 
12 years and 11 months old girl, which might be an early sign of this shelling process (30).
A limitation of this study is the relatively small number of growth plates that were analysed and 
the fact that some were derived from pathological conditions. To some extent, this is compensated 
by the fact that we were fortunate to obtain a tissue sample from a human growth plate just in the 
rapid process of undergoing epiphyseal fusion, which allowed us to investigate possible underlying 
mechanisms. In addition, the underlying mechanism of epiphyseal maturation and fusion will be 
the same for all growth plates regardless of the underlying disease of each patient since eventually 
longitudinal growth stopped in all patients by the end of puberty. When performing electron 
microscopy, the gold standard in cell death research, we found no clear signs of classical apoptosis 
in any of the human growth plates studied including the fusing one. It should be mentioned that 
fixation was not performed in the optimal way for electron microscopy. However membranes 
were not disrupted in the way one would expect if tissue damage had occurred secondary to 
fixation problems. Furthermore, all tissues were processed in the same way and there were clear 
differences in chromatin pattern and collagen fibres which were nicely preserved.
In summary, a unique piece of fusing human growth plate tissue clearly demonstrate that classical 
apoptosis is not likely to be involved in the process of human growth plate fusion. We found 
signs suggestive for hypoxia and necrosis, but the exact mechanism through which chondrocytes 
disappear during epiphyseal fusion in humans still needs to be defined.
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Abstract
Objective: Mesenchymal stem cells are multipotent cells capable of differentiation into several 
mesenchymal lineages. These cells have been isolated from various tissues such as adult bone 
marrow, placenta and fetal tissues. Since a specific phenotypical marker for MSCs is lacking, 
MSCs are currently characterized on the basis of phenotype and capacity to differentiate into 
multiple mesenchymal lineages. However, how the potential of these cells to differentiate into 
the chondrogenic lineage is influenced by the tissue of origin has not been examined. The aim of 
this study was to investigate whether MSCs isolated from different sources exhibit differential 
multilineage differentiation potential.
Design: MSCs from fetal and adult tissues were phenotypically characterized and examined for 
their differentiation capacity, based on morphological criteria and expression of extracellular 
matrix components. 
Results: Our results show that both fetal and adult MSCs undergo chondrogenesis under 
appropriate conditions. Nevertheless, MSCs of bone marrow origin, either fetal or adult, exhibit a 
higher chondrogenic potential than fetal lung and placenta derived MSCs, as demonstrated by the 
appearance of typical morphological features of cartilage, the intensity of Toluidine Blue staining 
and the expression of collagen type II, IX and X after culture under chondrogenic conditions. In 
addition, the capacity of MSCs to differentiate into chondrocytes was reduced upon passaging of 
cells.
Conclusions: MSCs are an attractive source for cartilage tissue engineering strategies. Hence, 
exploring the chondrogenic potential of different sources is of great interest for such a purpose. 
Our study indicates that bone marrow is to be considered as the preferred MSC source for cartilage 
engineering.
Introduction
Articular cartilage has a limited capacity of healing after injury. Traumatic damage and degenerative 
diseases of the cartilage such as osteoarthritis or rheumatoid arthiritis are common health 
problems worldwide. Therefore a lot of interest has recently emerged in techniques for cartilage 
tissue engineering. The current strategies of cartilage repair, based on the use of autologous 
chondrocytes, have some limitations including the small number of cells available with restricted 
proliferative capacity and the further damage at donor site of harvest. For these reasons, new 
techniques are now focusing on the use of mesenchymal progenitor cells to be delivered within 
an appropriate carrier system to repair and regenerate pathologically altered cartilage 1,2. In 
fact, mesenchymal stem cells (MSCs) play a role in bone and cartilage homeostasis and it has 
been shown that the chondrogenic activity of these cells is reduced in patients with advanced 
osteoarthritis (OA) 3. One of the mechanisms involved in the repair of damaged articular cartilage 
may be the de novo chondrogenesis from MSCs 4,5. Therefore, based on the in vitro observation 
of the differentiation into chondrocytes, on their expandability and availability, MSCs can be 
considered as an attractive candidate for purposes of cartilage engineering 6,7.
MSCs are multipotent cells with the ability to differentiate into several mesenchymal lineages, 
including osteoblasts, adypocytes and chondrocytes 8-10. Although MSCs were originally isolated 
from bone marrow 11, they have also been isolated from other tissue sources. MSCs have been 
identified in fetal tissues such as lung, bone marrow, liver and spleen in first- and second-trimester 
12,13. Placenta has been shown to be another rich source of MSCs of both fetal and maternal origin 14; 
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and MSCs have been also isolated from umbical cord blood, although in low frequency, and adipose 
tissue. At present no unique phenotype has been identified for MSCs; therefore the isolation and 
characterization of MSCs relies on the expression of a number of characteristic markers on culture 
expanded cells and on their ability to differentiate into the various mesenchymal differentiation 
lineages. 
In the present study, we investigate the multilineage differentiation potential of MSCs derived 
from 4 different sources and whether this capacity is influenced by the tissue of origin.
Materials and methods
Isolation and culture of human MSCs
Fetal tissues
Fetal lung (fL) and fetal bone marrow (fBM) were obtained from the same fetus from women 
undergoing elective termination of pregnancy between 15 and 22 weeks of gestation.  The study 
was approved by the hospital ethical committees and informed consent was obtained. Single cell 
suspensions of fetal lung were made by mincing and flushing the organ through a 100 mm nylon 
filter with IMDM medium (Cambrex, Verviers, Belgium) containing 1% penicillin/streptomycin 
(P/S; Cambrex, Verviers, Belgium) and 2% heat-inactivated fetal calf serum (FCS; Cambrex, 
Verviers, Belgium), i.e. washing medium. Single cell suspensions of fetal bone marrow were 
obtained by penetrating the long bones with a needle (23 gauge) and flushing the bones with 
washing medium. After washing, the cell suspension was depleted of red cells by incubation for 
10 minutes in NH4Cl (8,4 g/L)/KHCO3 (1/g) buffer at 4 °C. The cells were subsequently plated 
at 160.000/cm² in culture medium consisting of M199 (Gibco, Paisley, Scotland) supplemented 
with 10% FCS, P/S, Endothelial Cell Growth Factor (ECGF) 20 mg/ml (Roche Diagnostics GmbH, 
Mannheim, Germany) and heparin 8 U/ml in tissue culture flasks (Greiner Bio-One GmbH, 
Mannheim, Germany) previously coated with 1% gelatin for 30 minutes at room temperature.
Placenta   
Placentas (PL) were derived from second- and third-trimester pregnancies after informed consent 
and approval by the hospital ethical committees. Tissue specimens of placenta (maternal origin) 
were first washed with PBS; single cell suspensions were made by mincing and flushing the tissue 
through a 100 mm nylon filter with washing medium. The cells were subsequently cultured 
as described above. To confirm the maternal origin of these cells, molecular HLA-typing was 
performed on the PL-MSCs cultures.
Adult bone marrow
Adult bone marrow (aBM) samples were obtained from healthy donors for allogeneic stem cell 
transplantation under a protocol approved by the Ethical Review Board. Mononuclear cells were isolated 
by density gradient (Ficoll, 1.077 g/ml) and plated at 160.000/cm² in culture medium consisting of 
DMEM-Low Glucose (Gibco, Paisley, Scotland) supplemented with 10% FCS and P/S.
All cells were kept in a humidified atmosphere at 37 °C with 5% CO2. Three to five days after 
plating, non-adherent cells were removed and the medium was refreshed. When grown to 
confluency, adherent cells were detached with trypsin/EDTA (Cambrex, Verviers, Belgium) for 5 
minutes at 37 °C and reseeded for expansion or differentiation.
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Flow cytometric analysis 
Culture expanded fL-, fBM-, aBM- and PL-MSCs were phenotypically characterized by flow 
cytometry (FACSScan, Becton Dickinson). Fluorescein isothiocyanate (FITC) or phycoerythrin 
(PE) conjugated antibodies against CD166 (CLB, Amsterdam The Netherlands), CD105 (Ancell 
Corporation, Bayport, MN, USA), CD90 (Pharmingen, San Diego, CA), CD34, CD45 and CD80 
(Beckton Dickinson, San Jose, CA), CD31 (DAKO, Glostrup, Denmark), HLA-ABC (Instruchemie, 
Hilversum, The Netherlands), HLA-DR (Beckton Dickinson, San Jose, CA) were used, as well as 
isotype controls.
Osteogenic and adipogenic differentiation   
The adipogenic and osteogenic differentiation capacity of MSCs from the 4 different sources 
was determined as previously described 13. In short, to induce osteogenic differentiation, cells 
were cultured in a-MEM supplemented with 10% FCS, P/S, dexametasone (10-7 M) and ascorbic 
acid (50 mg/ml). b-glycerophosphate (5 mM) was added from day 7 onwards. For adipogenesis, 
insulin (10 mg/ml), indomethacin (0,25 M) and 1-methyl-3-isobutylxantine (IBMX, 50 mM) were 
added to this medium. Cells were incubated in differentiation medium for 3 weeks, with medium 
replacement twice a week, at 37°C with 5% CO2. To detect the osteogenic differentiation cells were 
stained for alkaline phosphatase (AP) activity using Fast Blue and for calcium depositions with 
Alzarin Red. The adipogenic differentiation was evaluated through the morphological appearance 
of fat droplets.
Chondrogenic differentiation
For chondrocyte differentiation, 200,000 MSCs were placed per well in 96-well suspension 
culture plates, U-shape, (Greiner Bio-One GmbH, Mannheim, Germany) and centrifuged at 1200 
rpm for 4 minutes to a pellet. Pellets were cultured at 37 °C with 5% CO2 in 200 ml of serum-
free chondrogenic medium consisting of DMEM-High Glucose (Gibco, Paisley, Scotland), 40 mg/
ml proline (Sigma, USA), 100 mg/ml sodium pyruvate (Sigma, USA), 50 mg/ml ITS+Premix (BD 
Biosciences, Bedford, MA), 1% Glutamax (Gibco, Paisley, Scotland), P/S, 50 mg/ml ascorbate-
2-phosphate (Sigma, USA), 10-7 dexametasone (Sigma, USA), 10 ng/ml Transforming growth 
Factor-b3 (TGF-b3, R&D Systems, Minneapolis) and  500 ng/ml Bone Morphogenetic Protein-6 
(BMP-6, kindly provided by dr. S. Vucikevic) The medium was refreshed every 3 days for 21 days. 
We investigated at least three samples per source and 3 different passages per sample.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Total RNA was extracted from 1 million undifferentiated MSCs and from pellets at day 21 
of the differentiation period, from each source, using RNAeasy kit (Quiagen Gmbh, Hilden). 
RNA was reverse transcribed into cDNA using First Strand cDNA Synthesis kit for RT-PCR 
(Roche Diagnostics Gmbh, Mannheim, Germany) according to the manifacturer’s instructions. 
cDNA was amplified using a GeneAmp PCR System 2400 (Applied Biosystems, Foster City, 
CA). Expression of collagen type II, IX and X mRNA was quantified by real-time quantitative 
PCR using the Bio-Rad iCycler with SYBR Green. Data were corrected for β2-microglobulin 
expression. The following oligonucleotide primers were used: collagen type II: forward 
5’-CCCTCTCCCACACCTTCCTC-3’ and reverse 5’-GGGTGAGGGATTCCAGGGAAA-3’; collagen type 
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IX: forward 5’-AGGACACAAGGGTGAAGAAGGT-3’ and reverse 5’-TTTTCCCCTTTGTCCCCAACTATG-3’; 
collagen type X: forward 5’-TTTTGCTGCTAGTATCCTTGAACTT-3’ and reverse 5’-AGGAGTACCTTGCTCT 
CCTCTTACT-3’; β2-microglobulin: forward 5’-TGCTGTCTCCATGTTTGATGTAT CT-3’ and reverse 
5’-TCTCTGCTCCCCACCTCTAAGT-3’. All PCR reactions were performed with 5 ng cDNA and 
according to the manufacturer’s protocol of the qPCR Core Kit (Eurogentec, Southampton, UK) in 
a final volume of 25 μl.
The cDNA was amplified using the following thermal cycling conditions: one cycle at 50 °C for 2 
min and 95 °C for 10 min, followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C. Each sample 
was assayed in triplicate and water was used as a negative control. Fluorescence spectra were 
recorded and the threshold cycle number (Ct) was read. For each source mean Ct was calculated 
and from this value the fold difference from expression in the human growth plate according to 
the equation 2-∆∆Ct. For visualization, this value was log-transformed and expressed in figure 2C.
Histological analysis
After 21 days of culture in chondrogenic medium, pellets were fixed in 10% formalin, dehydrated 
by treatment with graded ethanols and incubated in butanol overnight. Thereafter pellets were 
embedded in paraffin and cut into 5 mm sections using a Reichert Jung 2055 microtome (Leica, 
Rijswijk, The Netherlands). The sections were then mounted on glass slides and stained with 
Toluidine Blue. 
The immunohistochemical staining for collagen type X was performed on deparaffinized sections. 
To block non-specific activity, sections were pretreated with hydrogen peroxidase. Sections were 
stained with mouse monoclonal antibody against collagen type X (Quartett, Berlin, Germany). 
The binding of mouse IgG was detected by biotinylated rabbit-anti-mouse IgG (DAKO, Glostrup, 
Denmark), followed by incubation with horseradish-peroxidase-conjugated-streptavidine 
(Amersham Biosciences, UK). The peroxidase activity was revealed using 3-amino-9-ethylcarbazole 
(AEC) substrate. After sections were washed, they were counterstained with hematoxylin. 
Results
Morphology and immunophenotypic characterization of MSCs
MSCs isolated from all four different sources displayed the characteristic MSC-like spindle-shape, 
however subtle differences in morphology were present (Figure 1A). fL- and PL-MSCs showed a 
more elongated and thin shape compared to the rounder  and thicker shape of BM-MSCs.
MSCs from all samples were immunophenotypically analyzed at passage 2 or 3. The phenotypes 
of fL-, fBM-, aBM- and PL-MSCs were similar and in agreement with previous publication 9,13,14, i.e. 
CD90, CD105, CD166, HLA-ABC positive and CD34, CD45, CD31, CD80, HLA-DR negative (Figure 1B). 
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Figure 1. Morphology and immunophenotype of culture-expanded MSCs. 
(A) MSCs from the four different sources display the characteristic spindle-shaped morphology, however 
subtle differences are present. a, b: Morphology of fBM- and aBM-MSCs respectively, showing a splindle-
round shape. Magnification x5. c, d: Morphology of fL- and PL-MSCs respectively, displaying a spindle-thin 
shape. Magnification x10. (B) Immunophenotypic characterization of MSCs from a representative sample.
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Osteogenic and adipogenic differentiation 
To examine the differentiation capacity of MSCs from the different sources, cells were induced 
into osteoblasts and adipocytes and examined by histological stainings. fL-, fBM-, aBM-MSCs and 
PL-MSCs were all able to differentiate into osteoblasts as demonstrated by the histologic detection 
of alkaline phosphatase activity and calcium depositions, and into adipocytes as revealed by 
the formation of lipid droplets (data not shown). However, PL-MSCs showed a lower ability to 
form both osteoblasts and adipocytes, while fL-MSCs were less capable to differentiate into the 
adipogenic lineage, as compared to bone marrow sources (Table 1). 
The differentiation capacity into osteoblasts and adipocytes was maintained, unmodified, untill 
passage 7 (P7). 
Table 1. Differentiation potential of MSCs derived from different tissue sources
The presence of adipocyte-like morphology, the intensity of Alzarin Red and Toluidine Blue staining and the 
chondrocyte-like morphology are scored as: -, +/-, +, ++. The adipocyte-like morphology is defined by the 
appearance of fat droplets. The chondrocyte-like morphology is defined by the following features: decrease in 
cell density with distance between cells, rounded morphology of cells and nuclei, deposition of extracellular 
matrix, presence of chondrocytic lacunae. Only pellets that are scored + or ++ for both the Toluidine Blue 
staining and the chondrocyte-like morphology are considered positive for cartilage formation (last column 











N. of positive 
pellets/total N. of 
pellets evaluated
fL-MSC + ++ +/- +/- 0/4
fBM-MSC ++ ++ ++ ++ 3/3
aBM-MSC ++ ++ + ++ 4/4
PL-MSC +/- +/- - - 0/4
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The chondrogenic differentiation capacity of MSCs is influenced by the tissue 
of origin 
Next, the chondrogenic differentiation capacity of MSCs of different origin was examined and 
compared. FL- (n= 4 samples), fBM- (n= 3 samples, derived from the same fetus), aBM- (n= 4 
samples) and PL-MSCs (n= 4 samples, maternal origin) were centrifuged into micromasses, 
cultured as pellets and differentiated in serum-free medium containing ascorbate-2-phosphate, 
dexamethasone, TGF-b3 and  BMP-6. 
MSCs from all sources formed a pellet after centrifugation, although pellets consisting of fL- and 
PL-MSCs were frequently less stable and showed a more irregular shape compared to the pellets 
from fBM- and aBM-MSCs that were firm and spherical. Pellets derived from fBM- and aBM-MSCs 
were larger in size after 21 days of culture compared to those derived from fL- and PL-MSCs. In 
particular, fBM- and aBM-MSCs showed an increase in both the diameter and the area of the pellets 
after 3 weeks of culture in chondrogenic medium (data not shown). Furthermore, a 4.2- and a 
2.9-fold increase in weight was observed in pellets formed by fBM and aBM-MSCs respectively 
at day 21 of culture, whereas fL- and PL-MSCs exhibited a decrease in weight of pellets over the 
culture period (Figure 2A). These observations suggest that cartilage extracellular matrix has 
been syntesized and deposited in pellets from bone marrow cells, leading to the increase in size 
and weight. 
To more specifically analyze the process of chondrogenesis, the expression of collagen type II, IX 
and X was measured by Q-PCR on undifferentiated cells and on pellets 3 weeks after induction 
(Figure 2B). Pellets formed by fBM- and aBM-MSCs showed a marked increase in the expression of 
collagen type II, IX and X after the induction period, compared to fL- and PL-MSCs pellets. These data 
were confirmed by the histological analysis: fBM- and aBM-MSCs produced more proteoglycans, 
hence more extracellular matrix, and expressed more chondrocyte-like lacunae, as indicated by 
the intensity of the Toluidine Blue staining (Figure 2C). Moreover, the immunohistochemical 
staining for collagen type X was positive only in sections derived from fBM and aBM samples, 
suggesting that only these cells started to terminally differentiate into hypertrofic chondrocytes 
(Figure 2D). A scoring system was used to compare the different degrees of chondrogenic 
differentiation between the 4 sources; evaluating the intensity of the Toluidine Blue staining and 
the appearance of the typical chondrocyte-like morphology, both scored from – to ++. The stained 
sections from both fBM- and aBM-MSCs obtained the highest score with 100% of the samples 
evaluated demonstrating differentiatiation into chondrocytes; in fact, fBM- and aBM- cells showed 
the most intense Toluidine Blue staining and the typical morphological features of differentiated 
cartilage such as the decrease in cell density with distance between cells, the rounded morphology 
of cells, the deposition of extracellular matrix stained in purple and the presence of chondrocytic 
lacunae, whereas samples from fL- and PL-MSCs didn’t (Table 1). 
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Figure 2. Chondrogenic differentiation of MSCs from different sources. (page 156)
(A) Wet weights of the pellets from the four different sources at day 1 and 21 of the induction period (n = 3). 
(B)  Real-time RT-PCR analysis of collagen type II, IX and X during chondrogenic differentiation corrected 
for the housekeeping gene b2 microglobulin. Values are fold difference compared to expression in human 
growth plate (GP) and expressed as log (2--∆∆Ct) (C) Toluidine Blue staining on paraffin embedded sections 
after 3 weeks of differentiation. Representative pictures from each source at passage 3 are shown: a) fL-MSCs; 
b) fBM-MSCs; c) aBM-MSCs; d) PL-MSCs; e) and f) are enlargements of figure 2C b) and c) respectively, for 
detailed morphology. (D) Immunohistochemical staining for collagen type X on deparaffinezed sections after 
the induction period. Representative pictures at passage 3 are depicted: a) fL-MSCs; b) fBM-MSCs; c) aBM-
MSCs; d) PL-MSCs; e) and f) are enlargements of figure 2D b) and c) respectively, for detailed morphology.
The chondrogenic differentiation capacity of MSCs decreases with passage 
number
In order to examine whether the number of cell passages has an influence on the chondrogenic 
differentiation capacity of MSCs, different passages of fL-, fBM-, aBM- and PL-MSCs were evaluated. 
When considering fBM- and aBM-MSCs, a passage-dependent decrease in cartilage formation was 
observed (Table 2). In particular, the early passages (P2-3) displayed the most intense Toluidine 
Blue staining and all the typical features of differentiated cartilage, whereas the later passages (P4-
5 and P6-7) showed only a moderate or mild staining with less evidence of cartilage differentiation 
(data not shown). Moreover, the capacity of BM-MSCs to differentiate into chondrocytes declined 
between passage 6 and 8. For fL- and PL-MSCs, the influence of cell passage was not evident since 
little or no differentiation towards the chondrogenic lineage was observed overall.  
Table 2. Influence of cell passage on the chondrogenic capacity of MSCs from different tissue sources. 
P2-3 P4-5 P6-7
fL-MSC 0/4 0/4 0/4
fBM-MSC 3/3 3/3 1/3
aBM-MSC 4/4 4/4 2/4
PL-MSC 0/3 0/3 0/4
The differentiation capacity is expressed as number of positive samples on the total number of 
samples evaluated per passage-group. A sample is scored positive when satisfying the criteria 
described in Table 1. 
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Discussion
Skeletal defects resulting from disease, malformation or injury are an interesting area of 
application for stem cell therapy. The therapeutic effect of the transplantation of MSCs in children 
with Osteogenesis Imperfecta, a genetic disorder resulting in the abnormal production of collagen 
type I 15-17, suggests the potential of MSCs to ameliorate bone disorders. MSCs are an ideal candidate 
for strategies of tissue engineering since they are easily isolated and can be rapidly expanded to 
numbers that are required for clinical application 10,18,19.
In this study we compared the chondrogenic differentiation potential of culture expanded MSCs 
derived from fetal BM and lung, placenta and adult BM. In comparison with fetal lung and placenta, 
fetal BM derived MSCs exhibited a significant enhanced capacity to differentiate into chondrocytes, 
as evidenced by the increase in weight, diameter and area of pellets formed by bone marrow cells 
over the differentiation period, the increased levels in the expression of mRNA of extracellular 
matrix components, such as collagen type II, IX and X, the positivity of the immunohistochemical 
staining for collagen type X and the marked intensity of the Toluidine Blue staining. A similar 
prefered chondrogenic potential was observed for adult BM-derived MSCs, showing that 
BM as a source of MSCs was responsible for this differentiation potential, rather that the fetal 
developmental stage of the tissue. The chondrogenic differentiation was reduced and ultimately 
lost, after prolonged passages of the cultures. Although in vivo experiments are required to further 
substantiate the biological significance of these findings, our results suggests BM as the preferred 
source for cartilage tissue engineering.
MSCs have been shown to require specific culture conditions to induce differentiation towards the 
chondrogenic lineage. These requirements include a high cell density facilitating cell-cell contact 
and the use of serum-free medium with the addition of bioactive factors 20. In particular BMP-6, 
a member of the TGF-b superfamily of growth factors, has been demonstrated to enhance the 
chondrogenic differentiation of human MSCs in a pellet culture system 21,22. Our results confirm 
these findings and add that not only aBM-MSCs but also MSCs isolated from fetal tissues, namely 
lung and bone marrow, can undergo chondrogenesis under the same conditions.
In a study from in’t Anker and colleagues 13 it was shown that MSCs isolated from second-trimester 
fetal bone marrow, lung, liver and spleen exhibit a different potential to differentiate into osteoblast 
and adipocytes, despite a similar immunophenotype. Moreover, a recent study from Im et al 23 
demonstrated that adipose tissue-derived MSCs possess a lower osteogenic and chondrogenic 
potential than BM-derived MSCs. Also in our experiments, despite MSCs derived from the four 
different sources showed a comparable phenotypic characterization and morphology, the capacity 
to form cartilage was more expressed in fBM- and aBM-MSCs. Moreover, we found that PL-MSCs 
were less capable to form both osteoblasts and adipocytes, while fL-MSCs showed to have a lower 
ability to differentiate into the adipogenic lineage compared to bone marrow sources. These 
differences in the differentiation potential might reflect some intrinsic diversities of MSCs residing 
in the various tissues, suggesting that the relation between immunophenotype and function of 
MSCs needs to be further investigated. Alternatively, the frequency of cells with lineage-specific 
differentiation capacity may differ between tissue sources. Indeed, the identification of specific 
markers enabling to distinguish between different populations of MSCs would be an important 
tool in the understanding and employment of these cells in the clinical setting.
We found that the chondrogenic potential of MSCs decreases with the increase of the cell passage, 
as shown by the inferior growth in size and the mild intensity of the Toluidine Blue staining in 
pellets from the later passages (P6-7). These findings are in agreement with the study from Sekiya 
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et al 22 in which a decrease in the chondrogenic potential of adult bone marrow-derived MSCs was 
seen after each consecutive passage under very similar culture conditions. In Sekiya experience, 
only a selected population of MSCs, the so called small and rapidly self-renewing cells (RS cells), 
retained the ability to form cartilage at P5. This loss of chondrogenic potential may be due to 
the graduate elimination of MSCs with chondrogenic potential and overgrowth by MSCs that lack 
differentiation potential, or may be due to functional alterations in chondrogenic MSCs.
In conclusion, our results show that: I) MSCs of both fetal and adult origin undergo chondrogenesis 
under appropriate culture conditions; II) fBM- and aBM-MSCs express a higher chondrogenic ability 
than fL- and PL-MSCs, based on morphological, molecular, histochemical and immunohistochemical 
criteria; III) an inverse correlation between passage number and chondrogenic differentiation 
capacity of MSCs is present. Based on these observations and considering the attractive role that 
MSCs could play in strategies of cartilage tissue engineering, our data suggest that bone marrow 
cells are to be considered as the preferred MSC source to be employed for cartilage repair. 
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Abstract 
Most studies on growth plate (GP) maturation and fusion have been carried out in animal models 
not fully representing the human epiphyseal GP. We used human fetal bone marrow-derived 
mesenchymal stem cells (hfMSCs) differentiating towards chondrocytes as an alternative model 
for the GP. Our aims were to assess whether chondrocytes derived from hfMSCs are a valid model 
for the GP and to study gene expression patterns associated with chondrogenic differentiation.
Microarray and principal component analysis were applied to study gene expression profiles 
during chondrogenic differentiation. A set of 315 genes was found to correlate with in vitro 
cartilage formation. Several identified genes are known to be involved in cartilage formation and 
validate the robustness of the differentiating hfMSC model. Other genes like Bradykinin and IFN-γ 
signaling, CCL20, and KIT were not described in association with chondrogenesis before. KEGG 
pathway analysis using the 315 genes revealed 9 significant signaling pathways correlated with 
cartilage formation.
To determine which type of hyaline cartilage is formed, we compared the gene expression profile 
of differentiating hfMSCs with previously established expression profiles of human articular (AC) 
and epiphyseal GP cartilage. As differentiation towards chondrocytes proceeds, hfMSCs gradually 
obtain a gene expression profile similar to epiphyseal GP cartilage, but less resembling the 
fingerprint of AC. This study validates differentiating bone marrow-derived hfMSCs as an excellent 
model for the epiphyseal GP. The hfMSC model offers the opportunity to unravel molecular 
mechanisms underlying growth regulation as they occur in the human growth plate.
Introduction
Growth of the long bones of the human skeleton occurs as the result of a tightly orchestrated 
proliferation and differentiation program called endochondral ossification. In the epiphyseal 
growth plate of long bones, chondrocytes originating from mesenchymal stem cells subsequently 
undergo proliferation, hypertrophic differentiation, and programmed cell death before being 
replaced by bone. At the time of sexual maturation, growth first increases but at the end of puberty 
epiphyseal fusion and termination of growth occur. Our knowledge on the molecular mechanisms 
underlying growth regulation is limited, although estrogen has been identified as a key regulator 
of growth plate maturation and fusion (1). Gaining a detailed understanding of growth regulatory 
processes is essential to facilitate the development of novel strategies for the treatment of various 
growth disorders.
Commonly used animal models for studying growth plate regulation do not fully represent the 
human epiphyseal plate. For example, rodent growth plates do not fuse at the end of sexual 
maturation (2), and therefore do not display an important hallmark of human growth plate 
development. The shortcoming of the mouse model is clearly demonstrated by the contrast 
between the marginally affected growth phenotype of the estrogen receptor alpha (ERα) knock out 
mouse (αERKO) (3) and the prominent growth phenotype of a male patient lacking functional ERα 
(4), characterized by the absence of epiphyseal fusion and continuation of growth into adulthood.
The lack of representative animal models has led to the realization that alternative human 
models are essential to elucidate the mechanisms involved in growth plate regulation and 
fusion. However, human growth plate specimens are difficult to obtain, whereas in vitro models 
such as chondrosarcoma cell lines or articular cartilage-derived chondrocyte cultures have 
limited differentiation capacity, are often difficult to maintain under laboratory conditions or 
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tend to dedifferentiate. Furthermore, articular cartilage and growth plate cartilage have distinct 
functions and it is therefore questionnable whether articular cartilage-derived chondrocytes are 
representative for epiphyseal growth plate chondrocytes. 
Multipotent human mesenchymal stem cells (hMSCs) are a promising in vitro model to study 
chondrogenesis. They have been postulated as an alternative cell source for articular cartilage 
reconstruction and for studying endochondral ossification as it occurs in the epiphyseal growth 
plate (5). In this study, we explored the cartilage forming capacity of human fetal (hf)MSCs to create 
an in vitro model for the human growth plate. We have chosen human fetal bone marrow-derived 
MSC for their superior differentiation characteristics compared to adult bone marrow-derived 
MSCs (6). Efficient cartilage formation was demonstrated by immunohistochemical analysis and 
gene expression profiling was applied to identify genetic pathways involved in the differentiation 
process. In addition, the gene expression profiles of the differentiating hfMSCs were compared 
with global gene expression patterns of human articular and growth plate cartilage to assess 
whether differentiating hfMSCs represent either articular or growth plate chondrocytes. 
Materials and methods
Cell culture
The use of human fetal material was approved by the medical ethical committee of the Leiden 
University Medical Center and an informed consent was obtained from the women undergoing 
elective abortion. Cell suspensions of fetal bone marrow were obtained by flushing the long bones 
of fetuses with M199 washing medium. For the chondrogenic differentiation and microarray 
analysis, cells derived from a single 22 weeks old fetus were used. MSCs derived from other 
fetuses were also stimulated to undergo chondrogenic differentiation. Red cells were depleted 
by incubation for 10 minutes in NH4Cl (8.4 g/L)/KHCO3 (1g /L) buffer at 4°C. Mononuclear cells 
were plated at a density of 16×104 cells/cm² in M199 culture medium (Gibco) supplemented 
with 10% fetal bovine serum (FBS), 1% penicillin/streptavidin (P/S), fungizone, endothelial cell 
growth factor (ECGF) 20 µg/ml (Roche Diagnostics) and heparin 8 U/ml in culture flasks (Greiner)
coated with 1% gelatin. Cultures were kept in a humidified atmosphere at 37°C with 5% CO2. The 
culture medium was changed twice per week. After reaching near-confluence at passage 4 to 5, 
hfMSCs were harvested by treatment with 0.5 % trypsin and 0.5% ethylene diamine tetra acetic 
acid (EDTA; Gibco) for 5 minutes at 37°C and replated for chondrogenic differentiation. 
In vitro chondrogenic differentiation
hfMSCs (2×105 cells/well) were positioned into pellets by centrifugation at 1200 rpm for 4 
minutes in U-shaped 96-well suspension culture plates (Greiner) and cultured at 37°C with 5% 
CO2 in 200 µl of serum-free chondrogenic medium consisting of high-glucose (25 mM) Dulbecco’s 
modified Eagle’s medium (DMEM; Gibco) supplemented with 40 µg/ml proline (Sigma), 100 µg/
ml sodium pyruvate (Sigma, USA), 50 mg/ml ITS (insulin-transferrin-selenic acid) with Premix (BD 
Biosciences), 1% Glutamax (Gibco), 1% penicillin/streptavidin, 50 g/ml ascorbate-2-phosphate 
(Sigma), 10-7 M dexamethasone (Sigma), 10 ng/ml transforming growth factor-β3 (TGF-β3; R&D 
Systems), 500 ng/ml bone morphogenetic protein 6 (BMP6) and antibiotic and antimycotic mix 
(0.06% polymixin, 0.2% kanamycin, 0.2% penicillin, 0.2% streptavidin, 0.02% nystatin and 0.5% 
amfotericin. The medium was changed twice per week for 5 weeks. 
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Histological analysis
Two pellets per time point (after 1, 2, 3, 4, or 5 weeks of chondrogenesis) were used for histological 
evaluation. Pellets were fixed in 10% formalin, dehydrated by treatment with graded ethanols and 
processed for paraffin embedding. 5 µm sections were cut using a Reichert Jung 2055 microtome (Leica). 
For each pellet, only the sections from exactly the center of the pellets were mounted on glass slides. 
Before histological (toluidine blue) or immunohistochemical staining, sections were deparaffinized in 
xylene and graded ethanols followed by three washing steps phosphate buffered saline (PBS). 
For immunohistochemistry, sections were preincubated with blocking buffer (1% H2O2 in 40% 
methanol, 60% tris buffered saline) twice for 15 minutes at room temperature, followed by 
overnight incubation at 4ºC with mouse monoclonal antibody against collagen type II or type X in a 
1:100 dilution (Quartett). Next, sections were incubated with the secondary antibody biotinylated 
rabbit-anti-mouse IgG (DAKO) in a 1:300 dilution, followed by incubation with horseradish-
peroxidase-conjugated-streptavidine (Amersham Biosciences). Staining was visualized with 
3-amino-9-ethylcarbazole substrate in 0.2 mg/ml acetate buffer (pH 5.2) with 0.04% H2O2. 
After counterstaining with hematoxylin, the sections were mounted in Histomount (National 
Diagnostics). Pictures of the stained pellets were taken with a Nikon DXM 1200 digital camera 
using standardized settings.
RNA isolation 
Total RNA from 2·106 undifferentiated hfMSCs derived from the 22-weeks old fetus was extracted 
with Trizol (Invitrogen). After 1, 2, 3, 4, or 5 weeks of chondrogenesis, 60 pellets (per time point) 
were pooled and homogenized in 1ml 4M guanidine isothiocyanate solution (Sigma) and RNA 
was extracted according to the optimized method for RNA extraction from cartilage as described 
by Heinrichs et al. (43). The extracted total RNA was purified using the RNeasy kit according to 
recommendations of the manufacturer (Qiagen).
Gene expression profiling
High RNA quality was confirmed by capillary electrophoresis on an Agilent 2100 bioanalyzer 
(Agilent). Total RNA (100 ng) was amplified and labeled using the GeneChip Two-Cycle cDNA 
Synthesis Kit (Affymetrix) and the MEGAscript T7 Kit (Ambion). For gene expression profiling, 
labeled cRNA was hybridized in duplicate to Affymetrix Human Genome U133 PLUS 2.0 Array 
Genechips. All procedures were carried out according to the manufacturer’s recommendations.
Raw data from Affymetrix CEL files were analyzed using SAS software package Microarray Solution 
version 1.3 (SAS Institute). Custom CDF version 10 with Entrez based gene definitions (44) was 
applied to map the probes to genes. Gene annotation was obtained using the Affymetrix NetAffx 
website (http://www.affymetrix.com/analysis/index.affx). Quality control, normalization and 
statistical modeling were performed by array group correlation, mixed model normalization 
and mixed model analysis respectively. The normalized expression values for each gene were 
standardized by linearly scaling the values across all samples of the time course to a mean of 0 with 
an SD of 1. Analysis of differential gene expression was based on loglinear mixed model of perfect 
matches (45). A false discovery rate of a=0.05 with Bonferroni-correction for multiple testing 
was used to set the level of significance. The raw and normalized data are deposited in the Gene 
Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/; accession no. GSE-XXXX).
Microarray data analysis
The statistical analysis of the microarray data was based on the normalized mean expression values 
per probe at 6 time points with 2 replications at each time point (12 observations per probe). 
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In order to identify subgroups of probes with similar expression profiles over time, a principal 
component analysis (PCA) of the covariance matrix was carried out on the mean expression value 
for each probe at each time point. For each probe, factor scores for principal components 1, 2 and 
3 were obtained by regression analysis of the 12 array results (6 time points in duplicate) for 
that specific probe to those components. The first principal component corresponded with the 
general expression level during the whole experiment, whereas the second and third component 
corresponded with changes over time. Since our interest was to identify genes associated with the 
changes that occur during differentiation from stem cells towards chondrocytes, we focused our 
analysis on the second and third component. By construction, these factor scores had a mean of 
0 with an SD of 1. Generally, the distribution over the factor scores showed a normal distribution 
with outliers. We used a cut-off of ±3.29 to select outlying probes. This cut-off would select 0.1% 
of the probes, if the factors scores would follow a pure normal distribution that could be expected 
if the data were pure noise. The presence of replications allowed us to assess the statistical 
significance of the factor scores and to remove probes that were not significant at the α=5% level. 
In a separate study we compared the gene expression profiles of human articular cartilage (AC) 
and epiphyseal growth plate (GP) cartilage. A set of 1818 significant differentially expressed 
genes was identified, that can be used to discriminate between the two hyaline cartilage subtypes 
(Leijten et al., manuscript in preparation). All AC (n=5) and GP (n=5) samples were derived from 
9 to 17 year old female donors with no history of growth disorders. The gene expression profiles 
of the stem cells differentiating towards chondrocytes were compared with this list. Principal 
component analysis (PCA) with Pearson product-moment correlation was performed to compute 
correlations between the expression profiles.
Pathway analysis
Using sets of probes emerging from PCA, a search for relevant KEGG pathways was performed using 
the DAVID® Knowledgebase, a publicly available bioinformatics tool for functional annotation 
(http://david.abcc.ncifcrf.gov).
Quantitative real-time  polymerase chain reaction (qPCR)
RNA was transcribed into cDNA using the First Strand cDNA Synthesis kit for qPCR (Roche 
Diagnostics) according to the manufacturer’s protocol. Specific primer sets (available on request) 
were designed to amplify aggrecan (ACAN), pannexin 3 (PANX3), epiphycan (EPYC), collagen type 
II (COL2), and type X (COL10), SRY-box 9 (SOX9), WNT11, lymphoid enhancer-binding factor 1 
(LEF1), Gremlin 1 (GREM1), and the housekeeping genes β2-microglobulin, and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH). In order to test donor inter-variation, differentiated MSCs 
isolated from other fetal donors were used for qPCR analysis as well. 
All PCR reactions were performed in triplicate with 5 ng cDNA and according to the manufacturer’s 
protocol of the iQ™ SYBR® Green Kit (Biorad) in a final volume of 25 μl. The cDNA was amplified 
using the following thermal cycling conditions: one cycle at 50°C for 2 min and 95°C for 10 min, 
followed by 40 cycles of 15 s at 95°C and 1 min at 56°C. Fluorescence spectra were recorded and 
the threshold cycle number (Ct) was read. For each time point mean Ct was calculated and from 
this value the fold difference in expression between undifferentiated hfMSCs and differentiating 
cells according to the equation 2-∆∆Ct (normalized fold expression). For visualization, this value was 
log-transformed.
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Results
Chondrogenic differentiation by hfMSCs
Evaluation of protein and mRNA  expression
Immunohistological evaluation showed an increasing expression of cartilage markers with 
time and a gradual morphological change from stem cells to mature and hypertrophic 
chondrocytes (figure 1). The mean diameter of the pellets increased with time, as well as the 
amount of glycosaminoglycans, a major constituent of the cartilaginous extracellular matrix. 
Immunohistochemical staining for collagen type II demonstrated the presence of chondrocytes 
after 1 week of pellet culture. Hypertrophic chondrocytes were first detected after 3 weeks, as 
detected by immunohistochemical staining for collagen type X. At the last stage of differentiation, 
the pellets display a two-layered structure with a core that consists of chondrocytes and that is 
surrounded by a thin outer layer of undifferentiated thin spindle-shaped cells.
Figure 1
Expression of (A) glycosaminoglycans visualized by toluidine blue staining, (B) collagen type II 
immunohistochemistry (brown), and (C) collagen type X immunohistochemistry (brown) during 5 weeks of 
chondrogenic differentiation of hfMSCs to chondrocytes. 
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From each time point RNA was isolated and subjected to microarray analysis. Changes in gene 
expression of a subset of genes consisting of both established marker genes for chondrogenesis and 
differentially expressed genes identified by microarray analysis were validated using qPCR (figure 
2). In concordance with the observations of immunohistological markers of chondrogenesis, 
microarray data and qPCR showed time-dependent increases in the expression of the cartilage 
markers collagen type II, and type X, SOX9, and aggrecan mRNA. To further extend this analysis, 
we randomly selected 7 genes (pannexin 3, epiphycan, WNT11, LEF1, gremlin 1, Dickkopf 1, 
matrilin) that showed marked regulation over time based on microarray analysis. Again, qPCR 
demonstrated a strong correlation between the expression patterns revealed by both techniques 
(results for 5 of these genes are shown in figure 2E-I), providing further support for the robustness 
of our dataset. Repeating the qPCR analysis using RNA isolated from other fetal donors of MSCs 
that were stimulated to undergo chondrogenic differentiation rendered similar gene expression 
patterns as observed for the single 22-weeks old donor derived cells (data not shown).
Principal component analysis and KEGG pathway analysis
The sequential changes that occur during chondrogenic differentiation in the hfMSC model were 
studied with bioinformatics analysis of the microarray data. Using principal component analysis, 
three components were found to explain 99.6% of the variance within our dataset (figure 3.A). The 
factor loadings in figure 3.B show that component 1 describes a general level of gene expression, 
as expected. Component 2 shows to what extent gene expression changed with time during 
chondrogenic differentiation and component 3 signifies whether there was an additional, short 
term elevation or dip in expression around 2 to 3 weeks of differentiation. Since components 2 and 
3 were most likely to contain genes associated with the loss of stem cell characteristics or the gain 
of a chondrocyte phenotype, we focused on those components. 
Using the ±3.29 cut-off in combination with a 5% significance test, we distinguished four subgroups 
of probes. The precise definitions and the resulting numbers of these subgroups are given in figure 
3.C. The scatter plot in figure 3.D illustrates that the numbers of probes in subgroups 1 and 2 
are much larger than the 9 probes (0.05%) that would have been expected under purely random 
selection. Moreover, in these two subgroups nearly all probes in the first selection are significant 
at the 5% level, suggesting that the number of false discoveries in these two groups is quite small. 
More noise is presumably present in the smaller subgroups 3 and 4 based on factor 3 scores.
The profiles of the selected probes demonstrate that subgroup 1 containing the largest number of 
probes (n=146) describes a peak of expression on t0 followed by a decrease in expression thereafter. 
In contrast, the second largest subgroup of probes (n=105) in profile 2 demonstrates increasing 
expression levels from t0 onward. The smaller subgroups 3 and 4 demonstrate lower levels of 
expression with profile 3 (n=49) showing a short-term increase in expression at t1 followed by 
decreases thereafter and profile 4 (n= 15) displaying a short-term expression dip between t1-t2.  
A total of 83 out of 315 probes could not be annotated and was discarded from further analysis. 
The remaining 232 probes that could be matched to genes (supplementary table 1) were used to 
identify 9 KEGG pathways that were significantly associated with chondrogenic differentiation and 
contained 39 genes. (figure 4). Some genes were present solely in one pathway (n= 23), but others 
were found in 2 (n= 6) or 3 (n= 10) pathways (table 1). Three functional groups of genes were 
recognized: 1) growth factor (GF) and GF-related genes; 2) genes associated with the extracellular 
matrix; and 3) genes associated with signal transduction, cell cycle, and cell survival.
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Figure 2
Correlation between qPCR and microarray expression data for (A) aggrecan, (B) collagen II, (C) collagen X, (D) 
SOX9, (E) pannexin 3, (F) epiphycan, (G) WNT11, (H) LEF1, and (I) gremlin 1 during 5 weeks of chondrogenic 
differentiation of hfMSCs. qPCR data are expressed as delta delta CT values corrected for the housekeeping gene 
β2-microglobulin. The primary y-axis (left) indicates the qPCR results as normalized fold expression on a log-
scale. The secondary y-axis (right) indicates the microarray analysis results as least square means (lsm).
174 Regulators of growth plate maturation
Figure 3
Gene selection based on principal component analysis. A) variance explained by components 1-6 from principal 
component analysis. B) principal components 1, 2, and 3 as expression profiles. C) selection of probes based 
on their factor 2 and 3 scores. D) scatterplot view of gene data in respect to their correlation (factor score) to 
prinicpal components 2 and 3. Subgroups 1, 2, 3, and 4 are represented by blue, green, yellow, and pink dots, 
respectively. Side-placed graphs depict the gene expression profiles for genes found in the four subgroups.
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Figure 4
KEGG signaling pathways significantly associated with chondrogenic differentiation of hfMSCs. For each 
pathway, genes showing the same distinct expression profile during 5 weeks of chondrogenic differentiation 
are depicted as groups.
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Gene expression fingerprinting for cartilage subtype
Histological and gene expression analyses showed that the differentiating hfMSCs acquire a 
hyaline cartilage phenotype. Two major types of hyaline cartilage can be distinguished, namely 
articular and epiphyseal cartilage. In order to serve as a model for the epiphyseal growth plate, 
differentiating hfMSCs should obtain a growth plate signature. To test this, we compared the 
expression profiles of the differentiating hfMSCs with previously established profiles of human 
articular and growth plate cartilage (AC and GP, respectively, Leijten et al., in preparation). In a 
three-dimensional schematic representation, samples of AC and GP plot in two different groups 
(figure 5). As expected, AC, GP, and undifferentiated hfMSCs (hMSC_t0) plotted as distinct entities 
in a three-dimensional space. As differentiation progressed, the expression profile of the hfMSCs 
changed, and the differentiating chondrocytes gradually acquired a fingerprint resembling GP, 
but not AC. This analysis demonstrated that the hfMSCs differentiating towards chondrocytes 
acquired a GP cartilage phenotype. 
Figure 5
Three-dimensional overviews of gene expression data in respect to their correlation (factor score) to principal 
components 1, 2, and 3. Red dots, samples of articular cartilage; Green dots, samples of growth plates; Blue 
dots, differentiation time-range of hfMSCs (t0, undifferentiated hfMSCs; t5, mature chondrocytes). Dots 
indicate the mean factor score for all genes on the Affymetrix chip on the three principal components for one 
cartilage sample. Clouds represent the spread around the mean factor score in three dimensions. 
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Discussion
The present study was conducted in order to determine whether fetal bone marrow-derived 
MSCs are a representative human model for studying processes taking place in the epiphyseal 
growth plate and to identify associated signaling pathways. It has been reported that human 
bone marrow-derived MSCs display a better chondrogenic differentiation capacity than those 
derived from other sources, with fetal being superior over adult MSCs (6). Consequently, it seems 
appropriate to use fetal bone marrow-derived MSCs as a model for chondrogenesis. However, fetal 
MSCs are not easily obtained, due to ethical and legal considerations, and as a consequence, adult 
bone marrow-derived MSCs have been used in many previous studies (7-14). 
Chondrogenic differentiation occurred in our in vitro model, as illustrated by the progressive 
expression of the chondrocyte markers collagen type II and X and the cartilaginous matrix 
constituent glycosaminoglycan. The two-layered structure that developed in the pellet during 
chondrogenic differentiation indicates that the differentiation was more successful in the core of 
the pellet.
Further confirmation of chondrogenesis was obtained by analysis of mRNA expression of cartilage 
markers, which, in addition, also validated our microarray results. The observation of similar 
gene expression patterns for all analyzed markers during chondrogenic development of MSCs 
derived from other fetal donors indicates that the selected 22-weeks old fetal MSC-donor was 
representative for fetal bone marrow in general. 
Matrix mineralization was not observed after 5 weeks of differentiation, suggesting that the 
matrix was not ready for mineralization or that environmental stimuli necessary to induce this 
process were absent. 
Microarray analysis generated a multidimensional dataset of differentially expressed genes for 
each time point. Several methods for analyzing such complex data have been reported, many 
based on presence/absence analysis, which starts with the list of differentially expressed genes 
and applies a strict but arbitrary cut-off for differential expression of individual genes (9;14). 
Misinterpretation of the data can easily occur, since genes are assumed to be independent, whereas 
it is more likely that sets of correlated genes play a role in complex biological processes (15). Genes 
that are not considered differentially expressed, but that do play a role in important signaling 
pathways, may be wrongfully eliminated. Another analysis strategy applied by many groups is to 
report on a priori selected pathway(s) of interest, thereby disregarding the relative importance 
of this pathway in view of other potentially co-regulated or interacting pathways. Alternatively, 
we have applied PCA with restrictive criteria as a statistical selection method for identification 
of gene expression profiles associated with the acquisition of chondrocyte characteristics or the 
loss of a stem cell phenotype. Since biological replicates were not included in this study, such a 
stringent approach was necessary in order to minimize potentially false-positive results.
The gene expression data generated with this analytic approach are consistent with previous 
reports on in vitro cartilage formation by adult mesenchymal stem cells. We therefore conclude 
that PCA is a suitable and unbiased analysis tool for data reduction in multidimensional and 
complex microarray experiments. Using this method, 232 genes were identified to be significantly 
associated with chondrogenic differentiation, 39 of which were present in 9 significantly enriched 
KEGG pathways. These 39 genes could be classified in three major functional groups that are 
discussed in the following sections.
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Growth factor (GF) and GF-related genes
Growth factors from the transforming growth factor β (TGF-β), Wnt, Hedgehog and VEGF families 
have been recognized as major regulators of endochondral bone formation in embryonic and 
postnatal cartilage development (16;17). Some family members were also identified to be involved 
in chondrocyte differentiation in our in vitro model.
BMP2 and its downstream effector ID3 are upregulated early in differentiation consistent with 
previous reports on the importance of BMP signaling in chondrogenesis (18;19). Growth and 
differentiation factor 5 (GDF5), previous reported as stimulator of chondrocyte proliferation (20), 
was highly expressed at the earliest time point observed and downregulated thereafter. A similar 
expression profile was found for the BMP inhibitor follistatine (FST) that was previously shown to 
be expressed by proliferative, but not by hypertrophic chondrocytes (21).   
Previous in vitro studies have demonstrated that BMP2 interacts with Wnt and hedgehog family 
members and their downstream effectors, indicating that functional crosstalk between regulatory 
pathways occurs during chondrogenesis (19;22). Such interactions may have taken place in our in 
vitro model as well since several genes out of the Wnt and Hedgehog family were affected during 
differentiation, e.g. WNT5a, WNT11, FZD2, WIF1 and IHH. IHH expression reached a maximum 
after 3 weeks of differentiation, which is in agreement with a stimulatory, PTHrP-independent 
effect of IHH on terminal chondrocyte differentiation in the postnatal growth plate. 
Another major group of regulatory factors found to be involved in chondrogenesis was the 
superfamily of cytokines. Several genes in this group were changing significantly over time, e.g. 
CXCL12, CCL20, interferon-γ (IFN-γ), IFN-γ receptor IFNGR1, interferon-induced transmembrane 
protein 1 (IFITM1) and the cytokine RANKL (receptor activator for nuclear factor κ B ligand). To 
our knowledge a role for CCL20, IFITM1, IFN-γ and its receptor IFNGR1 has not been described 
before in chondrogenesis. 
Vascular endothelial growth factors (VEGF and VEGFC), originally described to promote epiphyseal 
vascularization prior to endochondral ossification, also regulate in vitro chondrogenesis (23-25). 
Both VEGF and VEGFC were significantly changing in expression level early in our model. 
Genes associated with the extracellular matrix 
Progression of chondrogenic differentiation depends on the coordinated expression of ECM 
components and on cell-matrix interactions (16). Several genes involved in focal adhesion, cell-
matrix communication, ECM receptor interaction and matrix remodeling were found to play a role 
in our in vitro model of chondrogenesis.
The expression of cartilaginous ECM proteins, such as collagens (COL1A1, COL1A2, COL2A1, 
COL5A2, COL11A1), chondroadherin (CHAD), cartilage oligomeric matrix protein (COMP), 
secreted phosphoprotein 1 (osteopontin, SPP1), and fibronectin type III (FNDC1), was upregulated. 
Apart from a structural role in the extracellular matrix, FNDC1, SPP1 and CHAD also function as 
integrin ligands and regulate cell-matrix signaling by binding to the cell surface plasma membrane 
protein integrinT. Aggregation of integrins in focal adhesions is induced by activity of myosin light 
chain kinase (MLCK) (26). Upon ligand-integrin binding, signaling complexes are activated that 
mediate downstream effectors of integrin signaling such as phosphoinositide-3-kinase (PI3K) 
(27), thereby stimulating cell proliferation (28). We observed early downregulation of integrin 
signaling-related proteins such as PI3K and MLCK.
Members of the complement and coagulation family of proteins were expressed during in vitro 
chondrogenic differentiation. Coagulation factor XIII (F13A1) expression was upregulated, other 
genes like complement component I (C1R), urokinase-type plasminogen activator (PLAU) and 
bradykinin receptor B2 (BDKRB2) were downregulated during differentiation in our model. These 
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proteins are associated with matrix mineralization (29-31) or matrix degradation in the growth 
plate (32-34). 
Genes associated with signal transduction, cell cycle, and cell survival
Several genes involved in the regulation of cell survival and proliferation and signal transduction 
were found to be important in our in vitro model of chondrogenesis. Caveolin 1 (CAV1), a 
multifunctional scaffolding protein located at cell surface caveolae, regulates TGF, Wnt, cytokine 
and VEGF signaling by modulating their downstream signaling cascades such as JAK/STAT, 
β-catenin/LEF1, MAPK/ERK and PI3K/AKT (35-38). The anti-apoptotic baculoviral IAP repeat 
containing 3 (BIRC3) has been shown to increase the survival of cultured human chondrocytes 
(39). Phosphoinositide-3-kinase (PI3K), proto-oncogene KIT, transcription factor JUN and FOS are 
all associated to the regulation of cell proliferation (40; 41). Expression of the nuclear envelope 
protein lamin B2 (LMNB2) was first upregulated and later in differentiation downregulated in 
our model. Constantinescu et al suggested a role for LMNB2 in suppressing differentiation of 
undifferentiated embryonic stem cells (42).
Conclusion
Many genes identified in this study were previously reported in association with chondrogenesis, 
validating the robustness of differentiating hfMSC as a model for cartilage formation. The 
implication of bradykinin and IFN-γ signaling, CCL20, and KIT are novel findings. Discrepancies 
between our results and reports by others may rely on differences between the source, and 
chondrogenic capacity of MSCs used, the experimental conditions for inducing chondrogenesis, and 
the gene expression analysis methods (9;10;13). Developmental genes essential for chondrogenic 
differentiation (e.g. SOX genes, IGF-I) were not identified, in line with other reports (11). Marginal 
changes in the expression of these genes may be sufficient for inducing major effects, but too 
subtle to be detected by most gene expression analysis methods, including PCA. Alternatively, 
changes occurring within the first days of differentiation may have been unnoticed due to the 
chosen time interval of analysis. 
This study has demonstrated for the first time that bone marrow-derived hfMSCs acquire a GP-, 
but less an AC-like signature during differentiation towards chondrocytes. These findings validate 
differentiating hfMSCs as an excellent model for the epiphyseal growth plate. The application of 
this model in future studies creates the opportunity to unravel molecular mechanisms underlying 
growth regulation in the human epiphyseal plate and allows the analysis of even the earliest stages 
of chondrogenic differentiation. The effects of specific signaling pathways and growth-associated 
hormones (e.g. estrogen), can be studied and (genetically) manipulated in this model, which may 
give an impulse to the development of novel treatment strategies in various growth disorders. 
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Supplemental table 1
Supplementary Table 1
Affymetrix ID Gene code Gene title
205856_at                       SLC14A1              solute carrier family 14 (urea transporter), member 1 (Kidd blood group)                                                                                               
205911_at                       PTHR1                parathyroid hormone receptor 1                                                                                                                                         
219148_at                       PBK               PDZ binding kinase                                                                                                                                                     
213182_x_at                     CDKN1C               cyclin-dependent kinase inhibitor 1C (p57, Kip2)                                                                                                                       
206737_at                       WNT11                wingless-type MMTV integration site family, member 11                                                                                                                  
203868_s_at                     VCAM1                vascular cell adhesion molecule 1                                                                                                                                      
218730_s_at                     OGN              osteoglycin (osteoinductive factor, mimecan)                                                                                                                           
200665_s_at                     SPARC                secreted protein, acidic, cysteine-rich (osteonectin)                                                        
223484_at                       C15orf48             chromosome 15 open reading frame 48                                                                                                                                    
206315_at                       CRLF1                cytokine receptor-like factor 1                                                                                                                                        
205497_at                       ZNF175               zinc finger protein 175                                                                                                                                                
204724_s_at                     COL9A3               collagen, type IX, alpha 3                                                                                                                                             
219410_at                       TMEM45A              transmembrane protein 45A                                                                                                                                              
218391_at                       SNF8                SNF8, ESCRT-II complex subunit, homolog (S. cerevisiae)                                                                                                                
210538_s_at                     BIRC3                baculoviral IAP repeat-containing 3                                                                                                                                    
201487_at                       CTSC                 cathepsin C                                                                                                                                                            
219134_at                       ELTD1                EGF, latrophilin and seven transmembrane domain containing 1                                                                                                           
212551_at                       CAP2                CAP, adenylate cyclase-associated protein, 2 (yeast)                                                                                                                   
206421_s_at                     SERPINB7             serpin peptidase inhibitor, clade B (ovalbumin), member 7                                                                                                              
219837_s_at                     CYTL1               cytokine-like 1                                                                                                                                                        
210220_at                       FZD2                 frizzled homolog 2 (Drosophila)                                                                                                                                        
207064_s_at                     AOC2                 amine oxidase, copper containing 2 (retina-specific)                                                                                                                   
218542_at                       CEP55                centrosomal protein 55kDa                                                                                                                                              
206423_at                       ANGPTL7              angiopoietin-like 7                                                                                                                                                    
231227_at                       ---           Transcribed locus, strongly similar to WNT-5A protein precursor           
229494_s_at                     CD63              CD63 molecule                                                                                                                                                          
223734_at                       OSAP                 ovary-specific acidic protein                                                                                                                                          
206614_at                       GDF5                growth differentiation factor 5 (cartilage-derived morphogenetic protein-1)                                                                                            
205713_s_at                     COMP                 cartilage oligomeric matrix protein                                                                                                                                    
230372_at                       ---           Transcribed locus, PREDICTED: similar to hyaluronan synthase 2 [Pan troglodytes]                                                       
1563724_at                      SACS                 Spastic ataxia of Charlevoix-Saguenay (sacsin)                                                                                                                         
203499_at                       EPHA2                EPH receptor A2                                                                                                                                                        
1556499_s_at                    COL1A1               collagen, type I, alpha 1                                                                                                                                              
219230_at                       TMEM100              transmembrane protein 100                                                                                                                                              
206790_s_at                     NDUFB1               NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 1, 7kDa                                                                                                             
204825_at                       MELK                 maternal embryonic leucine zipper kinase                                                                                                                               
212565_at                       STK38L               serine/threonine kinase 38 like                                                                                                                                        
1554997_a_at                    PTGS2                prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase & cyclooxygenase)                                                                                  
204894_s_at                     AOC3                 amine oxidase, copper containing 3 (vascular adhesion protein 1)                                                                                                       
203886_s_at                     FBLN2               fibulin 2                                                                                                                                                              
203153_at                       IFIT1              interferon-induced protein with tetratricopeptide repeats 1                                          
242517_at                       KISS1R               KISS1 receptor                                                                                                                                                         
1552340_at                      SP7                  Sp7 transcription factor                                                                                                                                               
203963_at                       CA12                 carbonic anhydrase XII                                                                                                                                                 
1554950_at                      AGC1                 aggrecan 1 (chondroitin sulfate proteoglycan 1, large aggregating proteoglycan)                                       
232451_at                       ---           MRNA; cDNA DKFZp564I0816 (from clone DKFZp564I0816)                                                                                                                    
227705_at                       TCEAL7               transcription elongation factor A (SII)-like 7                                                                                                                         
1570574_at                      GPR177               G protein-coupled receptor 177                                                                                                                                         
218273_s_at                     PPM2C                protein phosphatase 2C, magnesium-dependent, catalytic subunit                                                                                                         
224735_at                       CYBASC3              cytochrome b, ascorbate dependent 3                                                                                                                                    
239787_at                       KCTD4                potassium channel tetramerisation domain containing 4                                                                                                                  
226281_at                       DNER                 delta-notch-like EGF repeat-containing transmembrane                                                                                                                   
218839_at                       HEY1                hairy/enhancer-of-split related with YRPW motif 1                                                                                                                      
214710_s_at                     CCNB1                cyclin B1                                                                                                                                                              
231798_at                       NOG                Noggin                                                                                                                                                                 
204595_s_at                     STC1              stanniocalcin 1                                                                                                                                                        
209189_at                       FOS               v-fos FBJ murine osteosarcoma viral oncogene homolog                                                                                                                   
203297_s_at                     JARID2               Jumonji, AT rich interactive domain 2                                                                                                                                  
230137_at                       TMEM155              transmembrane protein 155                                                                                                                                              
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208078_s_at                     SNF1LK               SNF1-like kinase /// SNF1-like kinase                                                                                                                                  
217989_at                       DHRS8                dehydrogenase/reductase (SDR family) member 8                                                                                                                          
229125_at                       ANKRD38              ankyrin repeat domain 38                                                                                                                                               
205141_at                       ANG /// RNASE4       angiogenin, ribonuclease, RNase A family, 5 /// ribonuclease, RNase A family, 4                                                                                        
204712_at                       WIF1               WNT inhibitory factor 1                                                                                                                                                
1552960_at                      LRRC15               leucine rich repeat containing 15                                                                                                                                      
225155_at                       SNHG5                small nucleolar RNA host gene (non-protein coding) 5                                                                                                                   
204351_at                       S100P                S100 calcium binding protein P                                                                                                                                         
1569372_at                      TUBB2B               Tubulin, beta 2B                                                                                                                                                       
205097_at                       SLC26A2              solute carrier family 26 (sulfate transporter), member 2                                                                                                               
204881_s_at                     UGCG                 UDP-glucose ceramide glucosyltransferase                                                                                                                               
203434_s_at                     MME              membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase)                                                                                     
1568574_x_at                    SPP1             Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I)                                                                          
206908_s_at                     CLDN11               claudin 11 (oligodendrocyte transmembrane protein)                                                                                                                     
1556153_s_at                    NFKBIZ               Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta                                                                                     
210643_at                       TNFSF11              tumor necrosis factor (ligand) superfamily, member 11, RANKL                                                                                                                  
203305_at                       F13A1                coagulation factor XIII, A1 polypeptide                                                                                                                                
213791_at                       PENK                 proenkephalin                                                                                                                                                          
242324_x_at                     CCBE1                collagen and calcium binding EGF domains 1                                                                                                                             
213338_at                       TMEM158              transmembrane protein 158                                                                                                                                              
213139_at                       SNAI2                snail homolog 2 (Drosophila)                                                                                                                                           
217979_at                       TSPAN13              Tetraspanin 13                                                                                                                                                         
215420_at                       IHH              Indian hedgehog homolog (Drosophila)                                                                                                                                   
229645_at                       C18orf51             chromosome 18 open reading frame 51                                                                                                                                    
218717_s_at                     LEPREL1              leprecan-like 1                                                                                                                                                        
238332_at                       ANKRD29              ankyrin repeat domain 29                                                                                                                                               
205828_at                       MMP3                 matrix metallopeptidase 3 (stromelysin 1, progelatinase)                                                                                                               
209395_at                       CHI3L1               chitinase 3-like 1 (cartilage glycoprotein-39)                                                                                                                         
204337_at                       RGS4                 regulator of G-protein signalling 4                                                                                                                                    
201939_at                       PLK2                 polo-like kinase 2 (Drosophila)                                                                                                                                        
228844_at                       SLC13A5              solute carrier family 13 (sodium-dependent citrate transporter), member 5                                                                                              
218468_s_at                     GREM1                gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis)                                                                                                         
201467_s_at                     NQO1               NAD(P)H dehydrogenase, quinone 1                                                                                                                                       
224482_s_at                     RAB11FIP4            RAB11 family interacting protein 4 (class II)                                                                      
206239_s_at                     SPINK1               serine peptidase inhibitor, Kazal type 1                                                                                                                               
213492_at                       COL2A1               collagen, type II, alpha 1                                                                         
1552737_s_at                    WWP2               WW domain containing E3 ubiquitin protein ligase 2                                                                                                                     
204162_at                       KNTC2                kinetochore associated 2                                                                                                                                               
213622_at                       COL9A2               collagen, type IX, alpha 2                                                                                                                                             
202497_x_at                     SLC2A3               solute carrier family 2 (facilitated glucose transporter), member 3                                                                                                    
206309_at                       LECT1                leukocyte cell derived chemotaxin 1                                                                                                                                    
1556427_s_at                    LOC221091            similar to hypothetical protein                                                                                                                                        
201762_s_at                     PSME2                proteasome (prosome, macropain) activator subunit 2 (PA28 beta)                                                                                                        
201795_at                       LBR                  lamin B receptor                                                                                                                                                       
209946_at                       VEGFC                vascular endothelial growth factor C                                                                                                                                   
210432_s_at                     SCN3A                sodium channel, voltage-gated, type III, alpha                                                                                                                         
206439_at                       DSPG3                dermatan sulfate proteoglycan 3                                                                                                                                        
203498_at                       DSCR1L1              Down syndrome critical region gene 1-like 1                                                                                                                            
202912_at                       ADM                  adrenomedullin                                                                                                                                                         
221729_at                       COL5A2               collagen, type V, alpha 2                                                                                                                                              
1555345_at                      SLC38A4              solute carrier family 38, member 4                                                                                                                                     
210095_s_at                     IGFBP3               insulin-like growth factor binding protein 3                                                                                                                           
201601_x_at                     IFITM1              interferon induced transmembrane protein 1 (9-27)                                                                                                                      
205483_s_at                     ISG15              ISG15 ubiquitin-like modifier                                                                                                                                          
1554685_a_at                    KIAA1199             KIAA1199                                                                                                                                                               
221019_s_at                     COLEC12              collectin sub-family member 12 /// collectin sub-family member 12                                                                                                      
240448_at                       KIAA0802             KIAA0802                                                                                                                                                               
200790_at                       ODC1                 ornithine decarboxylase 1                                                                                                                                              
206932_at                       CH25H                cholesterol 25-hydroxylase                                                                                                                                             
205352_at                       SERPINI1             serpin peptidase inhibitor, clade I (neuroserpin), member 1                                                                                                            
228640_at                       ---           CDNA clone IMAGE:4800096                                                                                                                                               
205051_s_at                     KIT                  v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog                                                                                                          
204731_at                       TGFBR3               transforming growth factor, beta receptor III (betaglycan, 300kDa)                                                                                                     
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221823_at                       C5orf30              chromosome 5 open reading frame 30                                                                                                                                     
1554736_at                      ARHGAP29             Rho GTPase activating protein 29                                                                                                                                       
217997_at                       PHLDA1               pleckstrin homology-like domain, family A, member 1                                                                                                                    
226907_at                       PPP1R14C             protein phosphatase 1, regulatory (inhibitor) subunit 14C                                                                                                              
223235_s_at                     SMOC2                SPARC related modular calcium binding 2                                                                                                                                
202403_s_at                     COL1A2               collagen, type I, alpha 2                                                                                                                                              
204469_at                       PTPRZ1               protein tyrosine phosphatase, receptor-type, Z polypeptide 1                                                                                                           
223614_at                       C8orf57              chromosome 8 open reading frame 57                                                                                                                                     
212850_s_at                     LRP4              low density lipoprotein receptor-related protein 4                                                                                                                     
202965_s_at                     CAPN6                calpain 6                                                                                                                                                              
223316_at                       CCDC3                coiled-coil domain containing 3                                                                                                                                        
200974_at                       ACTA2                actin, alpha 2, smooth muscle, aorta                                                                                                                                   
213293_s_at                     TRIM22               tripartite motif-containing 22                                                                                                                                         
222020_s_at                     HNT             neurotrimin                                                                                                                                                            
210609_s_at                     TP53I3               tumor protein p53 inducible protein 3                                                                                                                                  
201739_at                       SGK               serum/glucocorticoid regulated kinase                                                                                                                                  
217995_at                       SQRDL                sulfide quinone reductase-like (yeast)                                                                                                                                 
204682_at                       LTBP2                latent transforming growth factor beta binding protein 2                                                                                                               
201195_s_at                     SLC7A5               solute carrier family 7 (cationic amino acid transporter, y+ system), member 5                                                                                         
206764_x_at                     MPPE1                metallophosphoesterase 1                                                                                                                                               
213060_s_at                     CHI3L2               chitinase 3-like 2 /// chitinase 3-like 2                                                                                                                              
205334_at                       S100A1               S100 calcium binding protein A1                                                                                                                                        
209955_s_at                     FAP             fibroblast activation protein, alpha                                                                                                                                   
204035_at                       SCG2                 secretogranin II (chromogranin C)                                                                                                                                      
217875_s_at                     TMEPAI               transmembrane, prostate androgen induced RNA                                                                                                                           
203879_at                       PIK3CD               phosphoinositide-3-kinase, catalytic, delta polypeptide                                                   
202709_at                       FMOD                 fibromodulin                                                                                                                                                           
1554737_at                      FBN2               fibrillin 2 (congenital contractural arachnodactyly)                                                                                                                   
205941_s_at                     COL10A1              collagen, type X, alpha 1(Schmid metaphyseal chondrodysplasia)                                                                                                         
202727_s_at                     IFNGR1               interferon gamma receptor 1                                                                                                                                            
226930_at                       FNDC1                fibronectin type III domain containing 1                                                                                                                               
207001_x_at                     TSC22D3              TSC22 domain family, member 3                                                                                                                                          
206960_at                       GPR23                G protein-coupled receptor 23                                                                                                                                          
203666_at                       CXCL12               chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1)                                                                                                      
204320_at                       COL11A1              collagen, type XI, alpha 1                                                                                                                                             
203058_s_at                     PAPSS2               3'-phosphoadenosine 5'-phosphosulfate synthase 2                                                                                                                       
205870_at                       BDKRB2               bradykinin receptor B2                                                                                                                                                 
201464_x_at                     JUN             v-jun sarcoma virus 17 oncogene homolog (avian)                                                                                                                        
226989_at                       RGMB                 RGM domain family, member B                                                                                                                                            
229740_at                       LOC643008            PP12104                                                                                                                                                                
203304_at                       BAMBI                BMP and activin membrane-bound inhibitor homolog (Xenopus laevis)                                                                                                      
218899_s_at                     BAALC                brain and acute leukemia, cytoplasmic                                                                                                                                  
224348_s_at                     H19                  H19, imprinted maternally expressed untranslated mRNA                                                       
209560_s_at                     DLK1              delta-like 1 homolog (Drosophila)                                                                                                                                      
222162_s_at                     ADAMTS1              ADAM metallopeptidase with thrombospondin type 1 motif, 1                                                                                                              
206115_at                       EGR3                 early growth response 3                                                                                                                                                
1562094_at                      MGC26963             Hypothetical protein MGC26963                                                                                                                                          
216952_s_at                     LMNB2                lamin B2                                                                                                                                                               
210948_s_at                     LEF1                 lymphoid enhancer-binding factor 1                                                                                                                                     
1563466_at                      MYLK                 Myosin, light polypeptide kinase                                                                                                                                       
212689_s_at                     JMJD1A               jumonji domain containing 1A                                                                                                                                           
205347_s_at                     TMSL8                thymosin-like 8                                                                                                                                                        
204967_at                       SHROOM2              shroom family member 2                                                                                                                                                 
218009_s_at                     PRC1                 protein regulator of cytokinesis 1                                                                                                                                     
212067_s_at                     C1R /// LOC643676    complement component 1, r subcomponent                                
1560259_at                      RORA                RAR-related orphan receptor A                                                                                                                                          
206432_at                       HAS2                hyaluronan synthase 2                                                                                                                                                  
1561065_at                      ANKRD6               Ankyrin repeat domain 6                                                                                                                                                
1555800_at                      ZNF533               zinc finger protein 533                                                                                                                                                
219747_at                       C4orf31              chromosome 4 open reading frame 31                                                                                                                                     
1558636_s_at                    ADAMTS5              ADAM metallopeptidase with thrombospondin type 1 motif, 5 (aggrecanase-2)                                                                                              
227497_at                       ---           CDNA FLJ11723 fis, clone HEMBA1005314                                                                                                                                  
1555527_at                      COL9A1               collagen, type IX, alpha 1                                                                                                                                             
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202768_at                       FOSB                 FBJ murine osteosarcoma viral oncogene homolog B                                                                                                                       
204221_x_at                     GLIPR1               GLI pathogenesis-related 1 (glioma)                                                                                                                                    
204774_at                       EVI2A                ecotropic viral integration site 2A                                                                                                                                    
206157_at                       PTX3                 pentraxin-related gene, rapidly induced by IL-1 beta                                                                                                                   
202643_s_at                     TNFAIP3              tumor necrosis factor, alpha-induced protein 3                                                                                                                         
234994_at                       KIAA1913             KIAA1913                                                                                                                                                               
227475_at                       FOXQ1                forkhead box Q1                                                                                                                                                        
219334_s_at                     OBFC2A               oligonucleotide/oligosaccharide-binding fold containing 2A                                                                                                             
218986_s_at                     FLJ20035             hypothetical protein FLJ20035                                                                                                                                          
228382_at                       FAM105B              family with sequence similarity 105, member B                                                                                                                          
205523_at                       HAPLN1               hyaluronan and proteoglycan link protein 1                                                                                                                             
224967_at                       UGCG                 UDP-glucose ceramide glucosyltransferase                                                                                                                               
213817_at                       ---           CDNA FLJ13601 fis, clone PLACE1010069                                                                                                                                  
212900_at                       SEC24A               SEC24 related gene family, member A (S. cerevisiae)                                                                                                                    
1552619_a_at                    ANLN             anillin, actin binding protein                                                                                                                                         
224609_at                       SLC44A2              solute carrier family 44, member 2                                                                                                                                     
203755_at                       BUB1B                BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)                                                                                                      
1555724_s_at                    TAGLN               transgelin                                                                                                                                                             
202450_s_at                     CTSK                 cathepsin K (pycnodysostosis)                                                                                                                                          
213861_s_at                     FAM119B              family with sequence similarity 119, member B                                                                                                                          
213248_at                       LOC221362            hypothetical protein LOC221362                                                                                                                                         
203570_at                       LOXL1                lysyl oxidase-like 1                                                                                                                                                   
230407_at                       ---           Transcribed locus, strongly similar to strawberry notch homolog 1; MOP-3                                                              
209567_at                       RRS1                RRS1 ribosome biogenesis regulator homolog (S. cerevisiae)                                                                                                             
210512_s_at                     VEGF                 vascular endothelial growth factor                                                                                                                                     
205289_at                       BMP2                 bone morphogenetic protein 2                                                                                                                                           
203065_s_at                     CAV1              caveolin 1, caveolae protein, 22kDa                                                                                                                                    
203758_at                       CTSO                 cathepsin O                                                                                                                                                            
205476_at                       CCL20                chemokine (C-C motif) ligand 20                                                                                                                                        
207826_s_at                     ID3                  inhibitor of DNA binding 3, dominant negative helix-loop-helix protein                                                                                                 
205479_s_at                     PLAU              plasminogen activator, urokinase                                                                                                                                       
201136_at                       PLP2                 proteolipid protein 2 (colonic epithelium-enriched)                                                                                                                    
203764_at                       DLG7                discs, large homolog 7 (Drosophila)                                                                                                                                    
209160_at                       AKR1C3               aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II)                                                                                
207977_s_at                     DPT             dermatopontin                                                                                                                                                          
205125_at                       PLCD1                phospholipase C, delta 1                                                                                                                                               
207980_s_at                     CITED2               Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2                                                                                      
204475_at                       MMP1                 matrix metallopeptidase 1 (interstitial collagenase)                                                                                                                   
1556209_at                      CLEC2B               C-type lectin domain family 2, member B                                                                                                                                
205830_at                       CLGN                 calmegin                                                                                                                                                               
219295_s_at                     PCOLCE2              procollagen C-endopeptidase enhancer 2                                                                                                                                 
205907_s_at                     OMD              osteomodulin                                                                                                                                                           
206869_at                       CHAD                 chondroadherin                                                                                                                                                         
223836_at                       KSP37                Ksp37 protein                                                                                                                                                          
204948_s_at                     FST                  follistatin                                                                                                                                                            
240955_at                       PANX3                pannexin 3                                                                                                                                                             
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General Discussion
Longitudinal bone growth occurs throughout childhood and is the key characteristic that 
distinguishes children from adults. During puberty longitudinal growth rate first increases, 
but finally as the growth plate further matures growth decreases and eventually ceases with 
epiphyseal fusion at the end of puberty. Mechanisms underlying growth plate maturation and 
epiphyseal fusion with termination of longitudinal growth are still largely unknown. With puberty 
estrogen levels increase and this is supposed to play an important role in growth plate maturation 
and epiphyseal fusion. In this thesis we investigated:
1. The route and effects of estrogens (17β-estradiol or/and SERMs) on growth plate 
structure and VEGF expression. 
2. Maturation of the growth plate: regarding proliferation and the cell cycle, the delayed 
growth plate senescence theory, pubertal changes and epiphyseal fusion. 
3. A relatively new human growth plate model using mesenchymal stem cells.
Actions of estrogens and selective estrogen receptor modulators 
Estrogens play a key role in longitudinal bone growth through growth plate maturation, 
epiphyseal fusion and augmentation of accrual of bone. In the human lack of estrogen action leads 
to continuation of growth and subsequently tall stature by absence of growth plate fusion (1;2). 
Conversely high levels of estrogen inhibit longitudinal bone growth and can clinically be used to 
prevent tall stature, but treatment is associated with side-effects (3). Therefore it is important to 
investigate the actions of estrogens in more detail.
In the sexually immature rat we observed an increase in body weight gain, tibia length and width 
of the growth plate with an increased proliferating zone after removal of estrogens by ovariectomy. 
Suppletion of estrogen showed the reverse effects in line with the clinical observations in 
humans. The effects of estrogen have been suggested to be mediated mainly through the nuclear 
receptors ERα and ERβ, which are both expressed in growth plate chondrocytes of several species, 
including the human (4-7). We detected these estrogen receptors in the rat predominantly in 
late proliferating and early hypertrophic chondrocytes and observed a decrease in ERα and ERβ 
staining with estrogen suppletion in chapter 2. 
Estrogen can exert its effects through a genomic or non-genomic pathway, however the 
contribution of these routes to longitudinal growth has not been clarified up to now. Desoxyestrone 
administration, a synthetic compound that exclusively acts through the non-genomic pathway, 
resulted in a decrease in longitudinal growth although to a smaller extent than 17β-estradiol. This 
indicates that estrogenic effects on longitudinal growth are regulated both through genomic and 
nongenomic pathways with genomic signalling prevailing.
Estrogen acts on a number of diverse tissues resulting in potential side-effects of estrogen 
treatment (3). Selective estrogen receptor modulators (SERMs) were developed to circumvent 
these side effects (8). 2-methoxyestradiol was suggested to be tissue-selective in the growth 
plate of female rats (9). We administered 2-methoxyestradiol to sexually immature rats and 
indeed found a decreased thickness of the proliferative zone in female rats and a decrease in the 
thickness of the total growth plate and of the hypertrophic zone in the male rat, but no general 
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effect on longitudinal growth was observed. Sibonga et al did find an effect on longitudinal bone 
growth when 2-methoxyestradiol was administered orally to older (10 weeks) and more mature 
rats (10). Therefore we conclude that 2-methoxyestradiol indeed has a growth plate selective 
estrogenic effect. However, more studies in animal and human models are needed to optimize 
the effects on longitudinal bone growth and to assess potential side-effects before clinical use 
can be considered. Recent studies have assigned 2-methoxyestradiol as a promising anticancer 
agent in the treatment of cancer, since it induces apoptosis in cancer cells (11;12). Nowadays more 
extensively investigated SERMs in relation to skeletal growth are raloxifene and tamoxifen. Both 
compounds act as estrogen agonists and impair longitudinal bone growth (13-15).
Estrogens can have a direct effect, but also an indirect effect on growth by stimulating the GH-IGF-I 
axis resulting in an increase of IGF-I levels (16;17). In our estrogen treated rats we were unable to 
measure circulating IGF-1 levels, but we did investigate local IGF-1 expression. We did not observe 
an effect on IGF-1 expression in the growth plate. 
VEGF expression in the growth plate
Estrogen and its receptors interact with various growth factors in order to control longitudinal 
growth (16-19). One of these growth factors is Vascular Endothelial Growth Factor (VEGF). It was 
previously shown that estrogen up-regulated VEGF expression in uterus and bone tissue (20;21). 
In chapter 3 we demonstrate that VEGF expression in chondrocytes was elevated by estrogen 
treatment in vivo and in vitro. Removal of estrogens by ovariectomy resulted in a decrease in VEGF 
expression. Moreover, pubertal human growth plate maturation resulted in an increase in VEGF 
expression. From these observations we concluded that estrogens regulate VEGF expression in 
the growth plate.
Vascular Endothelial Growth Factor (VEGF) is important in the final event of endochondral 
ossification, as it has a function in chondrocyte differentiation and chondrocyte survival (22-24). 
Inhibition of VEGF resulted in dramatic effects on longitudinal growth and the growth plate in 
previous studies (22;25). At the end of puberty longitudinal growth ceases with total replacement 
of avascular cartilage by highly vascularized bone eventually resulting in epiphyseal fusion. 
VEGF could play an important role in this process. Our results are in line with this hypothesis, 
since estrogen and pubertal maturation both upregulated VEGF expression in growth plate 
chondrocytes suggesting a potential role for VEGF in estrogen-induced growth plate fusion. 
However, this suggested role needs to be confirmed in future experiments.
Growth plate senescence, proliferation and p27
One of the postulated hypotheses for epiphyseal fusion is that estrogen accelerates the senescent 
decline and that the growth plate fuses when senescence reaches a critical point (26). Senescence 
is a term for structural changes like a decrease in height of different zones in the growth plate, but 
also for the decline in chondrocyte proliferation (26;27). Senescence might influence proliferation 
and the cell cycle of chondrocytes by orderly inactivation and activation of cyclin-dependent 
kinases and kinase inhibitors like p27Kip1 (p27). p27-deficient mice have an increased size of 
long bones and weight compared to wild-type mice, suggestive for a functional role for p27 in 
the regulation of longitudinal growth (28-30). In chapter 4 we detected p27 mRNA in the growth 
plates of 5-wk-old mice by real-time PCR. The p27 mRNA levels in growth plate tissues were 
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approximately 2-fold lower than levels in the surrounding bone tissue. No significant difference 
was detected in p27 expression in the separate zones. Previous studies suggested a role for p27 
in the differentiation of terminal growth plate chondrocytes. However, our results are in contrast 
with this since no elevated expression was seen in the hypertrophic zone (28;31;32). p27 ablation 
modestly increased chondrocyte proliferation in the growth plate and body length of 7 weeks old 
mice, however tibia length was not significantly greater than in controls. Presumably the increase 
in total length was a result of greater growth in the vertebrae and the increase in proliferation may 
have started shortly before sacrifice. The latter is supported by observations made by others who 
reported an increase in body size later in life, therefore most likely the increase in proliferation 
was too short to result in an increase in length of long bones (29;33). Another explanation for the 
modest effect of p27 in our study might be a difference in genetic background. Previous studies 
used a different background and have reported a more prominent growth phenotype (coisogenic 
129S4 mice). 
Treatment with glucocorticoids inhibited longitudinal growth in p27-deficient mice and controls 
to the same extent, indicating that p27 is not required for the negative effects of dexamethasone 
on longitudinal growth. Our findings in chapter 4 suggest that p27 negatively modulates growth 
plate chondrocyte proliferation, but it is not required for the conditional regulation of chondrocyte 
proliferation as induced by dexamethasone in the growth plate of rats. 
In chapter 7 we used microarray techniques on human growth plate tissues and detected a 
significant change in the cell cycle pathway with progression of puberty. 15 out of 84 genes in 
this pathway were affected and among these was p27. p27 showed an up-regulation in expression 
with pubertal maturation of the growth plate. This indicates that the cell cycle activity and thereby 
proliferation decreased in line with the senescence hypothesis in the human pubertal growth plate 
and the reduced chondrocyte proliferation during growth plate maturation.
The delayed growth plate senescence hypothesis and catch-up growth 
After a period of growth inhibition, the linear growth rate usually exceeds the normal range. 
This phenomenon is known as catch-up growth (34). Evidence from animal studies suggests that 
catch-up growth is due, at least in large part, to a delay in growth plate senescence. However, the 
relationship between catch-up growth and delayed growth plate senescence has only been studied 
in rabbits and rats (27;35). In chapter 5 we re-evaluated height and bone age measurements in 
patients with celiac disease before and on gluten-free diet. On gluten-free diet these patients 
experienced catch-up growth. We concluded that the pattern of catch-up growth in patients with 
celiac disease is consistent with the hypothesis of delayed growth plate senescence. We are the 
first showing human data in line with this hypothesis, however we cannot exclude that additional 
mechanisms like for example microRNAs and changes in gene expression may have contributed to 
the increase in height velocity as well.
Pubertal growth plate maturation
We had the unique opportunity to obtain two epiphyseal samples of one patient in different stages 
of puberty. Microarray analyses of these two samples were used to receive a first insight in the 
molecular processes and interactions occurring during human growth plate maturation in chapter 
6. Histological experiments and measurements showed a clear decrease in width of the total 
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growth plate, more widely spaced columns with less cells and consequently more extracellular 
matrix in the more mature growth plate. This confirmed earlier observations in rabbits and rats 
(36;37). Our microarray results were in line with our morphological data obtained with histology, 
showing many genes and pathways related to the extracellular matrix significantly affected with 
maturation. Progression of puberty did affect many genes in the cell cycle pathway. 
In addition, we have performed a detailed bioinformatic analysis on these two growth plate 
specimens. More specifically, we searched the promoter regions of genes that are differentially 
expressed in the two growth plate specimens with pubertal maturation for evidence of direct 
effects of estrogen, androgen, GH, IGF-I and PTHrP on their expression and analyzed these 
genes for their evolutionary conservation across 9 primates. Sequences evolutionary conserved 
along species are likely to have critical functional roles (38). This data provides for the first time 
evidence that Estrogen receptor, androgen receptor, STAT5B, ELK-1 and RUNX2 were found to 
have transcription factor binding motifs in genes involved in growth plate maturation, suggestive 
for a role of these transcription factors in pubertal maturation of the human growth plate.
In order to extend our microarray analyses in relation to pubertal growth plate maturation we 
collected additional human growth plate tissues. Growth plate tissues were obtained from 
patients who were undergoing surgery for a variety of disorders. Even though patients suffered 
from diverse disorders, we assume that the underlying mechanism of epiphyseal maturation and 
fusion is the same for all growth plates. Eventually longitudinal growth stops in all patients at the 
end of puberty. In chapter 7 a cross-sectional microarray analysis was performed on 6 female tibial 
growth plates of various pubertal stages. Results suggested many genes changing from prepuberty 
to early puberty, however most alterations occurred during late puberty. Overall changes in gene 
expression were very small and only few genes changed more than 2 fold with progression of 
puberty. This shows that there is no large change in expression patterns with progression of 
puberty and that there rather might be an effect of multiple small factors. The fact that we did not 
observe large changes is also in line with the senescence theory. This theory suggests that stem-like 
cells in the resting zone have a finite proliferative capacity, which is gradually exhausted resulting 
eventually in epiphyseal fusion (27;39).  Loss of DNA methylation is suggested to be a biological marker 
for growth plate senescence and this can not be detected by microarray analysis (40).
 Affected pathways were associated with extracellular matrix homeostasis, hormonal pathways 
and programmed cell death. These findings in affected pathways are in agreement with the 
observed results in the longitudinal study in chapter 6, however gene profiles were not fully 
overlapping and sets of other genes were at times in contrast as well.  
Epiphyseal fusion
The exact mechanism by which epiphyseal fusion occurs is not yet completely understood. In 
chapter 8 we investigated apoptosis as the final mechanism by which chondrocytes eventually die 
and are replaced by bone. At the chondro-osseous junction site of the growth plate, apoptosis is 
nowadays generally accepted as the mechanism by which terminally hypertrophic chondrocytes 
die (41;42). It is generally assumed that the same mechanism eventually also results in epiphyseal 
fusion. We performed a detailed study on apoptosis in terminal hypertrophic chondrocytes in the 
pubertal female growth plate and found no signs of classical apoptosis. In addition, we studied a 
unique tissue specimen of a late pubertal human growth plate in the process of epiphyseal fusion 
and found clear evidence that apoptosis is not likely to be involved in the end phase of growth plate 
fusion. We did observe a dense border of thick bone surrounding the growth plate remnant, signs 
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of hypoxia and early necrosis in this fusing growth plate. We hypothesize that the border of dense 
bone is functioning as a physical barrier for oxygen and nutrients to reach the fusing growth plate 
resulting in hypoxia and eventually cell death in a non-classical apoptotic way through necrosis 
or a mixture of apoptosis and necrosis. In line with this new hypothesis White et al. recently 
demonstrated bridging bone in the center of a distal human tibial growth plate obtained from a 
12.9 years old girl which might be an early sign of this shelling process (43).
Interestingly, in chapters 6 and 7 we found a significant increase in expression of the hypoxia-
inducible factor 2 alpha gene from prepuberty to early and late stage puberty. The HIF-1alpha 
gene was also found to be expressed, but no change was seen with maturation. These findings are 
in line with Stewart et al, who reported an up-regulated expression of HIF-2alpha mRNA during 
chondrocytes differentiation in vitro, but no change in HIF-1alpha mRNA expression (44). Hif-
2alpha knockout mice are small, what might indicate that this gene has an important role in the 
growth plate and subsequently in the regulation of longitudinal growth (45). 
Therefore we believe it could be a hypoxia related process leading eventually to cell death of 
growth plate chondrocytes. Indeed with our microarray experiments in chapters 6 and 7 we did 
find many affected genes changing with pubertal maturation that are involved in programmed 
cell death, e.g. proapoptotic and anti-apoptotic genes, but also genes involved in the regulation of 
autophagy. However, histological and electron microscopy analyses thus far showed no signs of 
classical apoptosis and no autophagosomes in the fusing growth plate in chapter 8. Apoptosis and 
autophagy are closely related and there is an overlap in signaling proteins (46;47). The results 
of our studies are in line with this and suggestive for a non-classical and perhaps intermediate 
mechanism of different types of cell death.
Growth plate models
Most of our knowledge regarding the regulation of the growth plate is based on animal studies. 
However most animal models only partially correspond to the human situation and many species 
differences are present.  In mouse and rat for example, in contrast to humans, growth plates do 
not fuse under the influence of estrogen at the end of puberty (48;49). This indicates that rodents 
are not perfectly representative for studies on growth plate fusion, excluding the use of transgenic 
approaches. 
In chapter 9 we investigated a promising relatively new human model for the growth plate, 
human mesenchymal stem cells (hMSCs). hMSCs are multipotent and can differentiate into the 
chondrogenic lineage. Originally MSCs were isolated from bone marrow, however nowadays 
they can be obtained from various tissue sources, like fetal tissues, placenta, umbilical cord 
blood and adipose tissue (35;50-54). In chapter 9 we investigated the chondrogenic potential of 
hMSCs originating from various tissues. Bone marrow derived MSCs appeared to have the best 
chondrogenic potential, with fetal bone marrow prevailing over adult bone marrow. A passage-
dependent decrease in the capacity of cartilage formation was seen in line with previous results 
in adult MSCs (55).
In chapter 10 we studied in detail the cartilage forming capacity of fetal hMSCs in order to explore 
in more detail the molecular processes and interactions taking place during early phases of 
chondrogenesis, chondrocyte proliferation and chondrocyte differentiation. To determine which 
type of hyaline cartilage is formed by differentiating hMSCs, we compared the gene expression 
profile with previously established gene expression fingerprints of human articular and epiphyseal 
growth plate cartilage. As differentiation towards chondrocytes proceeded, hMSCs gradually 
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obtained a gene expression profile that was more overlapping with the fingerprint of epiphyseal 
growth plate cartilage than of articular cartilage. This study validates differentiating fetal bone 
marrow-derived hMSCs as an excellent model for the epiphyseal growth plate. This new human 
model now opens the opportunity to elucidate clinical conditions influencing chondrogenesis 
and cartilage homeostasis in more detail as well as the opportunity to develop strategies for new 
treatment options for cartilage disorders.
Final remarks and suggestions for future studies
Patients with growth disorders are frequently presented to pediatricians. The etiology can only be 
established in a minority of these patients and even in such cases a causal treatment is usually not 
available. A better understanding of the mechanisms by which longitudinal growth is regulated at 
the level of the epiphyseal plate is therefore needed. We focused in our studies on the effects of 
estrogen and growth plate maturation and found interesting new clues for further study in order 
to design new treatment options.
17β-estradiol treatment is used from the mid-fifties to decrease final height, however there are 
several potential side-effects like an increased risk for breast and uterus cancer and decreased 
fertility (3). We showed a growth plate selective estrogenic effect in rats with 2-methoxyestradiol 
treatment. This could be a potential new treatment option, however more detailed studies on 
longitudinal bone growth and potential side-effects of 2-methoxyestradiol treatment in the human 
are needed.
Adult height is achieved at the end of puberty after the growth plate has fused and there is no 
longitudinal growth potential anymore. The process of epiphyseal fusion in the human is still 
largely unknown and modulation of this process could potentially lead to new treatment strategies. 
Delaying epiphyseal fusion is expected to result in an increase in adult height by allowing more 
time for growth supporting treatments. On the contrary, initiating epiphyseal fusion would help 
in the treatment of tall stature. In our studies we have shown that estrogen increases VEGF 
expression in growth plate chondrocytes and suggested that VEGF plays an important role in 
estrogen-induced growth plate fusion. 
We showed that apoptosis is not likely to be involved in the end phase of growth plate fusion, 
however we did detect signs of hypoxia in the fusing growth plate. Therefore we present a new 
hypothesis in which hypoxia plays a more important role in growth plate maturation and epiphyseal 
fusion. Both our morphological and microarray experiments are in line with this assumption. We 
hypothesize that hypoxia increases during maturation of the growth plate. At the end of puberty a 
border of dense bone is formed that surrounds the growth plate functioning as a physical barrier 
for oxygen and nutrients resulting in more hypoxia and eventually cell death in a non-classical 
apoptotic way. Increasing levels of VEGF might be a result of this process as well, since many 
studies reported an increase in VEGF expression by hypoxia (56-58). This model needs further 
investigations. It would be interesting to study Hif-1alpha and Hif-2alpha protein expression in 
our human growth plate collection. Moreover it would be useful to extend our collection of growth 
plates for investigations regarding maturation of the growth plate and the proposed hypotheses 
in more detail. Our microarray results are promising and contain a great amount of data; however 
more samples are needed to validate our findings. With a larger collection, results could serve as a 
database and clarify multiple research questions involving the growth plate. 
Without a large collection of human growth plates other methods and models are needed, like 
MSCs. We recommend using MSCs derived from human fetal bone marrow. These MSCs showed to 
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be a good model for the human growth plate and have the advantage that they can be genetically 
modified. Interesting experiments would be over-expression or down-silencing of certain growth 
factors and receptors like the estrogen-receptor. Ultimately this will help us in understanding in 
depth the molecular mechanisms that drive growth plate maturation and will help us to develop 
new strategies for the treatment of cartilage and growth disorders.
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Summary
Longitudinal bone growth takes place in the epiphyseal growth plates of the long bones and 
comparable structures in the vertebrae. Regulatory mechanisms within this epiphyseal plate are 
complex. Only in a minority of children with a growth disorder the aetiology can be definitely 
established and even in such cases a causal treatment is usually not available. 
During puberty longitudinal growth rate first increases, but finally as the growth plate further 
matures growth decreases and eventually ceases with epiphyseal fusion at the end of puberty. 
Epiphyseal fusion results in a complete arrest in longitudinal growth ruling out every possible 
non-surgical treatment option to increase longitudinal growth and thereby adult height. Therefore, 
modulation of timing of epiphyseal fusion might be beneficial in the treatment of growth disorders; 
e.g. extending epiphyseal fusion can potentially result in an increase in adult height by allowing 
more time for growth supporting treatments, while initiating epiphyseal fusion would benefit 
patients with tall stature. Little is known about the exact mechanisms underlying growth plate 
maturation and epiphyseal fusion. In this thesis we investigated growth plate maturation and 
epiphyseal fusion in more detail.
 With puberty estrogen levels increase and this is known to play an important role in growth 
plate maturation and epiphyseal fusion. We detected both estrogen receptor alpha (ERα) and 
beta  (ERβ) in the rat growth plate, predominantly in late proliferating and early hypertrophic 
chondrocytes and observed a decrease in ERα and ERβ staining with estrogen suppletion. We 
investigated the genomic and non-genomic pathway by which estrogen can exert its effects on 
ovariectomized rats with desoxyestrone administration, a synthetic compound that exclusively 
acts through the non-genomic pathway, and 17β-estradiol administration. Treatment resulted in 
different degrees of growth inhibiting effects. We concluded that estrogenic effects on longitudinal 
growth are regulated both through genomic and nongenomic pathways with genomic signalling 
prevailing.
Estrogen treatment has potential side-effects, that can be circumvented with selective estrogen 
receptor modulators (SERMs). We investigated the effects of 2-methoxyestradiol and confirmed a 
tissue-selective effect in the growth plate of sexually immature male rats. However, we were not 
able to detect an effect on longitudinal growth.
Estrogen and its receptors interact with various growth factors in order to control longitudinal 
growth. In this thesis we demonstrated that Vascular Endothelial Growth Factor (VEGF) expression 
in rat chondrocytes was elevated by estrogen treatment in vivo and in vitro. Removal of estrogens 
by ovariectomy resulted in a decrease in VEGF expression. Moreover, pubertal human growth 
plate maturation resulted in an increase in VEGF expression, suggestive for a role of VEGF in the 
process of epiphyseal maturation as well as epiphyseal fusion. 
Another effect of estrogen is acceleration of growth plate senescence, a term for structural changes 
like a decrease in height of different zones in the growth plate, but also for the decline in chondrocyte 
proliferation. We hypothesized that senescence might influence proliferation and the cell cycle 
of chondrocytes by orderly inactivation and activation of cyclin-dependent kinases and kinase 
inhibitors like p27Kip1 (p27). We did detect p27 mRNA in the growth plates of 5-wk-old mice by 
real-time PCR, but found no significant difference in p27 expression between the separate zones. 
In addition, we studied p27-deficient mice and found that p27 negatively modulates growth plate 
chondrocyte proliferation, but p27 was not required for the conditional regulation of chondrocyte 
proliferation as induced by dexamethasone in the growth plate of rats. In the human growth plate 
we did find a possible role for p27 in pubertal maturation of the growth plate, since microarray 
results showed an up-regulation in expression of the p27 gene with progression of puberty.
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After a period of growth inhibition, the linear growth rate usually exceeds the normal range, which 
is known as catch-up growth. Evidence from animal studies suggests that catch-up growth is due, 
at least in large part, to a delay in growth plate senescence. We investigated catch-up growth in 
celiac patients and concluded that the pattern of catch-up growth in these patients is consistent 
with the hypothesis of delayed growth plate senescence.
Structural growth plate changes associated with senescence as described before in the rabbit and 
rat growth plate are in line with our data in a longitudinal study of two human growth plates 
obtained from one patient. Histological investigations showed a clear decrease in width of the total 
growth plate, more widely spaced columns with less cells and consequently more extracellular 
matrix in the more mature growth plate. Microarray results on human growth plates revealed 
for the first time the expression profile of human growth plate cartilage. Results from these 
experiments also confirmed our histological findings, since many genes and pathways related to 
the extracellular matrix significantly changed with maturation. In addition, progression of puberty 
affected many genes in the cell cycle pathway, hormonal pathways and programmed cell death. 
Moreover in this study we identified for the first time a set of 394 genes involved in growth plate 
maturation. The promoter regions of these genes contained transcription factor binding motifs 
for the Estrogen receptor, androgen receptor, STAT5B, ELK-1 and RUNX2. Particularly, ELK-1 and 
RUNX2 binding sites were enriched compared to controls suggestion a role for these transcription 
factors in pubertal maturation of the human growth plate. Overall changes in gene expression with 
pubertal maturation were small, indicating that there maturation is associated with small changes 
in multiple factors. This is in line with the senescence theory, suggesting that stem-like cells in the 
resting zone have a finite proliferative capacity, which is gradually exhausted resulting eventually 
in epiphyseal fusion.
The exact mechanism by which epiphyseal fusion occurs is not yet completely understood. We 
performed a detailed study on apoptosis in terminal hypertrophic chondrocytes in pubertal 
female growth plates and found no signs of classical apoptosis at the chondro-osseous junction. 
In addition, we studied a unique tissue specimen of a late pubertal human growth plate in the 
process of epiphyseal fusion and found clear evidence that apoptosis is not likely to be involved 
in the end phase of growth plate fusion. We did observe a dense border of thick bone surrounding 
the growth plate remnant and signs of hypoxia. We also found a significant increase in expression 
of the hypoxia-inducible factor 2 alpha gene from prepuberty to early and late stage puberty. 
Microarray results revealed that many genes of which the expression changed with pubertal 
maturation are involved in programmed cell death, e.g. proapoptotic and anti-apoptotic genes, 
but also genes involved in the regulation of autophagy.  From these findings we speculate that 
growth plate fusion is a hypoxia related process eventually leading to a non-classical and perhaps 
intermediate mechanism of different types of cell death.
We investigated a promising and relatively new human model for the growth plate based on the 
use of human mesenchymal stem cells (hMSCs). hMSCs can differentiate into the chondrogenic 
lineage and bone marrow derived MSCs appeared to have the best chondrogenic potential, 
with fetal bone marrow prevailing over adult bone marrow. Fetal bone marrow-derived hMSCs 
showed to be an excellent model for the epiphyseal growth plate as during differentiation towards 
chondrocytes they gradually obtain a gene expression profile that was overlapping the fingerprint 
of epiphyseal growth plate cartilage. Many genes and pathways were identified as being important 
in different stages of chondrocyte differentiation. The hyaline cartilage formed by differentiating 
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Samenvatting
Lengtegroei vindt plaats in de epifysaire groeischijven die zich bevinden aan de uiteinden van 
de lange pijpbeenderen en in groeischijven in de wervelkolom. Deze groeischijven bevatten 
verschillende zones kraakbeencellen (chondrocyten) die zich in verschillende stadia van 
differentiatie bevinden. De mechanismen die een rol spelen in de regulatie van de groeischijf zijn 
complex en slechts in geringe mate bekend. Het is van belang om meer inzicht te krijgen in de 
mechanismen die de lengtegroei beïnvloeden, omdat bij kinderen met een groeistoornis slechts in 
een minderheid van de gevallen een onderliggende oorzaak kan worden gevonden. In de zeldzame 
gevallen dat er wel een oorzaak gevonden wordt is er dikwijls geen causale behandeling mogelijk.
Gedurende de puberteit neemt de groeisnelheid eerst toe, een fenomeen dat bekend staat als de 
pubertaire groeispurt, maar met voortgang van de puberteit neemt de groeisnelheid steeds verder 
af totdat de volwassen eindlengte is bereikt en de groeischijven sluiten. Nadat de groeischijven 
gesloten zijn, is het niet meer mogelijk om de groei medicamenteus te beïnvloeden. Voor de 
behandeling van groeistoornissen zou het daarom gunstig zijn als het proces van sluiting van de 
groeischijf zou kunnen worden beïnvloed. Bij kinderen met een kleine lengte zou bijvoorbeeld 
een verlenging van het proces van groeischijfsluiting kunnen leiden tot een grotere eindlengte, 
doordat meer tijd beschikbaar komt voor stimulering van de groei. Aan de andere kant zou het 
versnellen van de groeischijfsluiting een goede behandelingsmogelijkheid zijn voor patiënten met 
een te grote lengte. Het precieze mechanisme dat ten grondslag ligt aan de rijping en uiteindelijke 
sluiting van de groeischijf is grotendeels onopgehelderd. Meer kennis zou kunnen leiden tot 
het ontwikkelen van medicamenten die de timing van groeischijfsluiting beïnvloeden. In dit 
proefschrift is op verschillende niveaus en in diverse experimentele modellen de rijping van de 
groeischijf en het proces van groeischijfsluiting onderzocht. 
In de puberteit neemt de concentratie van oestrogenen in het bloed toe. Oestrogenen spelen 
niet alleen een belangrijke rol in de ontwikkeling van secundaire geslachtskenmerken tijdens de 
puberteit van een meisje, maar zijn ook betrokken bij de rijping en sluiting van de groeischijf, zowel 
bij jongens als bij meisjes. In ons onderzoek toonden we aan dat zowel de oestrogeen-receptor 
alpha (ERα) als de oestrogeen-receptor beta (ERβ) tot expressie komen in de groeischijf van de 
rat, voornamelijk in de laat-prolifererende chondrocyten en de vroege hypertrofe chondrocyten. 
Als oestrogeen werd toegediend, nam de expressie van beide receptoren af. Na toediening van 
desoxyestrone, een synthetisch oestrogeen dat alleen via non-genomische signalering zijn werking 
uitoefent, aan ratten met een status post ovariectomie (het verwijderen van de eierstokken), 
resulteerde dit in minder groeivertraging dan werd waargenomen met 17β-estradiol. Hieruit 
concludeerden we dat oestrogenen een effect op de lengtegroei uitoefenen via de genomische en 
ook via de non-genomische route, waarbij de genomische route waarschijnlijk overheerst. 
Behandeling met oestrogenen heeft naast een positieve werking ook mogelijke bijwerkingen, 
die vermeden kunnen worden met Selectieve Oestrogeen Receptor Modulators (SERMs). Wij 
onderzochten het effect van één van die SERMs, 2-methoxyoestradiol, op de lengtegroei en zagen 
inderdaad een weefsel-specifiek effect op de groeischijf van jonge ratten, maar geen meetbaar 
effect op de lengtegroei.
Oestrogeen en oestrogeen receptoren worden beïnvloed door verschillende groeifactoren en 
hormonen. In dit proefschrift onderzochten we de relatie tussen oestrogeen en de expressie van 
Vascular endothelial growth factor (VEGF) in de groeischijf. Ovariëctomie bij ratten resulteerde 
in een afname van de VEGF-expressie in de groeischijf, terwijl oestrogeensuppletie resulteerde in 
een toename van VEGF-expressie. In groeischijfpreparaten van meisjes zagen we op eiwit-niveau 
een toename in VEGF-expressie met het voortschrijden van de puberteit. Hieruit concludeerden 
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we dat VEGF-expressie beïnvloedt kan worden door oestrogeenspiegels en dat VEGF mogelijk een 
rol speelt in het proces van groeischijfsluiting. 
Van oestrogeen is ook bekend dat het de “senescence” (veroudering) van de groeischijf versnelt. 
Met deze term worden de structurele veranderingen in de groeischijf in de tijd aangeduid, 
zoals een afname in de hoogte van de groeischijfzones en een afname in proliferatie van de 
chondrocyten. In dit proefschrift onderzochten we de rol van een celcyclusremmer p27Kip1 
(p27) op de proliferatie van chondrocyten en de lengtegroei in de muis. In de groeischijf van 5 
weken oude muizen komt p27 op mRNA niveau in iedere zone van de groeischijf in ongeveer 
gelijke mate tot expressie. Muizen met een p27-deficiëntie (p27 knock-out) lieten een toename 
zien in de proliferatie van de chondrocyten. Er was echter geen duidelijk effect zichtbaar op de 
lengtegroei na 7 weken. Tevens bleek dat p27 niet nodig is voor het groeiremmende effect van 
dexamethason; p27 deficiënte muizen lieten namelijk een zelfde mate van vertraging zien als de 
“wild-type” muizen (muizen zonder de mutatie). In een ander experiment, waarin we de gen-
expressie bestudeerden in de humane groeischijf, zagen we dat de gen-expressie van p27 steeg 
met het voortschrijden van de puberteit. Deze bevinding wijst op een mogelijke rol voor p27 in de 
afname van chondrocytenproliferatie en daarmee de afname in groeisnelheid aan het einde van 
de puberteit.
Als na een periode van groeivertraging, bijvoorbeeld door een ziekte of bepaalde medicamenten, 
de ziekte adequaat wordt behandeld of de medicamenten worden gestopt, gaat de groeisnelheid 
vaak aanzienlijk omhoog. Dit fenomeen staat bekend als “inhaalgroei” (catch-up growth). Het 
is onbekend wat het achterliggende mechanisme is, maar dierexperimentele studies hebben 
aanwijzingen gevonden dat inhaalgroei tenminste voor een belangrijk deel te verklaren is door 
een vertraging in de “senescence” van de groeischijf. Om de hypothese te toetsen dat dit fenomeen 
ook bij kinderen met inhaalgroei een rol speelt, onderzochten wij de groei van kinderen met 
coeliakie (gluten-allergie) die na de start van een glutenvrij dieet een inhaalgroei vertoonden. 
Het groeipatroon van deze kinderen kwam inderdaad overeen met het groeipatroon van jongere 
kinderen, zoals men zou verwachten bij vertraging van de “senescence” gedurende de fase van 
groeivertraging. 
In een studie naar de veranderingen die optreden in de humane groeischijf over een periode van 
1 jaar tijdens de puberteit, zagen we structurele veranderingen die leken op de veranderingen 
die werden waargenomen in het proces van “senescence” bij ratten en konijnen. We zagen een 
significante afname in de totale groeischijfdikte en een afname van de dikte van elke afzonderlijke 
zone. Daarnaast zagen we een toename in de ruimte tussen de kolommen van chondrocyten, en 
daarmee ook een toename van de extracellulaire matrix in de groeischijf in de loop van de puberteit. 
Voor het eerst hebben wij met zogenaamde “microarray” experimenten laten zien hoe het gen-
expressie-profiel eruitziet van de humane groeischijf. De veranderingen in het gen-expressie-
profiel kwamen overeen met de histologische veranderingen die we microscopisch hadden 
waargenomen; veel genen die geassocieerd zijn met de extracellulaire matrix lieten een toename 
zien in expressie naarmate de maturatie van de groeischijf voortschreed. Tevens veranderde de 
expressie van veel genen die te maken hebben met de celcyclus, met hormoonsystemen en met de 
zogenaamde “geprogrammeerde celdood”. In de groep genen waarvan de expressie veranderde 
gedurende de puberteit vonden we veel genen met transcriptiefactor-bindingsplaatsen voor 
de oestrogeen receptor, de androgeen receptor, STAT5B, ELK-1 en RUNX2 in hun promoter 
regio’s die de expressie van het gen mogelijk reguleren. Met name de bindingsplaatsen voor de 
transcriptiefactoren ELK-1 en RUNX2 waren verrijkt ten opzichte van controles. Dit wijst op een 
rol van deze transcriptiefactoren in de maturatie van de groeischijf in de puberteit. In het algemeen 
was de verandering in gen-expressie gering, wat in overeenstemming is met de “senescence” 
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theorie, die suggereert dat stamcellen in de zogenaamde “reserve zone” een beperkte capaciteit 
hebben om zich te delen. Als het aantal stamcellen is uitgeput, zou dit volgens deze hypothese 
resulteren in sluiting van de groeischijf. 
Het precieze mechanisme waardoor de groeischijf uiteindelijk sluit is nog grotendeels onbekend, 
maar men neemt aan dat “apoptose” (geprogrammeerde celdood) hierin een rol speelt. Wij 
hebben een gedetailleerde studie verricht naar apoptose in de terminale hypertrofe zone van 
groeischijven van meisjes in verschillende stadia van puberteit. We hadden ook de beschikking 
over een groeischijf die zich in het laatste stadium bevond van sluiting. In geen van de groeischijven 
waren typische kenmerken te zien van apoptose. Wel zagen we een dikke en compacte rand van 
bot om de fuserende groeischijf heen en daarnaast ook tekenen van hypoxie en van necrose. In een 
microarray studie van humane groeischijven zagen we tevens dat de expressie van het hypoxia-
inducible factor 2 alpha gen (Hif-2 alpha) significant omhoog ging met het voortschrijden van 
de puberteit. Daarnaast veranderde ook de expressie van vele genen die geassocieerd zijn met 
geprogrammeerde celdood, zoals genen die betrokken zijn bij pro-apoptose, anti-apoptose en 
autophagie. Op basis van deze bevindingen veronderstellen wij dat hypoxie een rol speelt bij de 
sluiting van de groeischijf en dat chondrocyten uiteindelijk ten gronde gaan aan een specifiek type 
celdood.
In de laatste hoofdstukken van dit proefschrift bestudeerden we een relatief nieuw model voor de 
groeischijf, namelijk humane mesenchymale stamcellen (hMSCs) die kunnen differentiëren naar 
chondrocyten. Deze MSCs kunnen uit verschillende bronnen geïsoleerd worden. Wij concludeerden 
dat MSCs uit foetaal beenmerg het meest geschikt waren om tot chondrocyten te differentiëren. 
In een microarray studie zagen we dat het expressieprofiel van MSCs die differentieerden 
naar chondrocyten beter overeenkwam met dat van chondrocyten uit de groeischijf dan met 
chondrocyten uit gewrichtskraakbeen. Daarnaast zagen we in het differentiatieproces veel genen 
en groepen genen veranderen waarvan reeds bekend was dat ze een rol spelen in processen in 
de groeischijf. Dit geeft aan dat uit MSCs gedifferentieerde chondrocyten een uitstekend model 
vormen om de groeischijf en het chondrogene differentiatie proces in meer detail op verschillende 
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